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Abstract 
 
The Fanconi Anemia (FA) pathway is critical for repair of DNA damage interstrand 
crosslinks (ICL). Mutations in the pathway lead to a rare genetic disorder known as FA, 
where patient’s symptoms include a high predisposition to cancers, anemia and 
developmental defects. The pathway is complex, consisting currently of 15 proteins (in 
vertebrates). The key event of the pathway is the monoubiquitination of downstream 
targets FANCD2 and FANCI, which signals the recruitment of the DNA repair 
machinery. The E3 ligase activity that carries out the monoubiquitination event resides 
in the Fanconi Anemia Core Complex (FA CC), which consists of 7 proteins. Patient 
mutations in any of the FA CC proteins prevent the monoubiquitination of targets, 
FANCD2 and FANCI. Interestingly, E3 ligase activity is associated with only one of 
these 7 FA CC proteins, which is FANCL. 
 
The studies presented in this thesis unveil the structure of Human FANCL and the 
molecular details of FANCLs interactions, required for the key monoubiquitination 
event of the FA pathway. These observations provide an insight into the biochemistry 
underlying the FA pathway and the role of E3 ligases in selective monoubiquitination.	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Chapter 1. Introduction 
This section aims to give a comprehensive background of ubiquitination and Fanconi 
Anemia, the two areas studied in this thesis  
 
Ubiquitination 
Ubiquitin is a highly conserved eukaryotic protein, comprising 76 amino acids and 
found across all tissue types (Haas and Bright, 1985). Ubiquitin was first extracted from 
bovine thymus and found to be important in T cell differentiation (Goldstein et al., 
1975). Subsequent studies by Aaron Ciechanover, Avram Hershko and Irwin Rose were 
able to reveal the processes of ubiquitination required for protein degradation 
(Wilkinson, 2005), for which they were awarded the Nobel Prize for Chemistry in 2004. 
 
Structurally, ubiquitin consists of a 5-stranded β-meander and an α-helix, giving rise to 
the β-grasp ubiquitin superfold, with a flexible C-terminal tail (Fig.1) (Vijay-Kumar et 
al., 1987). This small globular protein functions as a reversible posttranslational 
modification (PTM), required for the regulation of a range of cellular processes, 
including cell cycle control, protein degradation and DNA repair (Jentsch et al., 1987, 
Goebl et al., 1988, Hershko et al., 1980, Ciechanover et al., 1980) (reviewed in (Pickart 
and Eddins, 2004)). Therefore problems that arise in the ubiquitin system give way to 
whole variety of diseases such as cancer and neurodegeneration. 
 




Figure 1 Structure of Ubiquitin 
Structure of a Ubiquitin molecule (PDB code 3JVZ) showing the 7 lysine residues on the 
surface of ubiquitin.  
 
The C-terminal tail of ubiquitin is covalently attached to an amino group of a substrate, 
typically a lysine residue. This attachment requires an enzymatic cascade. The addition 
of a single ubiquitin molecule is known as a monoubiquitination event, with some 
substrates undergoing multiple monoubiquitination events (Yin et al., 2010, Haglund et 
al., 2003). In addition to monoubiquitination, ubiquitin can also be conjugated to itself 
in multiple conformations. This is owing to the 7 lysines that reside on the surface of 
ubiquitin (Fig.1). Each lysine can be conjugated to another ubiquitin molecule, which 
gives rise to distinct chain topologies (Fig.2), resulting in a diverse range of signals and 
a versatile signalling system. For example, K48 linked chains have been shown to target 
the protein substrates to the proteasome (Chau et al., 1989) and K63 linked chains are 
involved in signalling pathways (Deng et al., 2000) and DNA repair (Spence et al., 
1995). Besides these homologous chain topologies there are the heterologous chain 
topologies, which are formed from a combination of lysine linkages (Ben-Saadon et al., 
2006). 
 




Figure 2 Structures of Ubiquitin Chain topologies 
A) K63 linked di-ubiquitin chain (PDB code 2JF5). B) K11 linked di-ubiquitin chain (PDB 
code 2XEW). C) K48 linked di-ubiquitin chain (PDB code 2LVQ). 
 
Recognition of ubiquitin, by either the enzymes involved in ubiquitination or the 
receptors that recognize the diverse ubiquitin signals, typically involves a ubiquitin 
binding domain (UBD) (Young et al., 1998, Hadari et al., 1992) (UBDs reviewed in 
(Hicke et al., 2005, Dikic et al., 2009)). There have been many UBDs structurally 
determined, revealing a range of different structural folds, such as zinc fingers, plekstrin 
homology domains and α-helical domains (Rahighi et al., 2009, Schreiner et al., 2008, 
Alam et al., 2004). 
 
Ubiquitin interacts with the UBDs usually through the canonical, surface exposed 
hydrophobic patch, surrounding Ile44 and encompassing residues Leu8 and Val70 
(Fig.3) (Beal et al., 1996, Sloper-Mould et al., 2001). Other interaction regions of 
ubiquitin include an acidic patch, surrounding residue Asp58 (Fig.3) and the C-terminal 
tail (Sloper-Mould et al., 2001, Penengo et al., 2006, Lee et al., 2006). Additional to the 
surface patches of individual ubiquitin molecules the specific chain linkages are also 
recognized by ubiquitin receptors. For example, K48 linked chains are selectively 
recognised by Mud1 involved in the DNA damage response (Trempe et al., 2005). Also, 
Chapter 1 Introduction 
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linear linked ubiquitin chains, formed through the amino group of the N-terminal 
methionine residue of ubiquitin, are recognised by NFκB essential modulator (NEMO) 





Figure 3 Ubiquitin surface 
Ubiquitin surface represented by green with the hydrophobic interacting patch coloured blue 
and the acidic interacting patch coloured pink (PDB code 3JVZ). 
 
Ubiquitin has several structurally and functionally related proteins, which are also 
involved in PTMs and known as ubiquitin-like (Ubl) proteins. These include: Small 
Ubiquitin-like Modifier (SUMO), Neural precursor cell expressed, developmentally 
down-regulated protein 8 (NEDD8), and interferon-stimulated 15kDa protein (ISG15) 
(Pickart and Eddins, 2004) (Fig.4). Importantly, studies of both ubiquitin and its related 
Ubls have helped in our understanding of the attachment of these proteins for their role 
as a PTM. Although ubiquitin and each Ubl all require their own set of enzymes to 
achieve each specific PTM, there is a generic conservation between the enzymatic 
cascades. That is, each PTM requires an E1, an E2 and an E3 enzyme. These enzymes 









Figure 4 Ubiquitin-like Proteins 
The ubiquitin-like proteins structures: SUMO (PDB code 3PGE) coloured blue, NEDD8 (PDB 
code 2BKR) coloured pink, ISG15 (PDB code 1Z2M) coloured cyan. All are overlaid in their 
respective colours with ubiquitin (PDB code 3JVZ) coloured green. 
 
 
1.1.1 Attachment of a Ubiquitin moiety 
The covalent attachment of a ubiquitin molecule onto a protein for protein degradation 
was first unveiled by Aaron Ciechanover, Avram Hershko, Irwin Rose and colleagues 
in the late 1970s to early 1980s. They undertook sophisticated biochemistry 
experiments, adding biochemical protein fractions to rabbit reticulocyte lysates, and 
observing that some proteins became covalently linked to ubiquitin. Furthermore, they 
revealed that these ubiquitinated proteins were being degraded by an ATP dependent 
protease/s (Ciehanover et al., 1978, Hershko et al., 1980). Later studies, using ubiquitin-
sepharose as an affinity purification material, revealed the enzymes that are required for 
the covalent attachment of ubiquitin onto substrate proteins (Ciechanover et al., 1981, 
Haas et al., 1982)(Hershko et al., 1983, Pickart and Rose, 1985) (Fig.5). These studies 
Chapter 1 Introduction 
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formed the foundation of our understanding of the ubiquitin enzymatic cascade, which 
consists of an E1 ubiquitin activating enzyme, an E2 ubiquitin conjugating enzyme and 
an E3 ligase. The process of achieving a ubiquitination event will be discussed in detail 
below. 
 
The human genome encodes for 2 E1 enzymes (Handley et al., 1991, Pelzer et al., 2007), 
~40 E2 enzymes and over 600 E3 ligases. The vast number of E2 and E3 enzymes 
allows for the targeting of thousands of different substrates and with differing ubiquitin 
signals.  
 
The activation and conjugation of ubiquitin, carried out by the E1 and E2 enzymes, are 
well understood (Fig.5 step 1 and 2). This is due to the innovative biochemical and 
structural studies of the E1 enzymes for ubiquitin (Lee and Schindelin, 2008, Lake et al., 
2001, Haas et al., 1982, Szczepanowski et al., 2005, Olsen and Lima, 2013) and the 
Ubls SUMO (Lois and Lima, 2005, Olsen et al., 2010) and NEDD8 (Walden et al., 
2003b, Huang et al., 2005a, Walden et al., 2003a). However, the final stage, ubiquitin 
ligation, where the E2 and E3 enzymes pair to facilitate the transfer of ubiquitin onto 
the substrate, is less well defined (Fig.5 step 3). This is due to the huge array of E3 
ligases and the potential ~24,000 E3-E2 enzyme pairs. Furthermore, the E2 and E3 
enzymes are subdivided into different families. Although a neat biological method for 
flexibility and versatility in the ubiquitin system it makes divulging mechanistic details 
for each specific ubiquitin attachment of individual substrates more complicated.  
 
The next sections will describe in detail each step in the ubiquitin pathway and the 








Figure 5 Ubiquitin Cascade 
A simple schematic of the ubiquitin cascade. 1) Ubiquitin (gold stars) activation requires the E1 
enzyme (green), magnesium and ATP which adenylates the C-terminal tail of ubiquitin. The 
catalytic cysteine of the E1 then attacks the adenylated tail of ubiquitin and forms a thioester 
intermediate and releases AMP + PPi. A second molecule of ubiquitin is then recruited by the 
E1 for adenylation. 2) The E1 can then bind the E2 enzyme (blue) through its ubiquitin fold-like 
domain (UFD). The catalytic cysteine of the E2 then attacks the thioester bound ubiquitin on the 
E1, forming a thioester bound ubiquitin conjugate with the E2. 3) The final stage requires the 
E3 ligase (purple) to bind the E2 and substrate (pink) and facilitate the isopeptide bond 
formation of the ubiquitin molecule onto the substrate. 
 
 
1.1.1.1 Ubiquitin activation and conjugation 
The E1 enzyme is responsible for activation of the ubiquitin molecule. A temperature 
sensitive mutant in mammalian cells, which resulted in cell cycle arrest, was identified 
as the E1 ubiquitin-activating enzyme (Finley et al., 1984, Ciechanover et al., 1985).  
These studies were the first to indicate the importance of ubiquitin dependent protein 
degradation in vivo. 
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The structural characterization of the E1 enzyme for ubiquitin, UBA1 (Lee and 
Schindelin, 2008) and the heterodimers SAE1-UBA2 (Lois and Lima, 2005) and 
APPBP1P-UBA3 (Walden et al., 2003b, Walden et al., 2003a) for SUMO and NEDD8 
respectively, reveal three distinct functional domains. They are: i) the adenylation 




Figure 6 Structure of the ubiquitin E1 enzyme, UBA1 
Structure of the ubiquitin E1 enzyme UBA1 bound with a ubiquitin situated in the adenylation 
domain (PDB code 3CMM). The adenylation domain responsible for adenylating ubiquitin’s C-
terminal tail is coloured green. Ubiquitin is coloured orange. The catalytic domain that forms a 
thioester by attacking the adenylated ubiquitin tail is coloured blue. A yellow star represents the 
E1 catalytic cysteine. The ubiquitin fold-like domain (UFD) that binds the E2 conjugating 
enzyme is coloured pink. 
 
Firstly, the activation of ubiquitin is achieved by the adenylation of its C-terminal tail 
(Haas et al., 1983, Haas et al., 1982, Ciechanover et al., 1981), which occurs on the E1 
adenylation domain (Fig.5 stage 1 and Fig.6). As adenylation is an energy dependent 
process, the adenylation domain also binds ATP (Lake et al., 2001, Lois and Lima, 
2005, Walden et al., 2003a), which allows for the catalysis and formation of an AMP-
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ubiquitin bound E1 intermediate. The adenylated ubiquitin C-terminal tail is then 
attacked by the catalytic cysteine of the E1s catalytic domain and releases the AMP 
molecule from ubiquitin’s C-terminal tail. This results in a thioester linkage formed 
between ubiquitin and the catalytic cysteine domain of the E1 (Haas et al., 1982, Olsen 
et al., 2010, Ciechanover et al., 1981). Before proceeding to the second stage of 
ubiquitin conjugation, the E1 must adenylate a second ubiquitin molecule. The 
adenylation of the second ubiquitin molecule allows a conformational change to take 
place in the E1 enzyme. The ubiquitin fold-like domain rotates by 110o and 
subsequently allows the binding of the E2 conjugating enzyme (Huang et al., 2007, 
Huang et al., 2005b, Lois and Lima, 2005, Olsen and Lima, 2013). The catalytic 
cysteine of the E2 can then attack the thioester bound ubiquitin -E1 in a 
transthioesterification reaction (Huang et al., 2007, Olsen and Lima, 2013). This results 
in the E2 enzyme becoming conjugated with ubiquitin via a thioester linkage (Fig.5 step 
2) to take forward to the final stage, ubiquitin ligation (Fig.5 step 3). 
 
1.1.1.2 Ubiquitin Ligation  
Ligation of ubiquitin requires an E3 ligase, which binds both the substrate and the 
ubiquitin conjugated E2 and co-ordinates the transfer of ubiquitin onto the substrate 
(Fig.5 step 3). However, some E2s have been shown to ligate ubiquitin directly onto a 
substrate in the absence of an E3, particularly the promiscuous family of E2s the 
Ube2Ds (Brzovic and Klevit, 2006, Wenzel et al., 2011). Additionally, the type of 
substrate ubiquitin modification i.e. a monoubiquitination versus a particular chain 
topology is thought to be dictated by the E2-E3 enzyme pair (Yin et al., 2009).  
Understanding how and why a specific substrate lysine is selected and restricted to a 
particular ubiquitin modification are major unanswered questions in the ubiquitin field. 
For modifying a particular substrate lysine, current evidence best supports the idea of 
the E3 positioning the lysine into the correct orientation for nucleophilic attack of the 
thioester bound ubiquitin intermediate (Calabrese et al., 2011, Kamadurai et al., 2013). 
In the case where there are many proximal lysines to the specific lysine to be modified, 
the surrounding lysine chemistry is thought to dictate selection (Sadowski et al., 2010). 
A combination of both these ideas is probable. Importantly though, for each cellular 
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process that requires a different ubiquitin modification, the mechanistic details must be 
understood. This will aid the understanding of not only ubiquitin biology but also the 
molecular determinants of cellular processes attributed to ubiquitination. The next 
sections detail the E2 enzymes and E3 ligases required for a ubiquitin ligation event. 
 
1.1.1.3 E2 conjugating enzymes 
There are approximately 40 E2 enzymes in the human genome, all of which contain a 
ubiquitin-conjugating fold (UBC), comprising a 4-stranded β-meander flanked either 
side by an α-helix (Fig.7). The catalytic cysteine that forms a thioester linkage with 
ubiquitin resides in the β-flap region adjacent to a well-conserved His Pro Asn (HPN) 





Figure 7 Structure of the E2 Ube2L3 
The left view is of the overall structure of the E2 Ube2L3 (PDB code 1FBV). E1 and E3 
binding region is represented by a pink oval. The catalytic cysteine is labelled, which is situated 
in the β-flap region. The right view is zoomed in on the β-flap region showing the catalytic 
cysteine and the adjacent HPN motif required for the nucleophilic attack from the amino group 
of a substrate lysine. 
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In the case of the Really Interesting New Gene (RING) E3 ligases (discussed in section 
1.1.1.4.) the E2’s HPN motif and residues surrounding the E2’s catalytic cysteine aid 
the nucleophilic attack on the E2-Ub thioester bond by the incoming lysine residue from 
the substrate (Yunus and Lima, 2006). The asparagine residue of the HPN motif is 
thought to stabilize the oxyanion intermediate during isopeptide formation and the 
histidine residue responsible for structural stabilization of the catalytic region (Wu et al., 
2003). For the Homologous to the E6-AP Carboxyl Terminus (HECT) E3 ligases 
(discussed in section 1.1.1.4.) the catalytic cysteine of the HECT attacks the thioester 
bound E2-Ub and then a substrate binds the HECT and attacks the thioester bound 
HECT E3-Ub intermediate. Additionally, residues that form a shallow groove from the 
catalytic cysteine on the E2 interact with residues from ubiquitin’s C-terminal tail and 
stabilize the E2-Ub intermediate (Hamilton et al., 2001). 
 
Importantly, the E2 enzymes must interact with both the E1 and E3 enzymes during the 
process of ubiquitination. Interaction with the E1 occurs on α-helix 1 (Huang et al., 
2005b) with this interaction region extended to the loop1 and loop2 residues for E3 
binding (Fig.7) (Zheng et al., 2000, Huang et al., 1999). The overlap of the E1 and E3 
interaction regions suggests a sequential enzymatic cascade, which has been observed 
for the HECT subfamily of E3 ligases (Eletr et al., 2005).  
 
As well as interacting with the E1 and E3 enzymes, some E2s have been shown to 
interact with ubiquitin non-covalently. This is the case for both Ube2D3 and Ube2G2, 
which interact non-covalently with ubiquitin through their ‘backside’ - the β-meander of 
the E2 (Brzovic et al., 2006, Li et al., 2009). For Ube2D3 the ‘backside’ binding of 
ubiquitin is required for processive ubiquitin chain building in conjunction with the E3 
BRCA1. In contrast, the function of the ubiquitin ‘backside’ interaction of Ube2G2 is 
still yet to be determined. 
 
Additional to the core UBC fold, some E2s have an N or C-terminal extension or in 
some cases both (reviewed in (van Wijk and Timmers, 2010)). Several functions have 
been assigned to particular E2 extensions. In the case of Ube2C, its N-terminal 
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extension regulates the number of substrate lysines that are ubiquitinated when bound to 
the multi-subunit E3 ligase, the anaphase-promoting complex (APC) (Summers et al., 
2008a). The C-terminal extension of Ube2K folds into a UBD, which interacts with 
ubiquitin molecules to build unattached K48-linked chains (Haldeman et al., 1997). 
However, the functions of many of the E2 extensions are yet to be defined. Table 1 









Ube2C UbcH10 N6Terminal K11 Cell6cycle
Ube2D UbcH5A/B/C
Ube2E UbcH6/9 N6Terminal
Ube2F NCE2 N6Terminal NEDD8




Ube2J NCUBE1/2 C6Terminal ER,protein,
quality,control
Ube2K HIP2 C6Terminal K48 Protein,quality,
control
Ube2L UbcH7/8 ISG15 Interferon,
signalling
Ube2M Ubc12 N6Terminal NEDD8 SCF,regulation




Ube2R CDC34 C6Terminal K48 Cell,cycle
Ube2S E26EPF C6Terminal K11 Cell,cycle
Ube2T HSPC150 C6Terminal monoubiquitination DNA,repair
Ube2U C6Terminal
Ube2V UVE1,UEV2/MMS2 V1,6,N6terminal
Ube2W C6Terminal monoubiquitination DNA,repair
Ube2Z Use1 Both  
Table 1 E2 enzymes, their extensions and functions 
 
Most E2s exist as monomers, but in some cases they can also dimerize. NMR and 
biophysical studies of Ube2W, show that it exists in both a monomeric and 
homodimeric state (Vittal et al., 2013). The dimerization interactions of Ube2W occur 
through 2 sites, one through the C-terminal extension and the other involving the loop1 
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and loop2 region. Functionally, monomeric Ube2W is involved in monoubiquitination 
(Alpi et al., 2008, Christensen et al., 2007), but the functional reasons for its dimeric 
state are still not understood (Vittal et al., 2013). In contrast, Ube2N forms heterodimers 
with either of the E2 variants Ube2V1 or Ube2V2, which lack catalytic cysteines (Deng 
et al., 2000, Hofmann and Pickart, 1999). The structural dimer of Ube2N-Ube2V2 with 
ubiquitin reveals the function for the essential dimerization. That is the heterodimer is 
required to position a second ubiquitin molecule in the correct orientation for building 
K63 linked chains (Eddins et al., 2006). 
 
Regulation of E2s by PTMs has also been documented. In the case of CDC34, the 
phosphorylation of its acidic loop regulates its function in its role of ubiquitination of 
substrates essential for cell cycle progression (Sadowski et al., 2007). Whether more 
E2s are regulated by PTMs is not clear. 
 
At first the E2 enzymes were overlooked as just intermediaries between the E1 and E3 
enzymes as a transporter of ubiquitin. However, the recent biochemical and structural 
work is indicating a more important role the E2 enzymes play with regards to the type 
of ubiquitin modification and regulation of ubiquitination events (Brzovic et al., 2006, 
Haldeman et al., 1997, Summers et al., 2008a). Future studies of E2 enzymes and their 
pairings will hopefully reveal the molecular details that govern the different types of 
ubiquitin modifications. 
 
1.1.1.4 E3 Ligases 
The generic function of an E3 ligase is to bind both the substrate and ubiquitin 
conjugated E2 for the ligation of ubiquitin onto the substrate. There are 3 different 
subgroups that make up the E3 ligases, the HECTs, the RINGs and the RING-in-
between-RINGs (RBRs).  
 
The HECT ligases are fairly well characterized as there are only a few of them, ~60. 
They possess a catalytic cysteine that attacks the thioester linkage conjugating the 
ubiquitin molecule to the E2 in a second transthioesterification reaction. (Huibregtse et 
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al., 1995, Scheffner et al., 1995, Kumar et al., 1997). In turn, the HECT thioester 
linkage is then attacked by the lysine residue of the substrate to form the ubiquitin 
ligation (Kamadurai et al., 2013). Conversely, the RING ligases do not form any 
catalytic intermediate with ubiquitin; rather they form a protein scaffold to facilitate the 
transfer of ubiquitin from the E2 onto the substrate (Seol et al., 1999, Skowyra et al., 
1999). The RBRs have only recently been classified as an individual subgroup of E3 
ligases. They function as a hybrid between the HECT and RING E3 ligases as they 
contain 2 RING domains but can also form a thioester linkage with ubiquitin like the 
HECTs (Wenzel et al., 2011, Spratt et al., 2013).  
 
The remainder of this section will detail the RING E3 ligases as the basis for this thesis 
surrounds the RING E3 ligase FANCL. 
 
The RING family are the largest of the E3 ligases and are a varied group of proteins that 
range in size and domain architecture. They can exist as single polypeptides, like c-Cbl 
involved in cell signalling pathways (Zheng et al., 2000) or as multi-protein complexes 
such as  the expansive family that is the cullin RING ligases (CRLs) (Zimmerman et al., 
2010). In the case of the CRLs, they are composed of an elongated cullin domain that 
binds a RING domain at its C-terminus and adaptor proteins at its N-terminus. An 
advantage of the multi-subunit E3 ligase is that the variety of adaptor proteins can 
recruit a range of substrates to be ubiquitinated, giving flexibility within the system 
(Zimmerman et al., 2010). However, the common feature for all RING E3 ligases is the 
RING domain. The RING domains are globular and approximately a10kDa in size with 
two structural zinc atoms co-ordinated by cysteine and histidines residues arranged in a 
cross-brace structure (Fig.8) (Deshaies and Joazeiro, 2009, Borden et al., 1995). There 
are the structurally related U-box and Plant Homeodomain (PHD) proteins, with only 
the U-box proteins possessing ubiquitin ligase activity (Aravind et al., 2003). However, 
in contrast to the RING and PHD domains the U-box domains do not contain zinc 
atoms. Instead the cysteines and histidines are swapped for charged and polar residues 
to form the cross-brace structure (Fig.8) (Aravind and Koonin, 2000). Furthermore, 
some RING E3 ligases must dimerize to function. Structural studies reveal the 
dimerization results in a dimeric RING domain (Brzovic et al., 2001, Liew et al., 2010). 
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Examples of dimeric RING E3 ligases include the heterodimer BRCA1/BARD1 
involved in genomic stability and tumour suppression (Hashizume et al., 2001) and the 





Figure 8 RING domain architecture 
A schematic of a RING domain where zinc atoms are represented by grey circles and X can be 
any residue. A structure based sequence alignment of RING and U-box domains. Grey bars 
represent zinc co-ordinating residues. Orange bars represent highly conserved residues with less 
conserved residues represented by yellow bars. Green circles represent hydrophobic residues 
involved in E2 binding. The 2 U-box domain proteins are highlighted in pink. They do not have 
zinc co-ordinating residues. 
 
 
Interactions of substrates can occur directly with the E3 ligase as in the case with b-Cbl 
(Dou et al., 2012a) or through various adaptor proteins as described above for the CRLs. 
Recognition of substrates by E3s is varied with no consensus sequence or structural 
motif. An exception though was discovered for substrates that are ubiquitinated by the 
multi-subunit E3 ligase, the APC. These substrates contain a TEK box motif that 
surrounds the lysine to be modified (Jin et al., 2008). The difficulty in obtaining 
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structures of protein-protein interactions, in this instance substrates bound to their 
corresponding E3 ligases, and the sheer number of E3 ligase and substrate pairs is a 
particular challenge for understanding substrate recognition.  
 
The catalytic role of RING E3 ligases is associated with binding their respective E2s 
conjugated with ubiquitin. The RING E3 ligase stimulates the release of ubiquitin from 
the E2 for transfer onto a substrate by a proposed allosteric mechanism owing to the 
distal nature between the RING binding region and the catalytic cysteine of the E2 
(Ozkan et al., 2005) (Fig.7 and 9). Recognition of the E2 occurs through a generic 
hydrophobic interface on the E2’s loop1-loop2 region and a conserved hydrophobic 
interface on the RING domain (Zheng et al., 2000, Plechanovova et al., 2012, Pruneda 
et al., 2012, Yin et al., 2009, Bentley et al., 2011, Dou et al., 2012b, Dou et al., 2013, 
Dominguez et al., 2004) (Fig.9).  
 
 
Chapter 1 Introduction 
 30 
 
Figure 9 RING and E2 interactions 
Structure of c-Cbl RING domain (green) bound to UbcH7 (blue) (PDB code 1FBV). Grey 
spheres represent zinc atoms. Alignments of RING domains and E2s. Grey bars represent zinc 
co-ordinating residues. Red bars represent highly conserved residues with less conserved 
residues represented by orange and yellow bars. Green circles represent hydrophobic residues 
involved in E2 binding. 
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The RING-E2 structures that are currently available are predominantly of the 
promiscuous Ube2D family. Also, 6 of the 9 structures of different RING-E2 pairs are 
of dimeric RINGs, leaving just 3 monomeric RING-E2 structures, 2 of which are of the 
same RING E3 ligase Cbl paired with different E2s, UbcH7 and Ube2D2 (Dou et al., 
2013, Zheng et al., 2000, Dominguez et al., 2004). Additionally, c-Cbl-UbcH7 is not a 
functional E3-E2 pair (Huang et al., 2009). Whilst all these RING-E2 structures have 
given us the generic interface of RING and E2 binding, the molecular basis for the 
selection of specific E2s by their corresponding RING E3 ligase still needs to be 
detailed. More biochemical and structural studies of diverse E3-E2 pairs and selective 
E2-E3 pairs are required.  
 
Until recently, understanding the mechanism of dimerization for certain RING E3 
ligases was unclear. Innovative structural studies have revealed the reason for 
dimerization and additionally, proposed the mechanism by which dimeric RING E3 
ligases can increase the transfer of ubiquitin. In contrast to the existing RING-E2 
structures, all 3 structural studies used a ubiquitin conjugated E2, Ube2D-Ub, bound to 
the dimeric RINGs (Plechanovova et al., 2012, Dou et al., 2012b, Pruneda et al., 2012). 
These structures reveal the second RING domain is responsible for interacting with the 
ubiquitin molecule conjugated to the E2. This interaction is key for locking the thioester 
bound C-terminal tail of ubiquitin into a favourable position to undergo nucleophilic 
attack by the incoming substrate lysine (Fig.10). 
 
More recently the same mechanism has been proposed for the monomeric RING E3 
ligase b-Cbl. The structure of b-Cbl bound to Ube2D2 conjugated with ubiquitin reveals 
an additional binding region to the RING domain of b-Cbl required for interacting with 
the conjugated ubiquitin molecule (Dou et al., 2013) (Fig.10). Furthermore, the key 
interaction occurring between b-Cbl and ubiquitin is mediated through a phosphorylated 
tyrosine of b-Cbl. Whether additional interacting regions and/or PTM are required for 
aiding the interaction with ubiquitin conjugated E2s for other monomeric RING E3 
ligases, needs further investigation. 
 
 




Figure 10 Structures of RING E3 ligases co-ordinating ubiquitin 
A) Structure of the homodimeric RING E3 ligase BRIC7 (first RING domain coloured green 
the second coloured magenta) bound to Ube2D2 (coloured blue) conjugated with ubiquitin 
(orange) (PDB code 4AUQ). This structure reveals the second RING molecule (pink) interacts 
with the ubiquitin molecule, which aids nucleophilic attack of thioester linkage between 
Ube2D2 and ubiquitin by the substrate lysine. B) Structure of the monomeric RING E3 ligase b-
Cbl (coloured green) bound to Ube2D2 (coloured blue) conjugated with ubiquitin (coloured 
orange) (PDB code 3ZNI). This structure reveals an additional region to the RING domain of b-
Cbl interacts with the ubiquitin molecule, which aids nucleophilic attack of thioester linkage 
between Ube2D2 and ubiquitin by the substrate lysine. The interaction requires the 
phosphorylated tyrosine 363 of b-Cbl. Grey spheres represent zinc atoms. 
 
 
Interestingly, other structural work has revealed additional binding regions of RING E3 
ligases for their E2s to either stabilize the RING-E2 interaction or regulate the type of 
ubiquitin modification. For the RING E3 ligase Rad18, a region termed Rad6 binding 
domain (R6BD) can bind the ‘backside’ of the E2 RAD6b (Ube2B), regulating Rad6 to 
only monoubiquitinate a substrate rather than form polyubiquitin chains (Hibbert et al., 
2011). Also, the RING E3 ligase gp78 has a G2BR domain, which again binds the 
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‘backside’ of its corresponding E2 Ube2G2, enhancing the affinity for gp78’s RING 
domain and facilitating the ubiquitination of substrates (Li et al., 2009).  
 
As observed for b-Cbl, PTMs such as phosphorylation, neddylation, and ubiquitination 
of RING E3 ligases is extensively documented (reviewed in (Pickart, 2001, Deshaies 
and Joazeiro, 2009)). The function of these PTMs is diverse, ranging from regulating or 
activating the RING E3 to aiding protein-protein interactions or cellular localization. 
 
Ubiquitination is essential to almost every cellular process and dysfunction in the 
system results in a whole range of different disease states. Therefore understanding 
ubiquitination and the cellular pathways, in which it is essential, is imperative. 
 
The next section will introduce FANCL a RING E3 ligase, the main subject of this 
thesis and a key component of the Fanconi Anemia (FA) DNA repair pathway, which 
when disrupted leads to FA. 
 




Fanconi Anemia (FA) was first described in 1927 by a Swiss paediatrician Guido 
Fanconi. FA is a rare genetic disorder characterized by a whole host of symptoms from 
short stature and skeletal defects to bone marrow failure, anaemia and a high 
predisposition to cancers (Alter, 1996). The current diagnostic test is to incubate patient 
cells with a DNA interstrand cross-linking (ICL) agent such as mitomycin C (MMC) 
and carrying out a chromosomal spread (German et al., 1987). Chromosomes of patients 
with FA treated with MMC display abnormal breakages, deletions and radials.  
Due to their inherent genomic instability and inability to repair DNA damage, patients 
are advised to avoid carcinogens that damage DNA, such as tobacco smoke, alcohol and 
overexposure to UV radiation from sunlight. The possible endogenous causes of FA 
DNA damage were discovered only recently (Langevin et al., 2011, Rosado et al., 2011). 
These studies have revealed that aldehydes from food sources and/or produced from 
natural metabolism processes, cause DNA damage that is repaired by the FA pathway. 
Furthermore, the group also linked aldehydes to the DNA damage of the haematopoietic 
stem and progenitor cells, leading to the aplastic anemia and bone marrow failure in FA 
patients (Garaycoechea et al., 2012). 
 
The molecular determinants of FA are attributed to the FA pathway, which is best 
characterized for its ability in repairing ICL DNA damage. Symptoms such as skeletal 
and developmental defects are not yet currently explained by the pathway. 
 
1.1.2 Fanconi Anemia Pathway 
The FA pathway is complex, currently consisting of 15 verified FA genes with a 16th, 
FANCQ/ERCC4/XPF (Bogliolo et al., 2013) awaiting verification, all which encode for 
the FA proteins (Fig.11 and Table 2). Additional to the FA proteins are the 5 FA 
associated proteins (FAAPs): FAAP10/MHF2, FAAP16/MHF1, FAAP20, FAAP24, 
and FAAP100 (Ling et al., 2007, Ciccia et al., 2007, Kim et al., 2012, Ali et al., 2012, 
Leung et al., 2012, Singh et al., 2010, Yan et al., 2010). Mutations in the any of the FA 
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proteins leads to genome instability with the FAAPs yet to been found mutated in 
patients. FA patients are subtyped into the different FA complementation groups (A, B, 
C ect.) by testing patient cell lines with several methods; immunoblotting for FA 
proteins, retroviral transfection, and direct gene sequence (Shimamura and D'Andrea, 
2003). 
 
ICL repair by the FA proteins occurs during S-phase where the replication forks 
converge and become stalled by the covalent linkage of the ICL between the 
complementary strands of DNA (Niedernhofer, 2007) (Fig.11). The FANCM-FAAP24 
heterodimer is responsible for recognizing the ICL (Coulthard et al., 2013, Ciccia et al., 
2007) and interactions with the histone fold proteins MHF1 and MHF2 involved in 
DNA remodelling (Yang et al., 2012, Singh et al., 2010, Yan et al., 2010).  
 
At the heart of the FA pathway is the FA core complex (CC), responsible for the key 
event, the specific monoubiquitination of substrates FANCD2 and FANCI (Fig.11) 
(Smogorzewska et al., 2007, Sims et al., 2007, Timmers et al., 2001, Garcia-Higuera et 
al., 2001). The FA CC comprises of 7 FA gene products: FANCA, FANCB, FANCC, 
FANCE, FANCF, FANCG, and FANCL (Garcia-Higuera et al., 1999, Garcia-Higuera 
et al., 2000, de Winter et al., 2000, Medhurst et al., 2001). FANCM is also thought to be 
a member of the FA CC due to earlier co-immunoprecipitation studies (Mosedale et al., 
2005, Meetei et al., 2005, Ciccia et al., 2007, Xue et al., 2008). However, more recent 
findings suggests FANCM recognises the ICL DNA damage and then recruits the FA 
CC through interactions with FANCF (Deans and West, 2009). Importantly though, a 
mutation in any member of the CC including FANCM results in loss of the 
monoubiquitination of substrates even though E3 ligase activity is only associated with 
one FA CC member, FANCL (Meetei et al., 2003). The FA CC and FANCL are further 
discussed in section 1.2.1.1 and 1.2.1.2. 
 




Figure 11 The Fanconi Anemia Pathway 
A schematic of the FA pathway at a stalled DNA replication fork (grey) caused by an ICL. 
FANCM and its associated proteins (coloured yellow) recognise the ICL DNA damage. The FA 
CC and its associated proteins (coloured green) with FANCL (coloured dark blue) bound to its 
respective E2 Ube2T are then recruited to carry out the monoubiquitination of substrates 
FANCD2 and FANCI (coloured pink and purple respectively). Once substrates are 
monoubiquitinated the DNA repair machinery (coloured pale blue) is recruited to repair the ICL. 
Cyan stars represent ubiquitin molecules. This figure was adapted from (Hodson and Walden, 
2012). 
 
The monoubiquitination of substrates signals for the recruitment of the DNA repair 
machinery: FANCP/SLX4, FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2 and 
FANCO/Rad51C, which are involved in homologous recombination and co-ordinating 
nucleases in conjunction with translesion synthesis (reviewed in (Kottemann and 
Smogorzewska, 2013)) (Levitus et al., 2005, Howlett et al., 2002, Levran et al., 2005, 
Litman et al., 2005, Reid et al., 2007, Xia et al., 2007, Kim et al., 2011, Stoepker et al., 
2011, Meindl et al., 2010, Vaz et al., 2010). The co-ordination of all the different repair 
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processes by the FA pathway is still not understood. Table 2 lists all proteins involved 








A 163 1455 60%
B 98 859 2%
C 63 558 13%
D1 384 3418 2%
D2 164 1451 3%
E 59 536 3%
F 42 374 3%
G 68 622 9%
I 150 1328 1%
J 141 1249 2%
L 42 375 0.20%
M 232 2048 0.20%
N 131 1186 0.60%
O 42 376 0.50%
P 200 1834 0.50%
Q 104 916 ?
FAAP10 10 81 -
FAAP16 16 138 -
FAAP20 20 180 -
FAAP24 24 215 -
FAAP100 100 881 -  
 
1.1.2.1 The Fanconi Anemia Core Complex 
The FA CC is large comprising 7 FA proteins and 2 FAAPs. The requirement for such a 
large multi-subunit complex is not clear, neither is its role in supporting FANCL’s E3 
ligase activity in vivo. These questions still remain unanswered due to one of the main 
challenges faced by researchers in the FA field - the difficulty in producing stable and 
highly purified recombinant FA proteins for use in biochemical and structural studies. 
 
Several groups have tried to ascertain the minimum requirements of a functional FA CC 
in vivo. An estimated molecular weight (MW) of the FA CC, including FANCM would 
be ~737kDa if the stoichiometery was 1:1:1:1:1:1:1:1. A biochemical study estimated 
the MW of the FA CC purified from chicken DT40 cells using Tandem-affinity tagged 
Table 2 Fanconi Anemia Genes 
and Associated Proteins 
A list of FA genes and FAAPs 
with their associated molecular 
weights (MW) and corresponding 
percentage of patients with 
mutations. Adapted from (Hodson 
and Walden, 2012). 
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FANCC protein as 1.5MDa (Alpi et al., 2007). Others have documented the existence 
of a cytoplasmic complex of 600kDa that increases to a 750kDa complex during mitosis, 
proposing a role of sub-complexes that come together to form a fully functional FA CC 
(Thomashevski et al., 2004).  
 
Many of the FA CC proteins currently do not have an assigned function, due to the lack 
of structure predictions from their primary amino acid sequences. FANCF is regarded 
as a scaffold protein for the FA CC, based on its partial structure (residues 156-357) 
revealing helical repeats (Kowal et al., 2007) indicative of scaffold proteins. 
Furthermore, FANCF has been shown to interact with FANCA, FANCC, FANCE and 
FANCG based on co-immunoprecipitation and yeast and mammalian 2 and 3-hybrid 
experiments (Medhurst et al., 2001, de Winter et al., 2000, Leveille et al., 2004). 
FANCA possess a nuclear localisation signal (NLS) (Garcia-Higuera et al., 1999, Naf et 
al., 1998) and patients with mutations in FANCA, which accounts for  ~60% of all FA 
patients (Table 2), typically have a defect in nuclear accumulation of FANCA 
indicating a possible role for FANCA in the cellular localization of the FA CC (Adachi 
et al., 2002).  
Again, FANCB, FANCC and FANCG are involved in numerous interactions with other 
CC members as shown by a variety of techniques including co-immunoprecipitation 
studies and yeast and mammalian 2 and 3-hybrid experiments. They have therefore 
been considered as stabilization proteins for the CC (reviewed in (Hodson and Walden, 
2012).  
The partial structure of FANCE, residues 273-536, reveals again a helical repeat 
structure indicative of a scaffold protein (Nookala et al., 2007). Interestingly, FANCE 
has been shown to bind the substrate FANCD2 using yeast and mammalian 2-hybrid 
studies (Gordon and Buchwald, 2003, Léveillé et al., 2006, Nookala et al., 2007, Pace et 
al., 2002). This interaction has prompted the proposal of FANCE as the substrate 
recognition protein of the FA CC (Pace et al., 2002). Conversely, more recent in vitro 
structure guided pull-down experiments have shown a direct interaction between 
substrates, FANCD2 and FANCI, and FANCL the E3 ligase (Cole et al., 2010). Further 
evidence from in vitro monoubiquitination assays reveal that FANCL in conjunction 
with its required E2, Ube2T, is capable of monoubiquitinating FANCD2 and FANCI 
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alone (Alpi et al., 2008, Sato et al., 2012). These studies support the idea that FANCE in 
vivo may be simply to stabilize substrates for monoubiquitination rather then a 
requirement for substrate recognition. 
 
The role of the FA CC for supporting FANCL’s E3 ligase activity is unclear. Further 
structural and biochemical studies will hopefully unveil the role for the individual FA 
CC members and the requirement for such a large FA CC. They may also reveal the 
molecular determinants for some of the pathologies currently not explained by the FA 
pathway. 
 
1.1.2.2 FANCL: The E3 ligase of the Fanconi Anemia pathway 
FANCL/pog was first identified in a mutant phenotype of mice, which were germ cell-
deficient due to the lack of proliferating primordial germ cells (Agoulnik et al., 2002). 
Agoulnik et al identified a single gene pog, responsible for the proliferation of the mice 
primordial germ cells. Additionally, they noted pog deficient mice had lower birth 
weights suggesting pog’s importance in embryonic development. Furthermore, the 
group predicted the structure of pog to contain a PHD domain at its C-terminus. Pog is 
now commonly referred to as FANCL and is the only member of the FA CC that 
possesses E3 ligase activity, FANCL (Meetei et al., 2003). However, we know from 
patients that the FA CC is required for the E3 ligase activity in-vivo in the FA pathway. 
 
Interestingly, a minimal FA pathway exists in all eukaryotes where they have at least a 
FANCD2 and a FANCL homologue (McVey, 2010, Zhang et al., 2009) with the 
exception of yeast only possessing a FANCM homologue (Mosedale et al., 2005). The 
conservation of the FA CC is only observed for the vertebrates (Titus et al., 2006) 
whereas the invertebrates differ greatly with requirements for a FA CC. For example 
Drosophila melanogaster possess only a FANCM and FANCL (Marek and Bale, 2006), 
Caenorhabditis elegans have no apparent FA CC (McVey, 2010) and the slime mould 
Dictyostelium discoideum has only a FANCE homologue (Zhang et al., 2009). 
Furthermore, FANCL is found to be expressed in all tissue types of mice, reflecting the 
importance of the FA pathway for the basic genomic stability in all cells (Zhao et al., 
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2006). Therefore since FANCL’s discovery many researchers have attempted to 
understand FANCL’s molecular details and interactions.  
 
Initially, when FANCL was first discovered it was one of the few proteins of the FA 
pathway that had a predicted structure from its primary amino acid sequence. It was 
proposed that FANCL contained 3 WD40 repeats followed by a PHD domain (Fig.12A 
and B) (Meetei et al., 2003, Agoulnik et al., 2002). A later study suggested that FANCL 
actually harboured an N-terminal RWD domain (Alpi et al., 2008). The differences in 
structure prediction and the need for understanding the molecular details of FANCL 
highlighted the importance of determining FANCL’s structure. Seven years after 
FANCL’s discovery the structure for Drosophila FANCL was published (Cole et al., 
2010). Importantly, the structure revealed a totally different domain architecture to that 
first predicted. Drosophila FANCL contains three distinct domains: an N-terminal E2 
like fold (ELF) domain, a central double RWD (DRWD) domain and a C-terminal 
RING domain (Fig.12C). Along with the structure, Drosophila FANCL’s biophysical 
characterization reveal it is a monomeric RING E3 ligase.  
 
Figure 12 Structure prediction of FANCL and Structure of Drosophila FANCL 
A) Structure of a β-propeller made up of 7 WD40 repeats (PDB code 1ERJ). B) Structure of a 
PHD domain (PDB code 3ZVZ). C) Structure of Drosophila FANCL (PDB code 3K1L). The 
ELF domain is coloured green, the DRWD domain is coloured blue and the RING domain is 
coloured pink. Grey spheres represent zinc atoms. 
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Previous work based on the predicted structure suggested key residues Arg226, Trp201, 
and Trp274 (human numbering) of FANCL were required for interactions with the FA 
CC (Gurtan et al., 2006). Mapping these residues onto the Drosophila FANCL structure 
indicated that these residues are involved in the core structural stability of FANCL. 
These mutations would therefore not disrupt interactions with the FA CC but most 
likely disrupt the overall structure of FANCL. (Cole et al., 2010).  
 
Importantly though, the Drosophila system has no apparent FA CC and the sequence 
conservation between Human and Drosophila FANCL is poor, ~ 20%. Additionally, we 
also know from patients that the FA CC somehow supports FANCL’s E3 ligase activity 
in vivo. Therefore to understand the difference in requirements for an FA CC and the 
molecular details of FANCL in vertebrates, the structure of a vertebrate FANCL is 
essential.  
 
1.1.2.3 Ube2T: The E2 enzyme of the Fanconi Anemia pathway 
As described earlier, for a ubiquitination event to take place an E2 enzyme must pair 
with the E3 ligase. An initial study involving yeast 2-hybrid experiments and 
subsequent siRNA cell experiments revealed that Ube2T is the E2 enzyme for the FA 
pathway (Machida et al., 2006) Further confirmation was observed in vivo by deletion 
of Ube2T from chicken DT40 cells and seeing the loss of FANCD2 monoubiquitination 
(Alpi et al., 2007). Interestingly, another E2 Ube2W, as well as Ube2T was shown to 
support the monoubiquitination of FANCD2 when paired with FANCL in an in vitro 
assay (Alpi et al., 2008). However, in contrast to Ube2T, Ube2W has not yet been 
demonstrated as part of the FA pathway in vivo.  
 
The same groups attempted to determine the molecular details of the FANCL-Ube2T 
interaction, based on the predicted structure of FANCL. Meetei et al demonstrated that 
FANCL’s PHD domain was sufficient for an interaction with Ubc4 in an in vitro pull-
down experiment (Meetei et al., 2003). Conversely, Alpi et al suggested the entirety of 
FANCL was required for the interaction (Alpi et al., 2008). As the structure of 
Drosophila FANCL revealed a different domain architecture to that predicted, 
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clarifying the molecular details of the FANCL-Ube2T interaction through additional 
biochemical and structural studies is required. Additionally, the FANCL-Ube2T 
interface could be a potential target of regulation of the FA pathway by therapeutics. 
 
The FANCL-Ube2T pairing has also been shown to autoubiquitinate FANCL (where 
FANCL is also the substrate) (Gurtan et al., 2006, Longerich et al., 2009, Alpi et al., 
2008, Machida et al., 2006). It is not yet understood whether autoubiquitination of 
FANCL occurs in vivo or what the potential function of autoubiquitination of FANCL is 
for. Interestingly, Ube2T has also been shown to autoubiquitinate itself both in vivo and 
in vitro (Machida et al., 2006, Alpi et al., 2008). In vivo Ube2T autoubiquitinates itself 
on Lys91, ~10Å from the catalytic cysteine (Fig.13) (Machida et al., 2006). Machida et 
al performed an in vitro FANCL autoubiquitination assay with Ube2T already 
autoubiquitinated at Lys91. They found that FANCL no longer becomes 
autoubiquitinated, concluding that Ube2T’s autoubiquitination at Lys91 hinders the 
catalytic activity of Ube2T and acts as a negative regulation mechanism (Machida et al., 
2006). Additional in vitro analysis revealed a second site of autoubiquitination that 
resides in Ube2T’s 43 amino acid C-terminal extension, predominately on Lys182 
(Machida et al., 2006, Alpi et al., 2008). However, Alpi et al report that mutation of the 
Lys91 to arginine and/or the deletion of the C-terminal extension does not affect 
FANCD2 monoubiquitination in vitro. The reasons for Ube2T autoubiquitination in 
vivo and its consequences for the FA pathway require further investigation. 
 
Ube2T has been structurally determined, revealing the typical UBC-fold for E2 
enzymes as described earlier in section 1.1.1.3. (Fig.13) (Sheng et al., 2012). 
Unfortunately, there was no observed electron density for the C-terminal extension. 
Therefore the structure and role of the C-terminal extension is still not understood. 
 





Revealing the molecular details and function of the FANCL-Ube2T pair through 
structural and biochemical work will be important for understanding the key event of 
the FA pathway, the monoubiquitination of FANCD2 and FANCI. Moreover, 
understanding the molecular details of this specific E3-E2 pair will help in the 
understanding of E2 selection by E3 ligases. 
 
 
1.1.2.4 Substrates of the Fanconi Anemia pathway, FANCD2 and FANCI 
The FA pathway substrates, FANCD2 and FANCI, are specifically monoubiquitinated 
by the FA CC on lysines 561 and 523 respectively, (Garcia-Higuera et al., 2001, Sims et 
al., 2007, Smogorzewska et al., 2007). Furthermore, FANCL is the member of the FA 
CC with E3 ligase activity and is independently capable of monoubiquitinating the 
substrates in vitro (Sato et al., 2012, Alpi et al., 2008).  
 
The importance for the specific monoubiquitination of FANCD2 was observed when a 
mutant FANCD2 Lys561Arg was unable to rescue FANCD2 knock out cells when 
Figure 13 Structure of Ube2T 
The structure of Ube2T (PDB code 1YH2). 
Ube2T adopts the typical UBC-fold of E2 
enzymes a 4-stranded β-meander (β1-β4) 
flanked by 2α helices (α1 and α2). The 
catalytic β-flap region is indicated with the 
catalytic cysteine86 indicated. Lysine91 is 
also labelled; this is the in vivo site for 
Ube2T autoubiquitination. 
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treated with cisplatin (an ICL agent) (Garcia-Higuera et al., 2001). Similarly, cells 
lacking a member of the FA CC that are sensitive to ICL treatment also lacked a 
monoubiquitinated form of FANCI (Smogorzewska et al., 2007). The first direct 
evidence that the FA pathway was involved in ICL repair came from a study using 
immunodepeleted FANCD2 and FANCI Xenopus egg extracts that were unable to 
repair a DNA plasmid containing ICL DNA damage (Knipscheer et al., 2009). 
Furthermore, the reintroduction of recombinant FANCD2 and FANCI and importantly 
their ability to be site specifically monoubiquitinated resulted in the repair of the ICL 
(Knipscheer et al., 2009). Collectively, these results indicate that the specific 
monoubiquitination of both the FANCD2 and FANCI proteins is the essential signal for 
the DNA repair of ICL damage. 
 
Interestingly, in-vitro ubiquitination assays using chicken proteins revealed that a 
mutant FANCD2 where the specific lysine563 was mutated to arginine was still 
monoubiquitinated by FANCL (Alpi et al., 2008, Sato et al., 2012). Importantly, Alpi et 
al demonstrated that the addition of FANCI to their in vitro assay resulted in site 
specific monoubiquitination of FANCD2 to lysine 563 (Alpi et al., 2008). Furthermore, 
the addition of FANCI also stimulated the monoubiquitination of FANCD2, without the 
requirement of FANCI being monoubiquitinated (Alpi et al., 2008). These results 
suggest that FANCD2 and FANCI exist and function as a complex.  
 
The existence of a FANCD2-FANCI complex is supported by earlier work, where 293T 
cells expressing a tagged FANCI was able to co-immunoprecipitate with endogenous 
FANCD2 (Smogorzewska et al., 2007). Additional siRNA knock down experiments of 
FANCI also showed a reduction in endogenous FANCD2, further supporting the idea of 
a FANCD2-FANCI complex (Smogorzewska et al., 2007, Sims et al., 2007).  
 
One study has looked at complex formation throughout the cell cycle by co-
immunoprecipitation experiments of FANCD2 and FANCI using Xenopus egg extracts 
(Sareen et al., 2012). They report that FANCD2 and FANCI exist as a weakly 
interacting complex for ~80% of the cell cycle. However, they also report that upon 
monoubiquitination of FANCD2 there is a decrease in the amount of FANCI interacting 
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with FANCD2 in complex. Additionally, the observation that FANCL binds the 
substrates individually, as shown by in vitro pull down experiments (Cole et al., 2010), 
and that the substrates can be monoubiquitinated individually (Alpi et al., 2008, Sato et 
al., 2012) supports the idea that FANCD2 and FANCI associate and dissociate from 
their role as a complex. 
 
Both FANCD2 and FANCI have sites that are phosphorylated. For FANCD2, the Chk1 
kinase phosphorylates Ser331, and the ATM and ATR kinases are responsible for 
phosphorylating Thr691 and Ser717 upon DNA damage (Zhi et al., 2009, Ho et al., 
2006). Both studies report that mutations of these sites to prevent their phosphorylation 
results in an increased sensitivity to ICL agents. However, only Ser331 phosphorylation 
is reported to be important for the monoubiquitination of FANCD2 in vivo (Zhi et al., 
2009). FANCI is also phosphorylated by the ATM and ATR kinases, stimulated by the 
presence of ICL DNA damage (Smogorzewska et al., 2007, Ishiai et al., 2008). The 
reported residues of FANCI that are phosphorylated are: Ser556, Ser559, Ser565, 
Ser617, Ser730, Thr952, and Ser1121. FANCI phosphorylation has been attributed to 
part of the activation of the FA pathway and a requirement for FANCI 
monoubiquitination (Ishiai et al., 2008). One study suggests that the phosphorylations, 
particularly of residues that cluster in the same region (Ser556, Ser559, Ser565 and 
Ser617) are a requirement for complex dissociation. Thereby allowing the subsequent 
monoubiquitination of FANCD2 and FANCI to occur (Sareen et al., 2012).  
 
The structures of the mouse substrates determined to a resolution of 3.4Å, reveal that 
FANCD2-FANCI exist as a complex in a 1:1 stoichiometery, in a non-PTM form 
(Fig.14) (Joo et al., 2011). The group also solved the structure of FANCI alone, again 
supporting the idea that the substrates are individual and come together to form a 
complex. The individual substrate structures from the complex superimpose with a root 
mean square deviation (rmsd) of ~1.7Å for ~82% of the residues, and are globally 
similar in structure, each taking on a saxophone-like shape (Fig.14) (Joo et al., 2011). In 
the complex structure, FANCD2 has a 59 amino acid region missing (residues 851-910) 
and the first 32 and last 35 amino acids missing from the N and C-terminus respectively. 
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Figure 14 Structure of substrate complex FANCD2 and FANCI 
Structure of the substrate complex of FANCD2 and FANCI (PDB code 3S4W). FANCD2 is 
coloured green and FANCI is coloured pink. The lysines that are specifically monoubiquitinated 
by FANCL are indicated as they are buried within the complex interface. 
 
 
Interestingly, the structure of the FANCD2-FANCI complex reveals both lysines on 
each respective substrate are buried within the ~7100Å2 complex interface (Fig.14) (Joo 
et al., 2011). Although there are small solvent channels leading to each of the lysines 
observed in the structure, how the FANCL-Ube2T pair can sufficiently access the 
lysines for ubiquitination remains unknown. The hypothesis that the phosphorylation of 
FANCI allows for the dissociation of the complex to access the lysines for 
monoubiquitination is appealing (Sareen et al., 2012). However, comparisons of the 
unbound FANCI structure and the complex structure reveal two points of interest for 
Chapter 1 Introduction 
 47 
the region that harbours the cluster of phosphorylation sites: i) the region in unbound 
FANCI is a disordered β-sheet, which undergoes a structural rearrangement to form 2 α-
helices when in complex with FANCD2. ii) the region is involved in the complex 
interface, with the suggestion that phosphorylation of these sites would aid the 
FANCD2-FANCI interaction (Joo et al., 2011).  
 
Additionally, the structure of mouse FANCI in complex with Y DNA has also been 
determined to a resolution limit of 7.8Å (Joo et al., 2011). Others have shown both 
FANCD2 and FANCI bind DNA, particularly double stranded DNA structures (Park et 
al., 2005, Longerich et al., 2009, Yuan et al., 2009). Substrate interactions with DNA 
has also been shown to stimulate the monoubiquitination events in vitro (Sato et al., 
2012). Whether the DNA aids in a conformational change for FANCL-Ube2T to access 
the lysines is not clear. A higher resolution structure will help test this hypothesis. 
 
The importance for the monoubiquitination of the substrates is clear. However the 
function of this specific PTM is not. Some suggest monoubiquitination stabilizes the 
substrates association to chromatin (Wang et al., 2004, Garcia-Higuera et al., 2001, 
Knipscheer et al., 2009). Others have shown it is required to recruit proteins involved in 
DNA repair such as the Fanconi Anemia associated nuclease 1 (FAN1) and DNA 
polymerase ν (POLN) through their UBD (Smogorzewska et al., 2010, Kratz et al., 
2010, MacKay et al., 2010, Moldovan et al., 2010). Moreover, FANCD2 has been 
shown to interact with the C-terminal portion of the downstream DNA repair protein 
FANCD1/BRCA2 in yeast 2-hybrid experiments without the requirement of 
monoubiquitination (Hussain et al., 2004). The functional reasons for the PTM of the 
substrates is still unclear and further work is required to understand the role for the 
monoubiquitination. 
 
There are many unanswered questions surrounding substrate monoubiquitination: Do 
the substrates dissociate? Do they undergo structural rearrangements? How does 
phosphorylation aid the monoubiquitination? What role does DNA play? These 
questions need to be addressed with further experimental work. 
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Thesis Aims 
At the heart of the FA pathway is the key monoubiquitination event of substrates 
FANCD2 and FANCI, required for the repair of ICL DNA damage. The E3 ligase 
responsible for the ligation of the ubiquitin moieties is FANCL, which is supported by 
the 6 other FA CC members in vivo. The basic requirements for an E3 ligase to achieve 
a ubiquitination event are: interactions with the substrates and the ubiquitin conjugated 
E2 enzyme. This is true for FANCL, where in vitro monoubiquitination assays have 
shown that FANCL incubated with the E2, Ube2T, and substrates is capable of carrying 
out the key monoubiquitination event of the FA pathway (Alpi et al., 2008, Sato et al., 
2012). However, the structural and molecular details that govern the interactions and 
mechanisms of Human FANCL are yet to be determined.  
 
Although the structure of Drosophila FANCL has been solved (Cole et al., 2010), the 
poor sequence conservation between Human and Drosophila FANCL suggests a 
difference in structure between the two species. Furthermore, the lack of an apparent 
FA CC in the Drosophila system compared to the absolute requirement for a FA CC for 
the monoubiquitination event, as seen in patients, again indicates the possibility of 
major structural differences. Therefore the main objective of this PhD project was: 
 
• To determine the structure of Human FANCL 
 
Furthermore, understanding the molecular details of FANCL’s many interacting 
partners is important for understanding its functional role as the FA pathways E3 ligase. 
Therefore the second aim of this PhD project was to use structure guided biochemistry 
to understand the FANCL complexes: 
 
• To determine the molecular details of FANCL’s interactions required for the key 
monoubiquitination event of the FA pathway. 
 
The following chapters detail the experiments and the results obtained, to fulfil these 
objectives.  
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Chapter 2. Materials & Methods 
This chapter describes the experimental methods used in this study to understand the 
molecular details of Human FANCL and its protein interactions. This chapter has been 
split into four sections, the molecular biology methods, the recombinant protein 
expression and purification methods, the biochemistry experiments and finally the 
crystallography and structural solution and analysis. 
 
Molecular Biology Methods 
The first part of the molecular biology methods describes the vectors used in this study, 
with an outline of the methodology employed to generate new vectors or alter existing 
ones. The second part follows, detailing the experimental procedures to generate the 
new constructs. 
 
2.1.1 Protein Expression Vectors 
2.1.1.1 Existing Vectors 
Some vectors used in this study had been previously established in the Walden Lab. 
These were the Champion™ pET SUMO (Invitrogen) vector containing DNA encoding 
the following proteins: Ube2t, Ube2t F63A mutant, Ube2t C-terminal deletion mutant 
(residues 1-154) and the human FANCL DRWD domain (residues 109-294) (Table 3). 
These constructs all have an N-terminal 6xHis-Smt3 (SUMO, S.cervisiae), affinity 
solubility tag encoded by the Champion™ pET SUMO vector. Additionally the pET 
RSF Duet-1 (Novagen) vector, containing DNA encoding the UbcH7 protein (Table 3) 
was also available. This vector was modified in the Walden Lab to contain a TEV 
protease cleavage site downstream of its 6xHis affinity tag.  
 
Additional to these existing vectors a variety of cloning methods were employed to 
generate new vectors for recombinant protein expression and are detailed below. 
Chapter 2 Materials and Methods 
 
 50 
2.1.1.2 Restriction Free Cloning (RF) 
Human FANCL domains, RING (residues 289-375) and DRWD-RING (residues 109-
375) were cloned from a synthetic DNA codon-optimized for E.coli expression 
(produced by GeneArt®) into the recombinant Champion™ pET SUMO vector (Table 
3). The Champion™ pET SUMO vector contains a 6xHis Smt3 affinity solubility tag. 
This vector was chosen due to its previous success in the Walden Lab as a good 
solubility tag and also because cleavage of the tag leaves no amino acids at the N-
terminus of the recombinant protein. Likewise the Xenopus tropicalis FANCL RING 
domain (residues 281-367) and Mouse Rbx1 were both cloned from I.M.A.G.E. clones 
(Geneservice) and were inserted into the recombinant Champion™ pET SUMO vector 
(Table 3). These constructs were all generated using a restriction free (RF) cloning 
method (van den Ent and Löwe, 2006). The first polymerase chain reaction (PCR) step, 
RF1, requires amplifying the domain/gene of interest from a DNA template. The 
primers for RF1 are designed so they anneal to the DNA to be amplified, with 25 base 
pair (bp) flanking regions. These flanking regions are complementary to the chosen site 
of insertion within the destination vector. The second stage, RF2 PCR, utilizes the 
amplified gene/domain PCR product from RF1 as a primer. This is due to the PCR 
product having these flanking regions at both its 5’ and 3’ end to anneal into the chosen 
site of the destination vector.  
 
2.1.1.3 Mutagenesis 
Human DRWD domain and Human RING domain mutants (Table 3) were generated 
using their corresponding wild type (WT) Champion™ pET SUMO vector as a 
template and the QuickChange® Site-Directed Mutagenesis (Stratagene) PCR method 
as per Stratagene guidelines. 
 
2.1.1.4 Generation of a Fusion Protein 
A fusion protein construct, human RING domain-linker-Ube2T, was used in this study 
to aid crystallization (Fig.15A).  







Figure 15 Schematic of the cloning for RING-Ube2T fusion construct  
A) A schematic of the fusion construct N to C-terminal RING (pink) with a linker region (blue) 
followed by Ube2T (green). B) The steps of cloning required for generating the RING-Ube2T 
fusion construct. Step 1 is the RF1 PCR of the FANCL RING domain using the pETSUMO-
RING vector as a template and RF1 designed primers indicated by arrows. The linear PCR of 
the RING DNA was then inserted into the pETSUMO-Ube2T vector in an RF2 PCR, step 2. 
The final stage, step 3, was to insert the linker region (blue). Primers (arrows, with the linker 
insertion residues represented as blue lines) were first phosphorylated (red dots). They were 
used in PCR to generate a linear piece of DNA, which was then ligated to form the final vector 
encoding the fusion protein. 
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The human RING domain (residues 289-375) was amplified in RF1 PCR to be inserted 
into the pET SUMO Ube2t vector, between the C-terminal of the SUMO affinity tag 
and the N-terminal of Ube2t during the RF2 PCR (Fig.15B step 1 and 2). A linker 
region was added (N-terminal, TGSTGSTETGYTQG, C-terminal) using Phusion Site 
Directed Mutagenesis (Thermo Scientific) PCR method. This mutagenesis method 
requires the phosphorylation of the primers first before the PCR, as the method 
generates linearized DNA. The linearized DNA can then be ligated together through the 
phosphorylation sites after the PCR to generate a closed plasmid (Fig.15B step 3). The 
primers were therefore designed so that the reverse primer annealed to the C-terminal of 
the RING domain, followed by the first 7 residues of the linker and the forward primer 
had the remaining linker residues followed by the primer annealing to the N-terminal of 
Ube2t. 
 
2.1.1.5 Gateway® Cloning Technology (Invitrogen) 
Previously in the Walden Lab Human Ubch5c had been cloned from an I.M.A.G.E. 
clone (Geneservice) into the pENTR™ TEV/D-TOPO® (Invitrogen) vector. This vector 
is for use with the Gateway® Cloning Technology (Invitrogen). This technology allows 
cloning the gene of interest into an entry vector (in this case pENTR™ TEV/D-TOPO® 
(Invitrogen)), which can then be used in simple recombination reactions with a variety 
of different destination vectors. The advantage of this method is compatibility with 
different expression systems, such as E.coli or insect cells, and vectors with a variety of 
different affinity and solubility tags.  
In order to express Ubch5c in E.coli, the recombination reaction was undertaken using 
the pENTR™ TEV/D-TOPO® (Invitrogen) vector containing Ubch5c and the 
pDEST17™ (Invitrogen) vector, using the LR Clonase® II enzyme mix (Invitrogen) 
following the manufacturer’s protocol. The resulting pDEST17™ vector contained a 
6xHis affinity tag followed by a TEV cleavage site upstream to the region encoding 
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DRWD (residues 109-294) pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli exsiting




6xHis-Smt3 SUMO Human Kanamycin E.coli SM
DRWD mutant V127A/Y128A pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli SM
DRWD mutant W212A/L214A pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli SM
DRWD-RING (residues 109-375) pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli RF
RING (residues 289-375) pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli RF
RING mutant W341A pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli SM
RING mut I309A pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli SM
RING mut Y311A pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli SM
Xenopus RING (residues 281-367) pET SUMO N-terminal 6xHis-Smt3 SUMO
Xenopus 
tropicalis Kanamycin E.coli RF
Rbx1 pET SUMO N-terminal 6xHis-Smt3 SUMO Mouse Kanamycin E.coli RF
RING-linker-Ube2t pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli RF & PM
Ube2t pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli exsiting
Ube2t mutant F63A pET SUMO N-terminal 6xHis-Smt3 SUMO Human Kanamycin E.coli exsiting
Ube2t mutant C-terminal deletion 
(residues 1-154) pET SUMO
N-terminal 
6xHis-Smt3 SUMO Human Kanamycin E.coli exsiting
UbcH7 pET RSF N-terminal 6xHis TEV Human Kanamycin E.coli exsiting
UbcH5c pDEST17 N-terminal 6xHis TEV Human Ampicillin E.coli Gateway
FANCD2 pDEST8 C-terminal 12xHis none Human Ampicillin Insect Cells
Gift from 
K.J. Patel
Xenopus FANCD2 pFastBac1 N-terminal FLAG none
Xenopus 





Xenopus FANCI pFastBac1 N-terminal FLAG none
Xenopus 









Table 3 Expression Vectors 
This table lists the vectors used in this study with their corresponding affinity tags, cleavage site, 
resistance gene, species for the gene/domain they encode and the expression system to generate 
the recombinant protein. The table also includes the method used to generate the vector, 
restriction free method (RF), Phusion site directed mutagenesis method (PM), QuickChange® 
Site-Directed Mutagenesis method (SM). J.M indicates Jennifer Miles of the Walden Lab 
undertook this work. 
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2.1.2 Experimental Procedures for PCR and Cloning Validation 
2.1.2.1 Polymerase Chain Reaction (PCR) 
DNA amplification for each construct was done using PCR. PCRs were carried out in 
thin-walled PCR tubes (Eppendorf) with a final reaction volume of 50µl. The reactions 
contained 5-50ng/µl template DNA, 0.16µM primer, 1mM deoxynucleotide 
triphosphates (dNTPs), 1x associated enzyme buffer, enzyme and for the RF protocol 
3% Dimethyl Sulphoxide (DMSO). The following enzymes were used depending on the 
PCR method employed: 0.1 unit (per reaction) of Phusion® High-Fidelity DNA 
polymerase for RF and Phusion Site-Directed mutagenesis methods and 2.5 units (per 
reaction) of PfuTurbo® DNA polymerase (Agilent Technologies) for QuickChange® 
Site-Directed Mutagenesis method. Details of temperature and cycling are in Table 4.  
 
Step Temp (oC) Time (seconds) No. of Cycles 
 RF PM SM RF PM SM RF PM SM 
Initial 
Denaturing 95 98 95 30 1 
Denaturing 95 98 95 30 10 30 
25-30 25-30 18 Annealing 55 65-72 55 60 30 60 
Extension 68 72 68 120/Kb 120/Kb 60/Kb 
Final 
Extension - 72 - - 
5-10 
minutes - 1 
Hold 4 Hold 1 
  
Table 4 Cycles for PCR methods 
The table outlines the different cycle programs used for the different PCR methods employed, 
restriction free cloning (RF), Phusion Site Directed Mutagenesis (PM) and QuickChange® Site-
Directed Mutagenesis (SM). Kb is the total amount of base pairs of the plasmid and PCR insert. 
 
Successful PCR reactions were assessed by gel electrophoresis on a 1% (w/v) DNA 
agarose gel in Tris Acetate Ethylenediaminetetraacetic acid (EDTA) (TAE) buffer (see 
Appendix A) and visualized by ultraviolet (UV) light. For successful RF1 PCR, the 
reaction required PCR clean up using the QIAquick PCR Purification Kit (Qiagen) 
following the manufacturer’s guidelines before proceeding to RF2. 10µl of all other 
PCRs were incubated with 20 units of Dpn1 enzyme (New England BioLabs) in 0.3ml 
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eppendorf tubes for 2-3 hours at 37oC, in order to remove template methylated DNA 
before transformation. Linearized DNA generated by the Phusion Site Directed 
Mutagenesis (Thermo Scientific) method required ligating to form a closed plasmid 
before transformation. DNA ligation was carried out by incubating 5µl of the DpnI 
treated PCR with 1x Quick Ligase Reaction buffer and 2.5 units of T4 DNA ligase 
(both from the Rapid DNA Ligation kit, Roche) in a 0.3ml eppendorf tube for 5 minutes 
at room temperature.  
 
2.1.2.2 Transformation 
Selection for modified plasmids was carried out by transforming 50µl of MAX 
Efficiency DH5α Competent Cells (originally from Invitrogen), made in the Walden lab, 
with 5µl of the DpnI/DpnI-ligated PCR. Cells and DNA were incubated on ice for 15 
minutes in 1.5ml Eppendorf tubes, followed by 45 second, 42oC heat shock and then 
replaced back on ice for 2 minutes. 300µl of Super Optimal with Catabolite repression 
media (SOC, produced by the LIF Cell Services) was added and cells were incubated at 
37oC, 180rpm for 45 minutes to 1hour. Transformed cells were then plated onto 
Lysogeny Broth (LB) agar plates with correct antibiotic selection (Table 3, for 
antibiotic preparation and concentration see Appendix A) and incubated overnight at 
37oC. 
 
2.1.2.3 Cloning Validation 
For successful PCR and transformations, colonies were observed on the LB agar plates. 
To ensure the correct modifications had occurred to the plasmids their DNA was 
amplified and sequenced. For DNA amplification colonies from LB agar plates were 
picked and grown overnight in 5mls of LB with correct antibiotic selection (Table 3) in 
14ml round bottom falcons (BD Falcon) at 37oC, 180rpm. DNA extraction was carried 
out using QIAprep Spin Miniprep kit (Qiagen) according to the manufacturer’s 
guidelines and plasmids were stored at -20oC. 
DNA plasmids were sequenced using BigDye® terminator mix v3.1 (BDT, Applied 
Biosystems) PCRs containing 150-200ng of DNA, 3.2pM of sequencing primer, and 
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8µl of BDT (from a 1 in 16 stock dilution) in a total reaction volume of 20µl in 0.3ml 
Eppendorf tubes. Reactions were subsequently placed in a thermal cycler (GS1, G-
Storm or TC-312, Techne) following the program in Table 5. The sequencing reactions 
were cleaned up using 2μl of 125mM EDTA, 2 μl of 3M sodium acetate, and 50μl of 
100% Ethanol. Reactions were vortexed briefly and left at room temperature for 15 
minutes. The reactions were then centrifuged for 30 minutes at 15,700rcf (Centrifuge 
5415D, Eppendorf) to pellet the DNA products. The supernatant was removed and the 
DNA pellet washed by adding 70μl of 70% ethanol and repeating the pelleting process 
by centrifugation. The supernatant was removed and the reactions were left to air dry to 
ensure all ethanol had evaporated. The LIF equipment park carried out the DNA 
sequencing using the Applied Biosystems 3730xI DNA Analyser. Sequences of the 




Step Temp (oC) Time (seconds) No. of Cycles 
Initial Denaturing 96 60 1 
Denaturing 96 10 
24 Annealing 55 5 
Elongation 60 4 minutes 
Hold 4 Hold 1 
  
Table 5 Cycles for Sequencing PCR 
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Protein Expression and Purification 
This section describes the methods to express and purify the recombinant proteins for 
the subsequent crystallography and biochemical studies in this project. 
 
2.1.3 E.coli Protein Expression and Extraction 
The following sections describe the methods to express and extract recombinant 
proteins using the bacterial expression system E.coli. The recombinant proteins, Human 
FANCL DRWD, RING and DRWD-RING domains, and their corresponding mutants, 
as well as the E2s (Ube2t, Ube2t mutants, UbcH5c and UbcHc7), mouse Rbx1 and 
Xenopus tropicalis RING domain were all expressed in E.coli.  
 
2.1.3.1 E.coli Growth and Harvesting 
Typically crystallography and in-vitro biochemistry require large amounts of 
recombinant protein. This study was no exception, with most of the recombinant 
proteins requiring preparations between 4 and 12 litres of E.coli at a time. 
 
To generate the E.coli cultures, 50µl of BL21 cells (made in the Walden lab, originally 
from Invitrogen) were transformed with 150ng-200ng of the desired protein expression 
plasmid (Table 3, see transformation protocol above page 55). Transformed cells were 
placed into a 250ml conical flask containing 100ml of LB media supplemented with the 
plasmid selection antibiotics (Table 3, for concentrations and antibiotic preparation see 
Appendix A) and incubated overnight at 37oC at 180rpm. The large-scale E.coli 
recombinant protein expression was carried out in 2L conical flasks containing 1L of 
LB media, supplemented with the plasmid selection antibiotics (Table 3), and in the 
case of constructs containing RING domains, 0.5mM ZnCl2 pH 1. Each 2L flask was 
inoculated with 5mls of overnight culture and incubated at 37oC at 180rpm. After 2 
hours the optical density at 600nM (OD600nM) was checked to ensure the E.coli had 
entered a log growth phase. Once the OD600nM had reached 0.6-0.8 (approximately 3-5 
hours) the temperature was reduced to 16oC. Protein expression was induced by the 
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addition of 250µM Isopropyl β-D-1-thiogalactopyranoside (IPTG, Calbiochem). In the 
case of the E2s (Ube2t, Ube2t mutants, UbcH7 and UbcH5c) expression was induced 
with 500µM IPTG. The cells were cultured overnight at 16oC, 180rpm. 
Cells were harvested by centrifugation at 4000rcf for 20 minutes at 4oC, (J6MC 
centrifuge, Beckman Coulter). 
 
All the remaining stages for protein extraction and purification were carried out on ice 
or at 4oC.  
 
2.1.3.2 E.coli Cell Lysis 
Cells were lysed by re-suspending the E.coli pellets in lysis buffer containing 0.5M 
NaCl, 0.1M Tris pH 8, 20mM imidazole and 250µM tris(carboxyethyl)phosphine 
(TCEP), supplemented with c0mplete EDTA-free protease cocktail inhibitor tablets 
(Roche, 1tablet for every 50ml of lysis buffer). Each litre of pelleted E.coli cells, was 
resuspended in 5mls of lysis buffer. The cells were further disrupted by sonication on 
ice. 30mls aliquots of re-suspended cells were sonicated for 10 seconds, repeated 4-6 
times with breaks of 30 seconds in between. Removal of cell debris was achieved 
through high-speed centrifugation at 32,000rcf for 45 minutes at 4oC (Allegra™64R, 
Beckman Coulter). The lysis supernatant containing soluble proteins was retained for 
batch affinity purification (see below page 60). 
 
2.1.4 Insect Cell Protein Expression and Extraction 
Insect cells were used to express the following recombinant proteins, the FA pathway 
substrates: Human His-FANCD2 and Xenopus laevis FLAG-FANCI and FLAG-
FANCD2, and the mouse E1 enzyme His-UBE1. 
The human His-FANCD2 contained a C-terminal 12xHis affinity tag and was a kind 
gift from M. R. Hodskinson and K. J. Patel (Pace et al., 2010). The Xenopus laevis 
substrates FLAG-FANCI and Strep-FANCD2 (affinity tags were N-terminal to the 
protein) were encoded in the pFastBac1 (Invitrogen) plasmid and were kind gifts from P. 
Knipscheer and J. C. Walter (Knipscheer et al., 2009). Jennifer Miles modified the 
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Xenopus laevis pFastBac1 (Invitrogen) Strep-FANCD2 to replace the Strep-tag with a 
FLAG tag. Jennifer Miles also carried out the Bacmid transposon reactions for the 
substrate proteins in order to generate baculovirus to infect the insect cells. The mouse 
His-UBE1 virus was a kind gift from K. Iwai (Sato et al., 2008). The LIF Protein 
Production Facility generated, amplified and titered all baculoviruses used in this study. 
 
2.1.4.1 Insect Cell Growth and Harvesting 
Insect cells were split every 3-4 days and split to approximately 2 x 106 cells. Cells 
were cultured in sf-900™ Serum free media (Gibco) supplemented with 10µg/ml of 
gentamycin and kept at 27oC at 120rpm in 2L roller bottles. Either sf9 or Hi5 insect 
cells were used to generate the recombinant proteins, by infection with baculovirus. 
Typically 1-2 litres of recently split (an hour before) insect cells with a cell count of 
approximately 2 x 106 were infected with a multiplicity of infection (MOI) of 0.1. MOI 
was calculated by the following equation: 
(MOI x volume of cells (mls) x (cell count))/virus titre 
 
The cells were incubated for 3 days at 27oC and a further day at 16oC to express the 
recombinant proteins and on the 4th day turned down to 16oC. Cells were then harvested 
by centrifugation at 1500rcf at 4oC for 15 minutes using the J6MC centrifuge (Beckman 
Coulter). The supernatant was discarded. 
 
2.1.4.2 Insect Cell Lysis 
The insect cell pellets were re-suspended in ice-cold lysis buffer containing 50mM Tris 
pH 8, 100mM NaCl, 0.5mM PMSF, 1mM EDTA and EDTA-free protease cocktail 
inhibitor tablets (Roche, 1 tablet for every 50ml of lysis buffer) for the Xenopus laevis 
FLAG-FANCI and FLAG-FANCD2, and the mouse His-UBE1. For the human His-
FANCD2 the lysis buffer contained 20mM Tris pH 8, 500mM NaCl, 10% glycerol, 
10mM BME, 10mM imidazole, 0.1% X-100, and 1mM PMSF.	  Each litre of pelleted 
cells was resuspended in 25mls of lysis buffer. Sonication was carried out on ice and 
each 25ml of re-suspended insect cells were sonicated 2x for 5 seconds. Cell debris was 
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then removed by centrifugation at 32,000rcf for 45minutes at 4oC (Allegra™64R, 
Beckman Coulter). The lysis supernatant containing soluble proteins was retained for 
batch affinity purification. 
 
2.1.5 Batch Affinity Purification 
All recombinant protein constructs contained an affinity purification tag to allow 
extraction from all other soluble proteins contained in the lysis supernatant. In order to 
extract the desired recombinant protein, a column matrix of Ni-NTA Agarose (Qiagen) 
was used for the His affinity tag and FLAG Agarose (Sigma) for the FLAG affinity tag. 
The agarose was first equilibrated in lysis buffer (all stages using lysis buffer from now 
onwards did not contain protease inhibitor tablets) and subsequently the lysis buffer was 
removed by centrifugation at 1000rcf at 4oC (Allegra™ X-22R, Beckman Coulter) and 
discarding the supernatant. The lysis supernatant containing the soluble proteins from 
the final stage of cell lysis was then added to the equilibrated agarose and placed on a 
roller at 4oC for at least 1 hour. For quantities of agarose used for the different 
constructs see Table 6.  
 
Unbound protein was removed by centrifugation at 1000rcf at 4oC for 10 minutes. The 
lysis supernatant was then discarded leaving the agarose with the bound affinity tagged 
recombinant proteins. The agarose was re-suspended in lysis buffer and placed on a 
gravity column. Additional lysis buffer, 10mls for each column volume (cv), (where 
1cv is 1ml of agarose used), was added to the column to further wash off any impurities. 
A final wash step followed by adding 10mls/cv of wash buffer to the gravity column 
(see Table 6 for specific construct wash buffers). 
 
 

































































































































































































































































































































































































































































































































































































































































































































Table 6 Protein Purification Table 
Approximate yield, is the final amount of protein yield after purification per litre of cultured 
cells. 
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2.1.6 Protein Purification 
Homogenous protein samples are essential for the techniques of crystallography and in-
vitro biochemistry. To achieve such samples, on column cleavage or stepwise elution 
and cleavage were carried out on the agarose bound recombinant proteins. As the final 
destination for the proteins required purity, it was also important that the proteases used 
were also highly purified (see Appendix C for protease expression and purification). A 
‘final polishing’ step to ensure for a highly purified protein sample was carried out by 
size exclusion chromatography. 
 
Where possible, recombinant proteins were released from their affinity tag by on 
column (agarose) cleavage. This method yields a purer sample by keeping any protein 
impurities bound to the agarose, on the agarose. The human FANCL DRWD and RING 
domains and their corresponding mutants, Ube2t and its mutants, Xenopus tropicalis 
FANCL RING domain, Mouse Rbx1 and the RING-linker-Ube2t proteins all underwent 
on column cleavage to remove their 6xHis-Smt3 tag with purified Ulp1 protease.  
For on column cleavage the washed agarose was re-suspended in 5-10mls of wash 
buffer (see Table 6 for wash buffer for different constructs) and placed in a 15ml falcon 
tube (BD Bioscience). To remove the 6xHis-Smt3 tag purified Ulp1 protease was added 
at a ratio of 1:15 (Ulp1: recombinant tagged protein w/w) to the 15ml falcon tube and 
left overnight on a roller at 4oC. A typical 12-litre Human DRWD prep yielded 
approximately 12mg of protein to which 1mg of Ulp1 protease was added. The 
following day the agarose was re-suspended and placed down a gravity flow column 
and the flow through containing the cleaved recombinant protein was collected. A wash 
step followed, where 2cv of wash buffer was placed down the gravity column and the 
flow-through collected. This step was repeated once more. The flow-throughs were 
pooled for the next stage of purification by size exclusion chromatography (see page 
65). 
 
For other constructs where on column cleavage was not appropriate or the affinity tag 
was to be retained, the recombinant proteins were eluted from the agarose with elution 
buffer (see Table 6 for specific construct elution buffer). In the case of His affinity tags 
imidazole was used as the eluent and for FLAG affinity tags the FLAG peptide (3xFlag 
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MDYKDHDGDYKDHDIDYKDDDDK, produced by the LIF Peptide Synthesis 
Service) was used as an eluent. Elutions were carried out by adding 2cv of elution 
buffer to the agarose in the gravity column, re-suspending the agarose and then leaving 
the agarose to settle. Once settled, the flow through containing the eluted protein was 
collected. This was repeated once more and the elutions pooled. In the case for the 
human His-FANCD2 protein, it was eluted in a stepwise gradient with 100mM-500mM 






After the stepwise elution the cleanest fractions for the Human His-FANCD2 protein 
assessed by reducing 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS PAGE gel, see Appendix B) were pooled and dialyzed (see page 64) before the 
protein was flash frozen in liquid nitrogen and stored at -80oC.  
Xenopus laevis FLAG-FANCI and FLAG-FANCD2 proteins and the mouse His-UBE1 
were eluted and left with the affinity tag attached. The Xenopus laevis FLAG-FANCI 
and FLAG-FANCD2 proteins were concentrated to between 1mg/ml and 3mg/ml using 
Centriprep Centrifugal Filter Unit (Amicon) then flash frozen in liquid nitrogen and 
stored at -80oc. The mouse His-UBE1 was further purified by size exclusion 
chromatography (see below page 65).  
Figure 16 Human His-FANCD2 
Elution Gel 
A 12% Reducing SDS PAGE gel 
showing the stepwise elutions of 
Human His-FANCD2. Elution’s 
containing 0.25M-0.5M imidazole 
were pooled and dialyzed. 
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The E2s UbcH5c and UbcH7 were cleaved from their affinity tag using TEV protease. 
In order to remove the 6x His affinity tag required using purified His-TEV protease (see 
Appendix B for detailed protease expression and purification). Additionally the human 
FANCL DRWD-RING construct was eluted rather then cleaved on column because the 
mw of the DRWD-RING construct (30kDa) was similar to Ulp1 protease (25kDa) mw, 
which could not be separated by further purification using size exclusion 
chromatography. Therefore a purified His-Ulp1 protease (see Appendix C for detailed 
protease expression and purification) that could later be separated by binding to Ni-
NTA agarose was used at a 1:15 (w/w, protease/DRWD-RING) for the human DRWD-
RING construct.  
For the eluted constructs that required tag removal, cleavage of the tag was carried out 
during a dialysis step to remove the imidazole from the buffer to allow for the later re-
binding of His tagged proteases to Ni-NTA agarose. The elutions and the appropriate 
protease (1:15 w/w of protease to recombinant protein) were placed in pre-equilibrated 
dialysis tubing (Spectra/Por®) with a mw cut-off 6-8,000 Da. The dialysis tubing was 
placed in a 2L plastic beaker containing pre-chilled (to 4oC) dialysis buffer (see Table 
6). A magnetic stirrer was used to gently stir the dialysis buffer overnight at 4oC. The 
following day Ni-NTA agarose was equilibrated in dialysis buffer and the eluted 
proteins containing the His-tagged proteases were added and left on a roller at 4oC for 
30 minutes to 1 hour. To collect the recombinant protein the agarose was re-suspended 
and placed down a gravity column and washed as described above for the on column 
cleaved constructs. 
 
All proteins were further purified by size exclusion chromatography except for the 
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2.1.7 Size Exclusion Chromatography 
As stated above, successful crystallization and in-vitro biochemistry depends on the 
purity and homogeneity of the protein sample. Therefore size exclusion 
chromatography was employed after on column cleavage or elution from agarose, as an 
additional purification step.  
 
The protein was concentrated as far as possible using a Centriprep Centrifugal Filter 
Unit (Amicon). The Centriprep Centrifugal Filter Units come in different MW cut-offs. 
Therefore depending on the protein construct made, different units were required. The 
molecular cut-off generally used was half that of the MW of the protein being made 
(see Table 6 for MW). The concentrated protein was then centrifuged at 15,700rcf at 
4oC for 5 minutes and filtered to remove any dust or protein aggregate before loading 
onto a size exclusion chromatography column. Either a Superdex 75 16 60 column (GE 
Healthcare) or Superdex 200 26 60 column (GE Healthcare) was first equilibrated into 
the final protein buffer (see Table 6) and then used for the final protein purification step 
(Fig.17, 18 and 19). The fractions were collected and analysed by SDS PAGE to 
ascertain protein purity (Fig.17, 18 and 19). Proteins were visualized by Coomassie 
Brilliant Blue staining (see Appendix B). Pure protein fractions were pooled and 
concentrated again using the Centriprep Centrifugal Filter Units and if required the 
Vivaspin concentrators for smaller volumes. 
 
Concentrated purified recombinant proteins were then used in crystallization trials or 
flash frozen in liquid nitrogen and stored at -80oC. 
 
All recombinant proteins were verified for their protein identification by mass 











Figure 17 Purification of E2s 
Chromatograms from size exclusion chromatography and SDS PAGE of purified E2s. 





Figure 18 Purification of E1 and other E3 domains 
Chromatograms from size exclusion chromatography and SDS PAGE of purified E1 enzyme 
(His-UBE1) and the RING protein Rbx1. 
 




Figure 19 Purification of FANCL domains 
Chromatograms from size exclusion chromatography and SDS PAGE of purified human 
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 Biochemistry Methods 
This section details the biochemistry experiments undertaken in this project. 
 
2.1.8 Protein Interaction Assays 
In order to assess protein-protein interactions a variety of in vitro biochemistry 
techniques were used, and are detailed below. 
 
2.1.8.1 Analytical Size Exclusion Chromatography (ASEC) 
ASEC was used to identify potential protein-protein interactions by assessing complex 
formation using size exclusion chromatography. 10-30µM of the potential interacting 
proteins were incubated on ice in interaction buffer containing 0.1M NaCl, 0.1M Tris 
pH8, and 250µM TCEP (in the case of interactions with human FANCL DRWD 
domain 0.5M NaCl was used), for at least 1hour in a final reaction volume of 500µl. 
The protein sample was then loaded onto a Superdex 75 10 300 column (GE 
Healthcare) and 0.5ml-1ml fractions were collected. Chromatogram peaks 
corresponding to a larger molecular weight species indicated protein complex formation. 
The proteins in the peak fractions were assessed with reducing SDS PAGE (see 
Appendix A) and stained with Coomassie Brilliant Blue (see Appendix B for recipe). 
When testing more then two interacting proteins using this method, the peak fractions 
were run on 4-12% SDS PAGE (Invitrogen) and stained with SimplyBlue™ SafeStain 
(Invitrogen) as per the manufacturer’s guidelines. The protein bands were analysed by 
mass spectrometry (LIF Protein Analysis and Proteomics facility) to identify the 
interacting proteins. 
 
2.1.8.2 Isothermal Titration Calorimetery (ITC) 
ITC was used to identify potential protein-protein interactions and to calculate the 
dissociation constant and stoichiometery of interactions already established by ASEC. 
Proteins were buffer exchanged using Micro Bio-Spin® Chromatography Columns 
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(Bio-Rad) following the manufacturer’s guidelines into the same buffer to ensure heat 
changes were not caused by buffer differences. Proteins samples were then subjected to 
filtering through Centrifugal Filter Units (Millipore) to remove any dust or aggregated 
particles. Once the protein samples were ready their final concentration was assessed 
using the proteins MW and extinction coefficient (EC) (Table 6) calculated by the 
ExPASy ProtParam software (http://www.expasy.ch/tools/protparam.html) and a 
NanoDrop® ND-1000 UV-Vis spectrophotometer at wavelength 280nm. Samples were 
loaded into the iTC200 microcalorimeter (Microcal, Northampton, MA). 205µl of 
protein was loaded into the cell and a total of 40µl of interacting protein was titrated by 
2.5µl injections from the syringe with a delay between injections of 4 seconds. Injection 
volumes of the titrant were optimized in order to produce enough data points to 
accurately calculate affinity constant and stoichiometery. Additionally, the time delay 
between injections was optimized to ensure a return to a steady-state baseline before the 
next injection. All experiments were carried out at 8oC with the recommended stirring 
speed of 1000rpm as per Microcal guidelines. For specific protein interaction 
experiments see Table 7 for protein concentrations and interaction buffers used. 























Table 7 ITC Protein-Protein Interactions 
This table shows the protein-protein interactions assessed by ITC and the interaction buffers 
used along with protein concentrations. 
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2.1.8.3 In vitro Pull Down Assay 
In vitro pull downs were used to assess human FANCL’s interactions with substrates 
FANCD2 and FANCI. 225nM of either Xenopus laevis FLAG-FANCI or human His-
FANCD2 proteins were incubated with excess (454nM) human FANCL DRWD 
domain or human FANCL DRWD domain mutants. Interactions were carried out in a 
total reaction volume of 1ml in interaction buffer containing 0.5M NaCl, 0.1M Tris pH8, 
250µM TCEP in 1.5ml eppendorf tubes. The reactions were left on a roller at 4oC for 1 
hour, then incubated with either 100µl of equilibrated anti-FLAG affinity gel (sigma) or 
100µl of Ni-NTA agarose (Qiagen) respectively and left again on the roller at 4oC for 1 
hour. Samples were then placed down gravity flow columns and washed with 10mls of 
interaction buffer. The resin/agarose was then re-suspended in 100µl of interaction 
buffer and had 50µl of 2x SDS buffer added and boiled for 2 minutes. 9µl of each 
sample was then loaded onto a 4-12% SDS PAGE gel (Invitrogen) and run using 
NuPAGE® MOPS buffer (Invitrogen) and subjected to western blotting analysis (see 
below page 73) to ascertain protein interactions. 
 
2.1.9  Protein Function Assays 
In order to assess FANCL’s function as an E3 ligase ubiquitin in vitro assays were used 
and are described below. 
 
2.1.9.1 Ubiquitin Thioester Charge Assay 
A ubiquitin thioester charge assay was used to assess the ability of the human FANCL 
DRWD domain to form a thioester bond between one of its cysteines and the C-terminal 
tail of ubiquitin. The total reaction volume was 10µl containing 2µM of protein to be 
assessed for thioester formation (His-Ubch7 (Boston Biochem) or human DRWD 
domain), 150nM E1 (Boston Biochem), 5mM ATP (Sigma), 50µM HA-Ub (Boston 
Biochem) in thioester charge reaction buffer; 50mM Tris pH 8, 250mM NaCl, 5mM 
MgCl2, 2mM dithiothreitol (DTT) in 0.3ml eppendorf tubes. Reactions were left for 30 
minutes at room temperature (~25oC) and terminated by adding 30µl of 2x non-reducing 
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SDS gel loading buffer (see Appendix A) to give a final volume of 40µl. From this 40µl, 
20µl of each reaction was taken and placed in a separate 0.3ml eppendorf tube and had 
1µl of 2M β-Mercaptoethanol (BME) added to reduce any thioester bond formation. To 
assess thioester formation 4µl of each sample (both non-reduced and reduced) were 
loaded onto 4-12% SDS PAGE and run using NuPAGE® MOPS buffer and assessed by 
western blot analysis using an HA antibody and an Human FANCL antibody (see 
western blot methods below page 73 and Table 8). 
 
2.1.9.2 In vitro Monoubiquitination Assay 
In order to determine the specific requirements for substrate monoubiquitination of 
FANCD2, in vitro monoubiquitination assays were used. Reactions were carried out in 
0.3ml eppendorf tubes containing 17nM His-UBE1, 0.64µM E2, 1.86µM E3, 4.2µM 
HA-Ub (Boston Biochem), 2mM ATP (Sigma), 0.5µM substrate and reaction buffer 
(50mM Tris pH7.5, 100mM KCl2, 2mM MgCl2, 0.5mM DTT) to a final volume of 25µl 
and were left at room temperature for 1.5 hours. Reactions were terminated by the 
addition 25µl of 4x NuPAGE® lithium dodecyl sulphate (LDS) buffer (Invitrogen) 
containing BME (460µl of 2x LDS and 40µl 14.3M BME) and boiling for 2 minutes at 
100oC in a heat block. 5µl of each reaction were then loaded onto a 4-12% SDS PAGE 
and ran for 60 minutes at 160V using NuPAGE® MOPS buffer. To analyse the 
monoubiquitination of the substrate western blot analysis probing for HA-Ub using an 
HA antibody was used (see western blot analysis below and Table 8). 
 
2.1.9.3 Western Blot Analysis 
For western blot analysis, proteins were transferred from SDS PAGE (Invitrogen) gels 
onto either polyvinylidene fluoride (PVDF) or Nitrocellulose (NC) membranes (iBlot® 
Gel Transfer Stacks, Novex, see Table 8) using the iBlot® Dry Blotting system 
(Invitrogen). The subsequent blocking, washing and antibody binding steps were carried 
out on a rocker. Membranes were blocked overnight using blocking buffer containing 
5% (w/v) milk, 150mM NaCl, 20mM Tris pH 8 and 0.1% Tween20 (Sigma) at 4oC. The 
following steps were all carried out at room temperature (~25oC). The next day the 
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blocking buffer was discarded from the membrane and 20mls of blocking buffer 
containing primary antibody was added for 1 hour. Once incubated the primary 
antibody was removed and the membrane washed by adding 20mls of blocking buffer 
for 5 minutes then discarded, and repeated twice more. The secondary horseradish 
peroxidase (HRP) antibody was added to the membrane in a total of 20mls of blocking 
buffer for 1 hour and the wash step repeated. For specific antibody concentrations and 
secondary antibodies used see Table 8. 
To develop the membrane Amersham ECL Western Blotting Detection Reagents 
(Ubiquitin thioester charge assay and in vitro pull down assay) or Amersham ECL 
Prime Western Blotting Detection Reagents (in vitro monoubiquitination assay) were 
added to the membrane according to manufacture’s protocol for 5 minutes on the rocker. 
The membrane was then carefully dried of excess liquid using paper towels and then 
wrapped in saran wrap and placed in a developing cassette. The membrane was then 

























HRP Abcam, ab49763 1 in 4,000 none none
Anti-HA LIF, Cell Services 1 in 10,000











Table 8 Antibodies 
This table lists the antibodies used in this study, their dilutions, where they were purchased, the 
host species in which they were produced and their corresponding secondary antibodies. The 
table also lists the type of membrane the antibodies prefer, either PVDF or nitrocellulose (NC). 
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 Crystallography and Structure Solution 
This section details the methods used for crystallizing the human FANCL domains as 
well as the software for structure solving. 
 
2.1.10 Protein Crystallization 
Crystallization of a protein can itself be a bottleneck in a structural project. This is 
because each protein has a different chemistry, requiring a different set of parameters to 
precipitate the protein into an ordered solid state – a crystal! There are many parameters 
that can be varied, such as the protein concentration, the type of precipitant, amount of 
the precipitant, the initial buffer of the protein itself, the ratio of protein to precipitant 
(well solution), pH, and temperature.  
 
For this study a typical initial crystallization screen used 4-6 commercially available 
sparse matrix screens (Table 9), testing two protein concentrations (typically 10mg/ml 
and 20mg/ml), resulting in a total of 597-1152 conditions tested. These crystallization 
experiments were vapour diffusion experiments that equilibrate overtime. Therefore all 
597-1152 conditions had to be checked regularly for crystal hits. 
 
Initial vapour diffusion crystallization screens were set up with recombinant protein 
directly after concentration from size exclusion chromatography. 95µl of each condition 
in a sparse matrix screen (Table 9) were dispensed into a 96 well MRC 2 drop tray 
(Molecular Dimensions) using a Matrix Hydra (Thermo Scientific). 0.2µl of protein and 
well solution drops were dispensed as sitting drops using a Mosquito® (TTP Labtech). 
The tray was then sealed and stored at 4oC for equilibration. Trays were checked at 4oC 
using a Nikon SMZ1000 light microscope daily for the first week and then every other 
day for the subsequent fortnight and then intermittently for the next 2-4 weeks.  
 





















Table 9 Crystallization Screens 
 
Where crystal hits were observed crystal conditions were optimized to produce larger 
and better diffracting crystals. Typical optimization trials also required optimizing the 
protein concentration resulting in a total of 480 conditions in the case to find the best 
diffracting crystal for the human DRWD domain. Optimization trays were again vapour 
diffusion experiments at 4oC but using hanging drop rather then sitting drop. The trays 
were designed as a 24 well format (trays from Hampton Research) and the well 
solutions were made individually and pipetted by hand. The tray was then left to cool to 
4oC before the 2µl drops were set up at 4oC on glass coverslips and placed over the 
corresponding well. All optimization trays were checked by eye as described previously 
using a light microscope. 
 
Once crystals had grown they were then prepared to take to a synchrotron radiation 
source. Crystals were picked by hand at 4oC using a range of MiTeGen loops. The 
crystals were then transferred into cryo-protectant for 1 minute and cryo-cooled using 
liquid nitrogen. The crystals were then transferred into cryo-cooled Unipucks ready to 
take to the synchrotron. 
 
When possible an in house x-ray source was used to determine the diffraction quality of 
the crystal as well as determine whether it was a protein crystal. 
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For a crystal to diffract there must be constructive interference from the scattered x-rays. 
The conditions required for diffraction from a crystal are described by Bragg’s Law, nλ 
= 2dsinθ. Bragg’s Law treats the scattered x-rays as if they were reflected from a set of 
parallel planes (denoted with miller indices (h, k, l)) within the crystal (Fig.20). For 
constructive interference of the scattered x-rays to occur, the path difference BC + CD 






Figure 20 Schematic of Bragg’s Law 
The dashed black lines represent planes of atoms in the crystal with the atoms represented by 
black dots. The distance between the planes is given the notation d. Blue lines represent the x-
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2.1.11 Structure Solution 
This section gives an overview of the methods used for structure solution, which will be 
discussed in more detail in the results chapters. 
 
2.1.11.1 Data Collection and Processing 
The structures solved in this project had data collected at Diamond Light source 
synchrotron radiation source on beamlines I24 and I03. Many crystals were screened in 
a range of different cryoprotectants for each crystallization project. This was to 
minimize radiation damage to ensure the highest possible resolution was obtained and a 
full complete dataset. 
Data collection strategies were determined at the beamline by analysing and indexing 
the initial test shots using Mosflm (Leslie and Powell, 2007) or the automated pipeline 
EDNA (Incardona et al., 2009). 
Before structure solution could take place all datasets were processed using Mosflm 
(Leslie and Powell, 2007) for the human DRWD data and D*trek (Pflugrath, 1999) for 
the RING-Ube2t structure. For the human DRWD domain a high-resolution dataset and 
a low-resolution dataset were merged after indexing and integration using XDS and 
scaled using XSCALE (Kabsch, 2010a, Kabsch, 2010b). The indexing, integration and 
scaling of a dataset allowed for one reflection file to be generated for a defined 
spacegroup. This reflection file contained all the reflection indices (h, k, l) with their 
measured intensities and sigma values for all reflections, which was then used for 
structure solution. 
 
2.1.11.2 Structure Solution 
In order to solve a structure there is one fundamental piece of information missing from 
the reflection indices in a dataset, which are the phases of the reflections. This is termed 
the ‘phase problem’. There are several methods macromolecular crystallographers use 
to overcome the phase problem, molecular replacement, isomorphous replacement 
(MIRAS, SIRAS), and anomalous x-ray scattering methods (MAD, SAD). This project 
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used molecular replacement, which generates initial phases from homologous structures. 
The program used to carry out the search method for a molecular replacement solution 
was Phaser (McCoy et al., 2007) either in the CCP4 or Phenix Suites (Afonine et al., 
2005, Winn et al., 2011). Phaser utilises the maximum likelihood theory for structural 
solution by first applying anisotropy correction functions to the data, converting the 
chosen model/s into structure factors, carrying out rotation and then translational 
searches, followed by packing function and a final rigid body refinement.  
Maximum likelihood theory is based on the probability of a hypothesis fitting the 
observed experimental data. In molecular replacement we are testing a series of 
hypotheses (similarity of the search model, orientation, position and packing of this 
model in the unit cell) to find a structural solution (a model) that has a high probability 
for explaining the observed diffraction data. A model that is more probable will have an 
increased likelihood and therefore the model with the maximum likelihood is selected 
for the structure solution.  
 
2.1.11.3 Structure Refinement 
The initial phases from a structural solution are rudimentary estimates and are not the 
ideal phases. To minimise the phase error and in turn improve the electron density maps 
to build a model that better represents the data, an iterative process known as refinement 
was carried out.  
Refinement is the optimization of a function that represents the agreement between the 
model and the experimental diffraction data. Therefore the iterative process of 
refinement is improving the fit of the calculated amplitudes from your model to the 
experimentally observed amplitudes from your diffraction data. This is achieved by 
altering the parameters of the model and the relative weighting of x-ray data to the 
model. Model parameters that can be altered include, geometrical restraints such as 
bond angles, lengths, and torsion angles, van der Waals interactions, temperature factor 
(B-factor), TLS groups, occupancies of atoms and incorporation of additional atomic 
structure factors as the model is built.  
To monitor the refinement process and prevent model bias a set of reflections (set aside 
before structural solution) known as the Free-R reflections were also used in the 
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refinement process. The final outcome is a protein model that best describes the 
observed diffraction data.  
Refinement for structures in this project was carried out using phenix.refine (Afonine et 
al., 2005) and the molecular graphics software used to display model co-ordinates and 
electron density maps was Coot (Emsley and Cowtan, 2004). Phenix.refine also carries 
out bulk solvent flattening and uses non-crystallographic symmetry (NCS) to improve 
the model.  
 
2.1.11.4 Structure Validation 
When as much of the electron density was interpreted as possible, the model was 
checked for geometry, and Ramachandran outliers using the program MolProbity 
(Davis et al., 2004). Omit maps were also generated to validate a model and check for 
model bias using the Phenix Suite (Echols et al., 2012). 
 
All structural images were produced using the program PyMOL (Delano, 2002). 
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Chapter 3. Results 1: Structure of the Human DRWD 
domain 
Although FANCL is the main catalytic unit responsible for the key monoubiquitination 
event in the FA pathway (Meetei et al., 2003), the sequence homology between Human 
and Drosophila FANCL is poor, ~20%. Additionally in patients, the FA CC is also 
required for the monoubiquitination of FANCD2, whereas in the Drosophila system 
there are currently no homologous proteins identified for a CC. As the Drosophila 
FANCL structure (Cole et al., 2010) revealed a totally different domain architecture to 
that predicted (Meetei et al., 2003), lacks sequence conservation with other species and 
has no apparent FA CC, we hypothesized there could be structural differences between 
the Human and Drosophila FANCL proteins. I therefore set out to determine the 
structure of Human FANCL. 
 
 Purification and Crystallisation of the Human DRWD domain 
A lot of time was dedicated by Ambrose Cole (previous member of the Walden Lab) to 
try and purify full-length Human FANCL and Human FANCL domains based on the 
predicted structure (Meetei et al., 2003). Although protein could be made, quality 
control analyses revealed that removal of the N-terminal tag for any of the constructs 
resulted in aggregation and insoluble material. Unfazed by the inability to produce 
Human FANCL material, Ambrose turned to the Drosophila system and subsequently, 
solved the structure of Drosophila FANCL (Cole et al., 2010). Therefore, based on the 
newly defined domains of the Drosophila FANCL structure, I revisited the possibility 
of expressing Human FANCL domains. Initially, constructs were designed on the 3 
Drosophila FANCL domains: ELF, DRWD and RING (Fig.21). Unfortunately, any 
construct incorporating the predicted Human ELF domain yielded aggregated, insoluble 
material. These constructs are listed in Table 10.  
 












ELF no loop residues 1-92
ELF half loop residues 1-100
ELF loop residues 1-109
ELF-DRWD residues 1-294
Ub-linker-ELF pET RSF



















Table 10 Human FANCL constructs to express the N-terminus 
 
However, I was able to express and purify the Human DRWD domain, residues 109-
294, which accounts for 50% of Human FANCL. A typical 12-litre E.coli prep would 
yield ~12mg of highly purified protein. An example of a typical size exclusion 
purification profile and SDS-PAGE analysis of collected fractions is shown in Figure 22. 
Figure 21 Structure of 
Drosophila FANCL 
Overall structure of Drosophila 
FANCL (PDB code 3K1L) with 
the three domains highlighted, ELF 
domain coloured green, DRWD 
domain coloured blue, and RING 
domain coloured pink. Zinc atoms 
are represented by grey spheres. 
 




Figure 22 Human DRWD domain Purification 
Profile from size exclusion chromatography of the Human DRWD domain. SDS-PAGE 




Once able to obtain highly purified Human DRWD domain protein, I set up initial 
sitting drop vapour diffusion crystallization trials, at 4oC. An initial crystal hit yielding 
crystal spherulites was observed in the INDEX HT screen (Hampton research) 
(Fig.23A). The crystallization condition contained 0.2M L-proline, 0.1M HEPES pH 
7.5 and 10% PEG 3,350. Additionally, the drop was set up at a 1:1 ratio of protein-to-
well solution with the protein at a concentration of 10mg/ml. Although promising, these 
spherulites are totally useless for x-ray diffraction experiments, as successful structure 
solution requires obtaining x-ray diffraction data from a single crystal. I therefore 
attempted to optimise the crystal condition to attain single crystals. The following 
parameters were varied for crystal optimisation: the percentage of PEG 3,350 
precipitant, the concentration of L-proline additive, the concentration of the protein, I 
also tested different buffers to vary the pH range. An optimised crystal condition 
containing 0.2M L-proline, 0.1M tri-sodium citrate pH5.5, and 2% PEG 3,350 with a 
protein concentration of 20mg/ml, yielded 2 crystal forms, squares and hexagonal rods 
(Fig.23B, C and D). Although not single crystals, both crystal forms were large enough, 
~100µM in length, to separate into individual crystals and use for diffraction 
experiments. Interestingly, the square crystal form was highly birefringent under 
polarising light in comparison to the hexagonal rod form (Fig.23D). Strong 
birefringence is more commonly observed with salt crystals (Giege et al., 1995).  




Figure 23 Human DRWD Crystals 
Images of Human DRWD domain crystals. A) Image of the initial crystal hit. B) and C) Images 
of the 2 Human DRWD domain optimized crystal forms. D) Image of the human DRWD 




I therefore tested both crystal forms for diffraction in-house, to establish whether the 
crystals were protein and for their diffraction quality. Only the square crystal form 
diffracted, with a resolution limit of 3Å at room temperature (Fig.24). To obtain a high-
resolution dataset, I picked and cryoprotected 18 of the square crystals in either 30% 
glycerol or 30% PEG 400 and took them for diffraction experiments at the Diamond 
Light Source synchrotron radiation facility. 




Figure 24 Diffraction Image from the Human DRWD domain crystal 




 Data Collection and Structure Solution of the Human DRWD 
domain 
This section describes the x-ray diffraction data collected from the Human DRWD 
domain crystals and the subsequent data processing required for the successful structure 
solution of the Human DRWD domain. 
 
3.1.1 Data Collection and Data Processing of the Human DRWD domain 
The Human DRWD structure was dependent, like all other X-ray crystal structures, on 
the success of collecting and processing a full dataset. Only once the data is processed 
can one move forward to finding a structure solution.  
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3.1.1.1 Data Collection 
In total, 18 DRWD domain crystals were tested for their diffraction quality at Diamond 
Light Source beamline I03 with a wavelength of 0.98Å. Datasets were collected for 
crystals observed with the highest diffraction resolution. Data collection strategies were 
based on three initial diffraction images at rotation angles 0o, 45o and 90o. iMosflm 
(Leslie and Powell, 2007) was then use to estimate the unit cell dimensions and 
determine the crystal spacegroup by autoindexing. Autoindexing in iMosflm locates 
strong diffraction spots (set by a minimum pixel size and intensity value) on the image/s 
and then uses these to index. Indexing predicts the crystal geometry – the Bravis lattice, 
unit cell dimensions and potential spacegroups by calculating the fit of the selected 
diffraction spots to all potential Bravis lattices and their related point groups. The 
crystal geometry with the highest symmetry and lowest penalty score (one that fits the 
diffraction spots best) is selected and used to calculate a strategy for the data collection 
parameters, - starting angle, oscillation and the degrees of data. iMosflm, like other data 
processing software, will predict the best data collection strategy for a given crystal. 
However, it is important to check the strategy to ensure a full set of unique reflections is 
collected for structure solution (Dauter, 2010). For crystals that have no symmetry, the 
minimum degrees of data to be collected from the crystal to ensure a complete set of 
unique reflections is 180o. However, the number of degrees of data collected can be 
further reduced by the crystal’s symmetry. This is dependent on the orientation of the 
crystal axes relative to the x-ray beam. If the highest symmetry axis of the crystal is 
aligned with the rotation axis of the crystal (the rotation axis is perpendicular to the x-
ray beam) the amount of data collected can be reduced due to the symmetry.  
iMosflm predicted unit cell dimensions of a = 147.6 Å, b = 102.5 Å, c = 65.8 Å, α = 90o, 
β = 94.1o, γ = 90o with a predicted spacegroup C2 for the DRWD crystal. The minimum 
degrees of data to be collected from a monoclinic crystal around either the a or c-axis is 
90o, due to the 2-fold symmetry operators. The DRWD crystal was already orientated in 
the x-ray beam as such that the c-axis was almost aligned (7.9o) to the rotation axis (ϕ) 
of the crystal (Fig.25A). Therefore the iMosflm strategy suggested only 95o of data 
needed to be collected for a full dataset from the DRWD crystal (Fig.25B). However, I 
collected 140o of data from the DRWD crystal in order to have redundancy in the data. 
 





Figure 25 Data Collection Strategy for the DRWD crystal 
A) The table taken from iMosflm data collection strategy indicating the crystal axis (a, b, c) 
closest to the crystal rotation axis (ϕ). In this case crystal axis c was 7.9o from the rotation axis. 
B) With the DRWD crystal orientated in the position defined by table the suggested amount of 
degrees of data to be collected is 95 to give 99.2% completeness. Pie charts were also taken 
from iMosflm data collection strategy. 
 
 
Additionally, completeness and data accuracy of the low-resolution data is more 
important then high-resolution data for molecular replacement (Dauter, 2010). I 
therefore collected 2 datasets from the same crystal, the first at a resolution limit of 
3.5Å and then a second dataset at a resolution limit of 1.75Å (Fig.25). For both datasets 
140 images were collected with a 1o oscillation, and a phi-starting angle of 0o. The 
beam exposure for the low-resolution dataset was 0.4 seconds to reduce diffraction spot 
overloads and a 4 second exposure time was used to collect the high-resolution data.  





Figure 26 Diffraction Images of the Human DRWD crystal 
Diffraction Images at a resolution limits of 3.5Å A) and 1.75Å B). 
 
 
3.1.1.2 Data Processing 
Each image in an X-ray diffraction dataset contains the intensities of the measured 
reflections (I) and how the reflections are related to one another geometrically. A 
dataset contains hundreds of images to capture all the information from the 3D crystal. 
Data processing allows all these images to be assembled into a single file containing all 
the measured intensities (I/σ) from all possible reflections, assigned to their 3D 
geometric place i.e. reflection indices (h, k, l). 
 
Inspection of the images, using iMosflm (Leslie and Powell, 2007), from all the high-
resolution datasets collected from the 5 different crystals, revealed one particular crystal 
with a high-resolution diffraction limit of 2.0Å (Fig.26). Both the high (1.75Å) and low 
(3.5Å) resolution datasets obtained from this DRWD crystal were processed separately. 
The two processed datasets were then scaled and merged together to form a single file 
containing all the data for structure solution. 
 
Initially, data processing was carried out using iMosflm and then merging and scaling 
the datasets using the programs sortmtz and SCALA in CCP4 (Winn et al., 2011). 
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However, SCALA was unable to merge the 2 datasets. The 2 datasets were then 
reprocessed using XDS (Kabsch, 2010b, Kabsch, 2010a). An initial XDS run 
(excluding integrate and correct jobs) for images 1-5 and 91-95 of each dataset was 
carried out to index the data. Indexing assigns the reflections with their reflection 
indices in reciprocal space and defines the crystal geometry – the bravis lattice, unit cell 
dimensions and spacegroup. Inspection of the log files showed that XDS was able to 
locate 2,754 and 5,126 strong spots for both the low and high-resolution datasets, 
respectively. For both datasets XDS estimated the unit cell dimensions of a = 147.6 Å, b 
= 102.5 Å, c = 65.8 Å, α = 90o, β = 94.1o, γ = 90o and selected the bravis lattice mC, 
which only has one spacegroup for protein crystals C2 (Table 11). The mosaic spread 





Table 11 Spacegroup selection for DRWD data 
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Once the unit cell and crystal geometry are assigned the data are then integrated. 
Integration defines the final intensity value for all reflection spots within a dataset. I 
therefore re-ran XDS for all 140 images in each dataset, with the defined unit cell and 
space group, for integration of the data.  
 
The final stage of data processing is scaling and merging the data. The measured 
intensities contain important information for structure solution and preserving the 
information is vital. However, the measured intensities for reflections will vary 
throughout a dataset due to the variability in the crystal diffracting power, radiation 
damage and the length the x-rays travelling through a crystal at different orientations. 
Therefore to collate the final data from both datasets into a single file format but 
preserve the intensity information, reflections with the same index (h, k, l) and 
symmetry related index, are scaled to give the same intensities. To perform the scaling 
and merging for the DRWD data, I used the program XSCALE (Kabsch, 2010a, Kabsch, 
2010b). All 140 images from each dataset were included, with a resolution limit set to 
2.0Å. The correlation between the 2 datasets was good, 0.966. The final overall 
measured intensity (I/σ) was 8.2, indicating a good signal detected for the data, with an 
overall Rmeas for assessing the data quality of 14.2% (Table 12). The overall 
completeness for the data was 99.1% (Table 12) with a multiplicity of 1.5. For the 
highest resolution, 2.0Å, the I/σ was 1.8 but had a particularly high Rmeas of 133.7%, 
indicating poor data quality (Table 12). Inspection of the diffraction images revealed 
radiation damage for the last 55 images of the high-resolution dataset. These images 
were not omitted until the refinement stage as they contained some data that would aid 
the structure solution. 
 




Table 12 Analysis from Scaling and Merging data in XSCALE 
 
 
3.1.2 Structure Solution of the Human DRWD domain 
The final output file from data processing contains all the miller indices (h, k, l) with 
their measured intensities and sigma values, for all reflections observed in the 
diffraction experiment. Importantly though, there is one key piece of information 
missing, the relative phase of the measured reflections, known as the ‘phase problem’. 
As the structure for Drosophila FANCL (PDB code 3K1L) already exists, I could use a 
method known as molecular replacement (MR) to solve the ‘phase problem’. MR 
utilises the phases from an existing homologous structure, in this case Drosophila 
FANCL, for structure solution. I used the program Phaser (McCoy et al., 2007) in CCP4 
(Winn et al., 2011), which uses maximum likelihood theory to find a structure solution. 
Firstly I had to convert the processed data .hkl output file from XSCALE into an .mtz 
file format using XDSCONV (Kabsch, 2010b, Kabsch, 2010a) for compatibility with 
Phaser. Phaser also requires an ensemble of the model from which it will calculate 
structure factors, which in turn will be used for finding a structure solution. Defining a 
good model for Phaser can determine the success of structure solution. As the sequence 
homology between Human and Drosophila FANCL is low, ~20%, I generated a model 
from the Drosophila DRWD domain, residues 109-292, mutated for the Human 
sequence, using the program chainsaw in CCP4 (Fig.27). 




Figure 27 Search model defined for Phaser 
Model utilised by Phaser for structure solution of the Human DRWD domain. The model was 
generated from the Drosophila FANCL structure (PDB code 3K1L) residues 109-292 and 
mutated by the software chainsaw for the Human DRWD sequence. 
 
Additionally, Phaser requires the predicted copy number of the DRWD protein 
molecules it is searching for in the asymmetric unit (ASU), which can be estimated by 
the Matthews coefficient. The Matthews coefficient predicts the number of protein 
molecules expected in the ASU, using the unit cell dimensions of the crystal and the 
molecular weight of the protein molecule to estimate the crystal solvent content 
(Matthews, 1968, Kantardjieff and Rupp, 2003). 5 copies of the human DRWD domain 
were predicted in the ASU for a crystal with an estimated 45.5% solvent content (Table 
13). I therefore instructed Phaser to search for 5 copies of the DRWD domain.  
 
Table 13 Matthews coefficient predictions for DRWD crystal. 
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Phaser utilises the maximum likelihood theory for rotation, translation and packing 
algorithms for successful structure solution. Possible solutions for identifying the 
molecules in the ASU are given rotation and translation function Z-scores, RFZ and 
TFZ respectively, and a packing function score. Increments in the log-likelihood gain 
(LLG) are observed between the individual solutions of the ASU. When Phaser has 
located all the predicted molecules in the ASU, it will output a structure solution for the 
x-ray diffraction data. Initially, Phaser was unsuccessful with finding a structure 
solution for the human DRWD domain data. Inspection of the log file revealed that 
Phaser was only able to locate 2 molecules of the Human DRWD domain in the ASU. 
Based on the Matthews coefficient, 2 molecules of the DRWD domain in the ASU with 
our assigned crystal geometries, would give an estimated crystal solvent content of 
78.2% (Table 13). Although this is a high solvent content for protein crystals, it is not 
unique (Bouma et al., 1999, Kim et al., 1999). I therefore re-ran Phaser to look for just 2 
DRWD molecules in the ASU to retrieve the structure solution (Table 14) and move 
forward to refinement. The refinement process would soon make it apparent if there 




Table 14 Output from Phaser for the Human DRWD domain structure solution. 
 
 
It is rare to observe high-resolution diffraction from a crystal with such a high solvent 
content. Inspection of the DRWD Phaser solution in Coot with symmetry molecules 
displayed reveals a crystal lattice with planes of well packed and ordered DRWD 
molecules down the b-axis of the unit cell, with large solvent channels running down 
the c-axis of the unit cell (Fig.28).  
 





Furthermore, PISA analysis (a program available in the CCP4 suite) reveals 
approximately 5% of the DRWD surface is involved in interactions with another 
DRWD molecule throughout the crystal, with some DRWD molecules interacting with 
up to 4 other DRWD molecules. The well-ordered nature of the crystal accounts for the 














Figure 28 DRWD Crystal lattice 
An image of the DRWD crystal 
lattice observed down the c-axis of 
the unit cell revealing large solvent 
channels (black). DRWD molecules 
are coloured green. 
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3.1.3 Refinement and Model Validation 
The initial output model and electron density maps from Phaser were inspected in Coot 
(Emsley and Cowtan, 2004) to ensure they correlated (Fig.29). 
 
 
Figure 29 Electron density maps and initial model output from Phaser of the Human 
DRWD domain 
Image taken from coot of the initial output model from Phaser of the Human DRWD structure 
represented by a brown line model. The initial electron density map is represented in blue 
chicken wire and the difference density maps in pink (negative density) and yellow (positive 
density) chicken wire. 
 
 
The iterative cycle, of manual model building in Coot to interpret electron density maps 
derived from the data, and computationally improving the calculated phases, was 
undertaken. This process is known as refinement and I employed the program 
Phenix.refine (Afonine et al., 2005), which uses maximum likelihood theory, to 
computationally improve and refine the calculated phases. To monitor the refinement 
process, R-factors are used to measure the fit of the model to the actual data. Two 
numbers are used; Rwork, which corresponds to the working set of data and Rfree, 
which are a set of reflections (5.1%, for the DRWD data) that are set aside and not 
refined against. Rfree is important as it helps prevent model overfitting associated with 
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this data and subsequently should always be higher then Rwork. However, the user 
should be aware that the randomly selected set of R-free reflections can be related to the 
Rwork set of reflections by NCS. This relation increases with the more NCS molecules 
present in the ASU. 
 
 Although the initial electron density maps and output model from Phaser correlated 
overall, there were regions of the model not explained by electron density and electron 
density not explained by the model (Fig.30).  
 
 
Figure 30 Electron density maps and initial model outputs from Phaser of the human 
DRWD structure 
Image taken from coot of the initial output model from Phaser of the Human DRWD structure 
represented by a brown line model. The initial electron density map is represented in blue 
chicken wire and the difference density maps in pink (negative density) and yellow (positive 
density) chicken wire. A green line model represents symmetry related molecules. 
 
 
Therefore before undertaking the manual refinement process I carried out a refinement 
step known as simulated annealing. The basis of refinement is to improve the agreement 
between the observed diffraction data and the model, by altering the parameters that 
define the model. The process of refinement can be described as the minimization of the 
function: M = Mxray + Msterochemical. This can be expanded to Mxray is the 
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diffraction data and Msterochemical is the geometery parameters of the model which 
includes bond lengths, bond angles, torsion angles and non-bonded interactions based 
on prior knowledge. However, use of a minimization function may result in becoming 
trapped in a local minimum and not a neighbouring, more favourable minimum. This is 
due to the nature of the minimization function being ‘downhill’. Simulated annealing 
can overcome the problem of being trapped in local minima by allowing shifts or jumps 
between minima. This is achieved by adding a temperature variable to the refinement 
process. The temperature is set high at the start of the refinement and then slowly 
reduced. The high temperature adds motions to the atoms and relaxes the restraints, 
allowing more exploration of phase space, which permits the refinement to pass through 
potentially worse models. As the temperature decreases the phase space explored is 
restricted as are the restraints and the potential for accepting worse structural solutions 
also decreases. In summary, if you are stuck with a current solution in a local minimum 
but have potentially better solutions (a global optimum), simulated annealing allows 
you to by-pass and then subsequently find a better solution. Indeed, this was the case for 
the Human DRWD structure solution as a decrease in both the Rwork and Rfree was 
observed (Table 15). 
 
 
Table 15 Output from Simulated Annealing 
 
After simulated annealing I begin the manual refinement process. One of the main 
problems in macromolecular refinement, as is the case with proteins, is the ratio 
between the number of experimental observations to the number of parameters being 
fitted to the data. To increase the ratio you either have to increase the number of 
observations or decrease the number of parameters. Translation Libration and Screw 
(TLS) and Non-Crystallographic Symmetry (NCS) are methods used during refinement 
to reduce the number of effective parameters being fitted to the data. TLS refinement 
allows for the inclusion of anisotropic motion in the B-factors for groups of atoms 
rather then anisotropic B-factors for individual atoms. Thus reducing the overall number 
of parameters. NCS decreases the number of model parameters by averaging the 
molecules in the ASU. Therefore TLS and NCS restraints were also used during 
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refinement to further enhance the model and improve the maps to interpret the model 
from. 
 
The final Human DRWD model, best interpreting the data, had a final Rwork and Rfree 
of 18.3% and 20.7%. Omit maps were also generated during refinement to reduce 
model bias. 
 
The model was validated for geometry, stereochemistry and rotamer outliers using 
MolProbity (Chen et al., 2010). The final Human DRWD model overall has good 
geometry with root-mean-squared deviation (rmsd) of 0.007Å for bond length and 1.0o 
for bond angles. Rotamer outliers were assessed using the Ramachandran plot, with 






Figure 31 Ramachandran plot 
of the Human DRWD model 
Ramachandran plot for all non-
Pro/Gly residues, indicating 
98.7% of the rotamers are in the 
favoured region. 
 




Structural Analysis of the Human DRWD domain 
 
This section describes the structure of the Human FANCL DRWD domain obtained 
from the x-ray diffraction data and structure solution processes detailed in the last 
section. 
 
The model of the Human DRWD domain contains 2 copies in the ASU, Chain A and 
Chain B. The 2 DRWD molecules superpose with an rmsd of 0.78Å. Chain A is 
complete, while Chain B has a region of disorder from residue 174-182. The region of 
disorder is due to a symmetry molecule and therefore has been modelled in multiple 
conformations to interpret the electron density as best as possible (Fig.32). Being the 
most complete model, all structural analysis on the human DRWD domain was carried 






Figure 32 Model of Chain B of the Human DRWD domain disordered loop region 
Both image were taken in Coot. A) The model of Chain B of the human DRWD domain 
coloured pink and the symmetry related molecule coloured brown. B) The electron density 
maps are overlaid represented as blue and pink chicken wire. 
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3.1.4 Overall Structure of the Human DRWD domain 
Overall the structure of the Human DRWD domain adopts a fused bilobal shape with 
dimensions of ~70Å x ~25Å x ~20Å (Fig.33). Each lobe is composed of a 4-stranded β-
meander followed by a β-element in the N-terminal lobe and a α-helix in the C-terminal 
lobe (Fig.33A). Additionally, a α-helix resides at the very N-terminus of the DRWD 
domain, before the first β-meander, and at the very C-terminus following the second β-





Figure 33 Structure of the Human DRWD domain 
A) Secondary Structure representation of the Human DRWD domain. The N-terminal lobe is 
coloured blue and the C-terminal lobe is coloured green. B) A surface representation of the 
Human DRWD domain. 
 
 
The two lobes are fused by a long kinked α-helix, spanning ~45Å in length of the 
DRWD domain (Fig.33A). The two lobes are also stabilized by core hydrophobic 
residues His148, Phe169, Ile194, Leu197, Phe200, Trp201 and additional residues, 
Ser144, Arg146, Glu147, Asp168, Lys198, Asp202, Arg221, Ser222, contributing to an 
electrostatic and hydrogen bonding network (Fig.34). 




Figure 34 Interface between the 2 lobes of the Human DRWD domain 
The interface between the N-terminal lobe (pink) and C-terminal lobe (purple) of the Human 
DRWD domain. Dashed lines represent electrostatic and hydrogen bonding interactions. 
 
3.1.5 Structural Comparison of the Human and Drosophila DRWD 
domains 
The low sequence homology, ~20%, between the Human and Drosophila FANCL 
proteins and the lack of a FA CC in the Drosophila system suggested that structural 
conservation may not occur. However, the successful structure solution using the 
Drosophila DRWD domain in MR, certainly indicates a structural global similarity 
between the Human and Drosophila FANCL proteins. I therefore undertook structural 
comparisons of the Human and Drosophila DRWD domains. A superposition of the 2 
DRWD domains revealed an rmsd of 2.0Å, indicating that the FANCL protein is 
globally structurally conserved between vertebrates and invertebrates. Interestingly, 
inspection of the overlaid models revealed a secondary structural difference in the N-
terminal lobe (Fig.35). After the 4-stranded β-meander an α-helix follows in the 
Drosophila DRWD domain, whereas in the human DRWD domain the α- helix is in 
fact a β-element (Fig.35). To determine whether the β-element is possibly conserved 
across vertebrates, I carried out structure based sequence alignments between the 
Human and Drosophila DRWD domain and other FANCL species (Fig.36). Indeed, the 
sequence alignments suggest the secondary structural element swap is likely to be 
conserved in other vertebrates (Fig.36). 




Figure 35 Comparison of the Human DRWD domain and Drosophila DRWD domain 
The human DRWD domain is coloured blue for the N-terminal lobe and green for the C-
terminal lobe. The Drosophila DRWD domain is coloured magenta for the N-terminal lobe and 
pink for the C-terminal lobe. 
 
 
Figure 36 Structure Based Sequence Alignment of the Human DRWD domain and 
Drosophila DRWD domain 
Red boxes highlight conserved residues, with less conserved residues highlighted by orange 
boxes. YPXXXP and HPXXXP motifs are highlighted in blue. Secondary structure elements of 
the DRWD domains are shown above the sequences, with pink representing Human and green 
representing Drosophila. Red and green circles represent the hydrophobic and additional 
residues, respectively, involved in the interface between the 2 lobes of the human DRWD 
domain. Purple bar highlights a cysteine found on the β-element of the Human DRWD domain. 
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Additionally, the sequence alignments also reveal that the hydrophobic core observed 
between the 2 lobes of the DRWD structure is well conserved (Fig.36). However, 
greater variability of the residues is noted for the additional interactions required for this 
interface (Fig.36). 
 
The evolutionary reason for the element swap is unclear. To gain an idea for the 
function of the β-element and overall for the DRWD domain I compared the human 
DRWD domain to known protein structures using the DALI server (Holm and 
Rosenstrom, 2010). Unsurprisingly, Drosophila FANCL was flagged as the closest 
structural homologue. I therefore re-ran the search submitting the 2 Human DRWD 
lobes separately; residues 109-194 for the N-terminal lobe and residues 195-294 for the 
C-terminal lobe (Fig.37A). Interestingly, the closest structural homologues for both 
lobes are the E2 enzymes, due to their central UBC fold comprising of a 4-stranded β-
meander (Fig.37B). Furthermore, the C-terminal lobe also had significant hits from 
proteins possessing an RWD-fold. Interestingly, Alpi et al predicted an RWD like fold 
for the N-terminal region of FANCL based on the observation of the YPXXXP motif 
(Alpi et al., 2008) (Fig.36). The YPXXXP motif is typically observed for UBC and 
RWD-folds (Doerks et al., 2002, Nameki et al., 2004). The Human DRWD domain 
possesses the YPXXXP motif in the N-terminal lobe and the similar HPXXXP motif in 
the C-terminal lobe (Fig.36).  
 
The RWD-fold is structurally related to the UBC-fold, as it comprises the 4-stranded β-
meander but is followed by an α-helix rather then the catalytic β-flap observed in UBC 
folds (Fig.37B). A superposition of the UBC-fold from the E2, Ube2T (PDB code 
1YH2) with the N-terminal DRWD lobe and superposition of the C-terminal lobe with 
the RWD protein GCN2 (PDB code 1UKX) revealed an rmsd of 2.0Å and 2.8Å 
respectively (Fig.37C). The superpositions reveal that the Human DRWD domain 
comprises a UBC-fold fused to an RWD-fold, rather then 2 RWD-folds as observed in 
the Drosophila DRWD (double-RWD) domain. Therefore the Human DRWD domain 
will now be referred to as the Human URD (UBC-RWD) domain for the remainder of 
this thesis. 
 





Figure 37 Structural Comparison of the Human URD domain 
A) The N-terminal lobe coloured blue and the C-terminal lobe coloured green of the Human 
URD domain. B) UBC fold of Ube2T (PDB code 1YH2) coloured green with the catalytic 
cysteine represented by a purple star. RWD fold of GCN2 (PDB code 1UKX) coloured orange. 
C) The N-terminal lobe of the Human URD domain coloured blue overlaid with the UBC fold 
from the E2 enzyme Ube2T (PDB code 1YH2) coloured green. The purple star indicates the 
position of the catalytic cysteine of Ube2T. The C-terminal lobe of the Human URD domain 
coloured green is overlaid with the RWD fold from GCN2 (PDB code 1UKX) coloured orange. 
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The DALI comparisons of the Human URD domain indicate the β-element swap in 
vertebrates is closely linked to the UBC-fold observed in E2s. Catalytic E2s can form a 
thioester linkage between their catalytic cysteine and the C-terminal tail of ubiquitin 
(Hamilton et al., 2001) through the interaction with an E1 enzyme (Huang et al., 2005b, 
Walden et al., 2003b). A closer inspection of the Human URD structure and sequence 
of the β-element, reveals a cysteine located in the position of that found in catalytic E2s 
(Fig.36 and 37C). I therefore hypothesized that the N-terminal lobe of the URD domain 
may be able to form a thioester linkage with ubiquitin, as seen for the catalytic E2s. To 
test this hypothesis I undertook an in vitro thioester assay. Incubation of the E2 enzyme, 
UbcH7, with E1, ATP, HA-Ub and assay buffer is capable of producing a thioester with 
ubiquitin (Fig.38). This is observed by a higher molecular weight species on an anti 
HA-Ub western blot under non-reducing conditions (Fig.38, E2 lane 1). Adding the 
reducing agent DTT reduces the thioester bond between UbcH7 and Ub, resulting in the 
loss of the observed higher molecular weight species (Fig.38, E2 lane 2). I carried out 
the same experiment for the Human URD domain. Although the Human URD domain 
possesses the UBC-fold with a cysteine in the same structural position as the catalytic 
E2s, the assay clearly indicates that the Human URD domain is incapable of forming a 






Figure 38 Thioester Assay 
Anti-HA-Ub and anti-FANCL western 
blots of the thioester assay. Lane 1 is 
the non-reduced sample, lane 2 is the 
reduced sample. 
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My structural comparisons between the Human URD domain and the Drosophila 
DRWD domain indicate a global structural conservation across the FANCL proteins. 
Importantly, this observed conservation validates the use of the different model systems 
used to study FA, such as the chicken and frog systems. However, my analyses also 
reveal a secondary structural difference between vertebrates and invertebrates and the 
reason for this difference is still unclear. The inability to express and purify the N-
terminal portion of Human FANCL suggests that domain associations in FANCL may 
differ between the vertebrates and invertebrates. Additionally, this secondary structural 
difference may be required for interacting with the FA CC that is essential for efficient 
FANCD2 monoubiquitination in higher species. Understanding the function and reason 
for the secondary structure difference and test the possible hypotheses discussed will 
require further structural and biochemical work. 
 
3.1.6 Surface Analysis of the Human and Drosophila DRWD domains 
FANCL has a number of proteins with which it must interact in order to function as the 
E3 ligase in the FA pathway. These include: binding the E2, Ube2T, and the substrates, 
FANCD2 and FANCI, and certainly in the case of human FANCL, must interact with 
the FA CC. Although there is global structural conservation between the Drosophila 
DRWD and Human URD domains, the low sequence conservation indicates possible 
surface differences. Additionally, the surface differences may reflect the difference in 
requirement for a FA CC between the 2 species. I therefore carried out a series of 
structural surface analyses to identify regions of difference. 
 
First, I analysed the surface conservation between the Human URD domain and 
Drosophila DRWD domain. Overall the surface conservation is ~32%, with the 
majority of the conservation residing in the C-terminal lobe, ~20% (Fig.39). The N-
terminal lobe, where we observe the secondary structural difference, has a surface 









Figure 39 Surface Conservation between the human URD and Drosophila DRWD domains. 
 
 
Most protein-protein interactions occur between surface exposed hydrophobic residues, 
due to the fact that hydrophobic residues do not like exposure to water molecules. The 
human system seems to have additional protein interactions through the requirement of 
the FA CC, suggesting the Human URD domain may have greater surface 
hydrophobicity then the Drosophila DRWD domain. I therefore mapped the surface 
exposed hydrophobic residues on both the human URD domain and the Drosophila 
DRWD domain (Fig.40). Indeed, the surface analyses reveal a greater surface 
hydrophobicity on the human URD domain (Fig.40). A total of 22 hydrophobic residues 
are surface exposed in the Human URD domain, 40% of which are bulky hydrophobic 
residues (tryptophan, phenylalanine and tyrosine). In comparison, the Drosophila 
DRWD domain has 18 surface exposed hydrophobic residues, with only 28% of those 
being bulky hydrophobic residues. Interestingly, the N-terminal lobe, which has the 

















Figure 40 Comparison of the Hydrophobic surface between the human URD domain and 
the Drosophila DRWD domain 




Members of the FA CC, FANCA, FANCE and FANCG, as well as both substrates, 
FANCD2 and FANCI, have all been shown to undergo phosphorylation (Yamashita et 
al., 1998, Wang et al., 2007, Qiao et al., 2004, Smogorzewska et al., 2007, Zhi et al., 
2009). Phosphorylation of a residue alters its chemical nature, making the residue more 
polar due to the negative charge of the phosphate group. To ascertain possible surface 
differences between the Human URD and Drosophila DRWD domains, I also carried 
out electrostatic potential analyses using pdb2pqr (Dolinsky et al., 2004) and apbs (Unni 













Figure 41 Comparison of the Electrostatic surface between human URD domain and the 
Drosophila DRWD domain 
 
 
Interestingly, the only main electrostatic potential difference is seen on the more 
conserved C-terminal lobe (Fig.41). This occurs on the Drosophila DRWD domain, 
where there is a large region of positive electrostatic potential, compared to a much 
smaller negative region in the Human URD domain (Fig.41). 
 
The structural comparisons and surface analyses reveal differences between the Human 
URD and Drosophila DRWD domains. Whether these surface differences are a result of 
differences in requirements for a FA CC remains to be established. 
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Chapter 4. Results 2: Protein Interactions of Human 
FANCL 
The basic requirements for an E3 ligase to ubiquitinate a substrate are, binding the E2 
enzyme conjugated with ubiquitin, and binding the substrate to be modified. FANCL, 
along with its E2, Ube2t, has been shown, in vitro, to be the basic catalytic core of the 
FA pathway for monoubiquitination of FANCD2 and FANCI (Alpi et al., 2008, Sato et 
al., 2012). In order to understand the mechanistic details of FANCL activity, defining 
the domains and residues involved in these protein-protein interactions is crucial.  
The substrates, FANCD2 and FANCI, have both been shown to interact with a 
construct encompassing the DRWD-RING domains of FANCL, in the Drosophila 
system (Cole et al., 2010). Interestingly E2 binding is less well defined for FANCL. 
Before any structural evidence, bioinformatics analysis predicted FANCL contained 3 
WD40 repeats and a PHD domain (Meetei et al., 2003). Based on these predictions, 
Machida et al demonstrated GST tagged FANCL PHD domain was responsible for 
binding Ube2T (Machida et al., 2006). Conversely, Alpi et al suggested a requirement 
for the entirety of FANCL for binding Ube2T (Alpi et al., 2008). 
 
As the Drosophila FANCL structure revealed a domain architecture different to that 
predicted (Cole et al., 2010), and my Human URD structure confirmed the structural 
conservation of FANCL across species, I wanted to re-address the questions: 
• Where does Ube2T bind FANCL?  
• What domain and residues of FANCL are required for substrate binding? 
 
 FANCL interactions with Ube2T 
Addressing the question of E2 binding was dependent on producing soluble Human 
FANCL RING domain material. Due to the flexible linker region between the DRWD 
and RING domain observed in the Drosophila FANCL structure and using sequence 
alignments of FANCL homologues, I designed several Human RING domain constructs 
to increase my chances of generating soluble protein. 2L E.coli test expressions of these 
constructs revealed one in particular, residues 289-375 of FANCL, which yielded 
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0.6mg/L of highly purified material. Typically, I carried out 12L E.coli cultures to 
obtain ~7.2mg of RING domain protein for the experiments discussed in this thesis. An 




Figure 42 FANCL RING domain Purification 
FANCL RING domain chromatogram profile from size exclusion chromatography. SDS-PAGE 
gel of fractions collected from purified RING domain peak. 
 
 
Subsequently, I assessed the ability to bind Ube2t with either the RING or URD domain 
of FANCL. In order to do so, I incubated each domain with Ube2t and analysed for 
complex formation by analytical size exclusion chromatography (ASEC). ASEC is 
advantageous for protein interactions as it is a solution based, tag-free technique. Indeed, 
Ube2T clearly forms a complex with the RING domain of FANCL (Fig.43). An SDS-
PAGE gel of the collected fractions from ASEC, confirmed that both the RING domain 
and Ube2T were present in the higher molecular weight peak (Fig.43). However, 
complex formation was not observed when Ube2T was incubated with the URD domain 
of FANCL (Fig.43). 




Figure 43 Ube2T interacts with the RING domain of FANCL 
Analytical size exclusion chromatograms of the URD or RING domain of FANCL incubated 
with Ube2T (green line). Ube2T (red line) and the URD or RING (blue line) chromatogram 
profiles are overlaid. Observation of a larger molecular weight peak (shift to the left) indicates 
complex formation, as is the case with RING-Ube2T interaction. SDS-PAGE gel of fractions 
collected from the RING-Ube2T complex peak, confirming both Ube2T and the RING domain 
are present in the complex peak. 
 
 
Results from the ASEC demonstrate that FANCL is a typical RING E3 ligase, binding 
the E2, Ube2T, through its RING domain. The structure of the RING E3 ligase c-Cbl 
with the E2, UbcH7 revealed a conserved hydrophobic binding interface (Fig.44A) 
(Zheng et al., 2000). The interface involves a highly conserved phenylalanine on the E2 
(F63) pi stacking against a tryptophan (W408) on the helix of the RING domain of c-
Cbl (Fig.44A). The conservation of these binding residues suggests a canonical mode of 
binding for all RING domains with their respective E2s. Both the phenylalanine and the 
tryptophan residues are conserved in Ube2t (F63) and the RING domain (W341, 
Human numbering) respectively, also suggesting FANCL binds Ube2T canonically. 
Indeed, incubation of purified Ube2tF63A mutant with the FANCL RING domain 
abolishes complex formation, when assessed by ASEC (Fig.44B). This result further 
supports that FANCL is a typical RING E3 ligase, interacting with Ube2t in a canonical 
fashion. 





Figure 44 FANCL binds Ube2t canonically 
A) Structure of the RING-E2 complex, c-cbl-UbcH7 (PDB code 1FBV). c-Cbl is shown in 
green, UbcH7 shown in blue. Grey spheres represent zinc atoms. The insert picture shows the pi 
stacking between the conserved F63 of UbcH7 and W408 of c-Cbl-UbcH7 interface. B) 
Analytical size exclusion chromatogram of the RING domain of FANCL incubated with 
Ube2TF63A mutant  (green line). Ube2T (red line) and the RING (blue line) chromatogram 
profiles are overlaid. There is no observation of complex formation between the RING domain 
and Ube2tF63A mutant. 
 
To further characterize the FANCL-Ube2t interaction, to gain stoichiometery and 
affinity information, I undertook isothermal titration calorimetery (ITC) experiments. 
ITC was the chosen technique; as it is a solution based, tag free system, where one 
protein is periodically titrated from a syringe into an experimental cell containing the 
potential interacting protein. As the protein is titrated and a protein-protein interaction 
occurs, heat will either be released into (exothermic) or taken from (endothermic) the 
environment, resulting in a heat change to the experimental cell. A reference cell 
containing water is used to keep the experimental cell at a constant temperature with a 
calorimeter measuring the amount of power required to do so. The raw data shows these 
spikes of power, from every titration, throughout the experiment. As you titrate more 
protein throughout the experiment the spikes decrease, as there is less unbound protein 
available in the experimental cell. The binding isotherm, stoichiometry and affinity 
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information can be calculated from the integration of the area under each spike plotted 
against the molar ratio between the two proteins. Microcal Origin software version 7.0 
is used for the calculations. 
 
ITC is a particularly protein ‘hungry’ technique, as well as requiring highly purified 
proteins to obtain good data. Therefore, 17mg/ml (750µM) of Ube2T was required for 
titrations and 1.5mg/ml (65µM) of URD domain or 0.7mg/ml (70µM) of the RING 
domain for the experimental cell were typical amounts required for the ITC experiments 
discussed below. Additionally all experiments were carried out a minimum of 3 times. 
Titration of Ube2T into the URD domain of FANCL revealed no interaction (Fig.45). 
The initial ASEC of FANCL RING domain and Ube2T suggested a stoichiometery of 
1:1. Indeed, titration of Ube2t into the RING domain revealed a stoichiometery of 1:1 
with a dissociation constant (Kd) of 0.454µM ± 0.128µM (Fig.45). Interestingly, 
titration of the mutant Ube2tF63A into the RING domain did not abolish binding, as 
seen in ASEC (Fig.44B), but reduced the binding affinity 11-fold, Kd 5µM ± 2µM 
(Fig.45). 
 




Figure 45 ITC profile of Ube2T interactions with FANCL 
ITC profiles from URD-Ube2T, RING-Ube2T and RING-Ube2TF63A interactions. 
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The affinity observed for the RING-Ube2t interaction is unusually high in terms of 
ubiquitin biology. Interactions between RING domains and their E2s are typically in the 
micro-molar range (Yin et al., 2009, Brzovic et al., 2003). Interestingly, Ube2t has a 
~50 amino acid C-terminal extension, with no known function. Other E2s possess N or 
C-terminal extensions and in some cases both (van Wijk and Timmers, 2010). The role 
for the extensions are varied, ranging from cellular localisation, to regulation of E1 or 
E3 interaction, to type of Ub modification (Summers et al., 2008b, Merkley and Shaw, 
2004, Haldeman et al., 1997, Huang et al., 2008, Coccetti et al., 2008). As the affinity 
between the RING domain and Ube2T is particularly high and the mutant Ube2tF63A 
does not completely abolish RING binding (Fig.45) I hypothesized the C-terminal 
extension of Ube2t could be involved in binding the RING domain. Incubation of the 
RING domain with ΔUbe2T (residues 1-154) still forms a complex, as observed by 
ASEC (Fig.46). I therefore can conclude, based on this observation and the lack of 
interaction observed between the URD domain and Ube2T, the that the C-terminal 
extension of Ube2T has no role in binding FANCL RING and URD domains. 
 
It is clear from both my ASEC and ITC data that FANCL is a typical RING E3 ligase, 
as I demonstrate the RING domain is responsible for canonical binding of the E2 in the 












Figure 46 ΔUbe2T can still form a complex FANCL RING domain. 
Analytical size exclusion chromatogram of the RING domain of FANCL incubated with 
ΔUbe2T mutant (red line). ΔUbe2T mutant (blue line) and the RING (green line) chromatogram 
profiles are overlaid. Complex formation is observed between the RING domain and ΔUbe2T 
mutant. SDS-PAGE gel of fractions collected from the RING-ΔUbe2T complex peak, 




 FANCL interactions with substrates, FANCD2 and FANCI. 
Previously the ELF domain of Drosophila FANCL was ruled out of substrate binding 
(Cole et al., 2010). As my data clearly show the FANCL RING domain is required for 
Ube2T binding, we proposed that the Human URD domain of FANCL was responsible 
for binding substrates, FANCD2 and FANCI. An in vitro pull-down experiment was 
employed to assess the ability of the Human URD domain to bind His-FANCD2 or 
FLAG-FANCI immobilized on beads. The URD domain was pulled down by both His-











Figure 47 FANCL URD domain binds substrates, FANCD2 and FANCI 
A) In-vitro pull-down of His-FANCD2 and FLAG-FANCI with wild type (WT) URD domain 
or patch mutant URD domains. B) Size exclusion chromatograms of WT URD domain (pink) 
overlaid with URD patch mutants. Patch 1 orange line, Patch 2 blue line, Patch3 cyan line, 




To gain a deeper molecular understanding into FANCL-substrate binding I wanted to 
define the residues of FANCL involved. Firstly, I generated highly purified patch 
mutants of the FANCL URD domain (Fig.47B and C, Fig.48), based on my surface 
exposed hydrophobic analysis (discussed above in chapter 3). Patch 1 had residues 
L149 and F166 mutated to alanine, patch 2 had residues L248, F252, L254 and I265 
mutated to alanine, patch 3 had residues V127 and Y128 mutated to alanine, and finally 
patch 4 had residues W212 and L214 mutated to alanine (Fig.48). 
 
 






Figure 48 Surface patches of the URD domain mutated for substrate binding 
Surface exposed hydrophobic patches of the Human URD domain mutated to ascertain residues 
involved in substrate binding. Sequence alignments across FANCL homologues for each patch 
are found underneath the corresponding structure of the patch. Residues in the sequence 
alignment with green circles above are those that were mutated to alanine. Red bars highlight 
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Each patch mutant of the URD domain was assessed for binding with substrates in the 
in vitro pull-down experiment. Only patches 2 and 4 showed a reduce binding for both 
FANCD2 and FANCI (Fig.47A). This suggests residues W212, L214, L248, F252, 
L254, I265 are involved in substrate binding. Interestingly, both of these patches reside 
on the C-terminal end of the URD domain, which overall is the more conserved end of 
the URD domain (see chapter 3). Additionally, residues W212, L214, L248 and L254 
(human numbering) are well conserved across FANCL homologues (Fig.48).  
 
The structure of the substrates reveals they can exist as a complex (Joo et al., 2011). 
However, my in vitro studies and the in vitro monoubiquitination assays by others (Sato 
et al., 2012, Alpi et al., 2008) indicate the individual substrates are capable of binding 
FANCL alone for their subsequent monoubiquitination. To understand the mechanisms 
of substrate binding further, and to see if FANCL has a preference to bind one substrate 
more then the other, I set out to determine the kinetics and binding affinities of the 
substrates to FANCL. The preliminary surface plasmon resonance (SPR) experiments, 
where His-FANCD2 was immobilized to the chip surface revealed a Kd for the URD 
domain of ~17nM (Fig.49). I also tested the 2 URD domain mutants (URD patch 
mutant 2: L248A, F252A, L254A and I265A and URD patch mutant 4: W212A and 
L214A) that showed reduced binding for the substrates in my in vitro pull down 
experiments (Fig.47). The SPR experiments of the URD mutants showed no binding to 
His-FANCD2 (Fig.49), supporting the data of the in vitro pull down experiments. 
 




Figure 49 Analysed SPR data of URD domain His-FANCD2 interactions 
Analysed single cycle kinetic experiments of His-FANCD2 with WT URD domain or URD 
domain patch mutants 2 or 4. WT URD domain interaction with His-FANCD2 reveals a Kd of 
~17nM. 
 
These data have not yet been repeated and are therefore preliminary. Further studies are 
required using both substrates and the substrate complex for understanding the 
mechanisms underlying substrate binding by FANCL. 
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The basic requirement for a ubiquitination event requires the E3 ligase to bind the E2 
and substrate. As I have assigned the URD and RING domains of FANCL for these 
functions I hypothesized that a URD_RING construct of FANCL would be sufficient 
for the monoubiquitination of FANCD2. In order to assess the function of the FANCL 
domains for monoubiquitination of FANCD2 I first had to purify a Human URD_RING 
construct of FANCL (Fig.50A). To test the function of the URD_RING domain 
construct and the individual human FANCL domains, I undertook an in vitro 
monoubiquitination assay. Incubation of the URD_RING construct with E1, Ube2T, 
HA-Ubiquitin and reaction buffer resulted in the clear monoubiquitination of FLAG-







Figure 50 URD_RING domain of FANCL monoubiquitinates FANCD2 
A) Size exclusion chromatograms for the FANCL constructs, URD_RING (red line), URD 
(green line) and RING (blue line). B) Anti-HA Ubiquitin western blot of an in-vitro 
monoubiquitination assay of FLAG-FANCD2 with differing domains of FANCL as E3 ligase. 
All lanes contain E1 enzyme, Ube2T, FLAG-FANCD2 and HA-Ub. Lane 1 has no E3 ligase, 
lane 2 is the URD domain only, lane 3 is the RING domain only, lane 4 contains a 1:1 ratio 
separate URD domain and RING domain and lane 5 contains the URD-RING construct. 
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Interestingly, to a lesser extent, monoubiquitination of FLAG-FANCD2 was also 
observed for the RING construct alone (Fig.50B, lane 3 and 4). A possible explanation 
for this observation is the RING domain could also be involved in substrate binding due 
to its close proximity to the substrate-binding region on the DRWD domain based on 
the Drosophila FANCL structure. Additionally, the C-terminal extension of Ube2T 
could be involved in substrate recognition and binding, and when coupled with the 
RING domain, capable of monoubiquitinating FANCD2. Further structural and 
biochemical characterization are required to address these possibilities. 
 
From my structure based, biochemical analyses it is clear that FANCL is a typical 
RING E3 ligase, binding Ube2T via the RING domain. Additionally, I have shown that 
substrate recognition occurs on the URD domain and specified the residues involved. 
Interestingly, our in vitro monoubiquitination assay implies the ELF domain of FANCL 
is redundant for the monoubiquitination of FANCD2 and further studies are required to 
address the possibilities of the RING domain and Ube2T for binding substrates. 
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Chapter 5. Results 3: Structure of the human RING-
Ube2T complex 
The key catalytic unit of the FA pathway is the FANCL-Ube2T complex (Alpi et al., 
2008, Sato et al., 2012). The complex carries out the critical signalling event, the 
monoubiquitination of FANCD2, for recruitment of the DNA repair machinery. 
Understanding the molecular details of the FANCL-Ube2T interaction is important for 
both understanding the monoubiquitination event of the FA pathway and RING-E2 
pairings. 
 
So far, I have demonstrated that the FANCL RING domain is required for binding 
Ube2T, and that the complex has an unusually high affinity, Kd ~0.45µM, for RING-E2 
interactions (Hodson et al., 2011). Although the FANCL-Ube2T interaction appears 
canonical, the mutation of the canonical Phe63 residue of Ube2T does not completely 
abolish FANCL-Ube2T complex formation (discussed in chapter 4). Additionally, other 
RING E3 ligases have been show to co-ordinate with a variety of E2s (Christensen et al., 
2007, Windheim et al., 2008, Rodrigo-Brenni and Morgan, 2007). However, for the 
monoubiquitination of FANCD2, FANCL exclusively pairs with Ube2T (Alpi et al., 
2007, Machida et al., 2006). These observations suggest that the exclusivity of the 
pairing and the high affinity are controlled by additional binding factors. Therefore to 
understand all the molecular determinants of the FANCL-Ube2T interaction I set out to 
determine the structure of the complex. 
 
Crystallization of FANCL-Ube2T complex 
One variable for successful crystallisation is the purity of the protein sample. Therefore 
crystallographers dedicate a lot of time to producing the purest, most homogenous 
protein sample possible. Crystallization of protein complexes can therefore be even 
more challenging than a single protein, as you are incorporating a dynamic equilibrium, 
resulting in a heterogeneous sample. Therefore to increase my chances of crystallising 
the FANCL-Ube2T complex, I only used complex RING-Ube2T material direct from 
size exclusion chromatography (shown in chapter 4) for crystal trials. Additionally, I 
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was also able to prepare the URD_RING construct in complex with Ube2T. A typical 
12L E.coli culture of the URD_RING–Ube2T complex would yield ~7mg of highly 
purified material (Fig.51). I therefore set up URD_RING-Ube2T crystal trials in parallel 
with the RING-Ube2T trials. All the crystallisation experiments in this chapter were 
vapour diffusion and carried out at 4oC. Summaries of the different variables tested for 




Figure 51 Purification of the URD_RING-Ube2T complex 
Chromatogram profile from size exclusion chromatography of the URD_RING-Ube2T complex 
(blue line). The URD_RING domain size exclusion profile is overlaid (red line). SDS-PAGE 
gel of fractions collected from purified URD_RING-Ube2T complex peak, indicating both 





















10mg/ml 1)to)1 4oC 0.5M)NaCl 672
15mg/ml 1)to)1 4oC 0.5M)NaCl 672
RING.ΔUbe2T(complex 18mg/ml 1)to)1,)2)to)1 4oC 0.1M)NaCl 576
10mg/ml 1)to)1 4oC 0.5M)NaCl 576





Table 16 Initial Crystallisation Trials for the FANCL-Ube2T complex 
Table listing the different variables tried for different constructs of the FANCL-Ube2T complex 
to obtain crystals of the interaction interface. 
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The RING-Ube2T complex trials gave 2 initial crystal hits, condition A from the 
PEGRx HT screen and condition B from the PEG/ION HT screen (both screens from 
Hampton Research) (Fig.52). Both crystal hits yielded very small crystals, in showers. 
Condition A contained 0.1M tri-sodium citrate pH 5.5, 24% PEG 400 and 0.2M 
ammonium acetate, giving rise to ~10µM x ~10µM square plate crystals (Fig.52A). 
Condition B contained 0.04M citric acid, 0.06M Bis Tris propane/pH 6.4 and 20% PEG 
3,350, yielding very fine needles of ~25µM in length (Fig.52B). Additionally, condition 
A was set up with a drop ratio of 2:1, protein:well solution, using RING-Ube2T 
complex at 18.7mg/ml and condition B with a drop ratio of 1:1, with a protein 




Figure 52 Crystal hits of RING-Ube2T complex 
A) Initial crystal hit from the Hampton Research PEGRx HT screen. B) Initial crystal hit from 
Hampton Research PEG/ION HT screen. 
 
The first step for initial crystals hits are to test their diffraction quality to ensure i) they 
diffract and ii) they are protein crystals. Both crystal forms were too small to test for 
diffraction in-house, due to the size of the x-ray beam, which is ~300µM in diameter. A 
small crystal with a large x-ray beam leads to a very poor signal-to-noise ratio. As my 
crystals were particularly small I needed to generate larger crystals for diffraction 
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experiments. Additionally, larger crystals are generally easier to manipulate for crystal 
picking. I therefore set up optimisation trials based on the initial crystal conditions in 
the hope of yielding larger crystals. Unfortunately reproducing the crystals in either 
condition proved very challenging. I therefore focused my efforts on condition A, as 
there was no precipitation observed in the drop compared to the alternate condition 
(Fig.52) and the crystals were slightly easier to manipulate. However, with various 
attempts at optimisation of these crystals I was still unable to produce larger crystals. 
An example of the problematic crystallisation was a fine precipitation screen that I 
designed (Fig.53). Simply changing the PEG 400 precipitant by 0.3% affected the 
ability of the RING-Ube2T complex to crystallize (Fig.53A, comparison of well H3 to 
H4). Additionally for this optimisation trial, I also set up different drop ratios of protein-
to-well solution at 1:1 (Fig.53C) and 2:1 (Fig.53A, well H4). Again, crystallization of 
the RING-Ube2T complex was only observed in the 2:1 ratio format. These 
observations all reflect the difficulty of crystallizing the RING-Ube2T complex. I also 
utilised the Additive screen from Hampton research to try and reduce the amount of 
crystal nucleation, however, I was still not able to obtain larger crystals for diffraction 
experiments. 
 





Figure 53 Optimisation Crystals of the RING-Ube2T complex 
A) Images of vapour diffusion drops from my fine precipitant screen. In the top left corner of 
each image is the well number. Arrows indicate an increase of precipitant, PEG 400, or the 
increase of buffer pH. B) A zoomed in image of the vapour diffusion drop 1 in well H4, 
showing crystals of the RING-Ube2T complex at a protein-to-well solution ratio of 2:1. C) 
Image of vapour diffusion drop 2 in well H4. Drop 2 differs to drop 1 imaged in A, as it has a 
protein-to-well solution ratio of 1:1, rather than 2:1. 
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Although the crystals I had produced of the RING-Ube2T complex would have been 
too small for traditional data collection methods, Diamond Light Source synchrotron 
facility have developed the first microfocus beamline, I24, in Europe in 2008. The 
microfocus beamline is ideal for crystals of my size, as the beam can be tuned to a 5µM 
x 5µM beam size without loss of the total flux of the beam. I therefore harvested my 
crystals and took them for diffraction experiments at I24. In all I tested 26 crystals in 
three different cryoprotectants, 25% and 30% glycerol and 25% ethylene glycol. 
Although the diffraction pattern was protein, unfortunately the crystals diffracted to a 
maximum resolution of ~11Å (Fig.54). This diffraction resolution is too poor to resolve 
side chain or backbone atoms required for understanding the binding interface of the 
FANCL-Ube2T complex. Furthermore, the diffraction pattern itself was too poor to 
obtain any structural information, as not even a spacegroup for the crystal symmetry 




Figure 54 RING-Ube2T crystal diffraction image 
Diffraction image obtained at Diamond Light Source, I24, from a RING-Ube2T crystal from 
condition A, which contained 0.1M tri-sodium citrate pH 5.5, 24% PEG 400 and 0.2M 
ammonium acetate. Diffraction resolution was to ~ 11Å. 
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Crystal trials of the URD_RING-Ube2T complex were unsuccessful, as no initial 
crystal hits were observed. I also attempted crystallisation of both the RING domain and 
URD_RING construct in complex with ΔUbe2T with the C-terminal extension missing 
(Table 16). Again, these crystal trials were unsuccessful as well. 
 
Obtaining different crystallisation conditions of the RING-Ube2T complex certainly 
indicated the ability of the complex to crystallize. However, the difficulty with 
optimising and reproducing the crystals, suggested a problem with the sample itself. 
The fact that I purified the RING-Ube2T complex with the same buffers and followed 
the same method each time, suggested that there was some variation in the sample 
beyond my control. I attributed this variation to the dynamic equilibrium occurring 
between the two proteins, leading to heterogeneity within the sample. The resulting 
heterogeneity was therefore leading to difficulty in crystallization and poor crystal 
diffraction. To try to overcome the dynamic equilibrium effect, I designed a fusion 
construct. I linked the C-terminus of the RING domain to the N-terminus of Ube2T 
with a 14-residue linker (TGSTGSTETGYTQG) (Fig.55A) (Pellegrini et al., 2002, 
Thakur et al., 2010). Throughout the remainder of this thesis the fused protein will be 










Figure 55 RING_Ube2T fusion protein 
A) A schematic of the RING_Ube2T fusion protein. B) Purification of the RING_Ube2T fusion 
protein. A size exclusion chromatography profile with corresponding collected peak fractions 
analysed by an SDS-PAGE gel. 
 
 
The first hurdle with fusing the two proteins was ensuring that I could generate highly 
purified soluble material. Indeed, my RING_Ube2T fusion construct was soluble and 
eluted from size exclusion chromatography around the expected molecular weight of 
~33kDa (Fig.55B). 
 
The purified material was used in initial crystallization trials, which were successful, 
producing crystals with dimensions of ~30µM x ~30µM x ~25µM. (Fig.56). The 
crystallisation condition for the RING_Ube2T protein was 1.6M ammonium sulphate, 
0.1M NaCl, and 0.1M HEPES pH 7 (Crystal HT screen, Hampton research) at 
~11.8mg/ml in a ratio of protein-to-well solution of 1:1. 
 




Figure 56 Crystals of the RING_Ube2T fusion complex 
Crystals of the RING_Ube2T complex obtained from the Hampton research Crystal HT screen. 
 
 
I was able to pick 16 of the RING_Ube2T crystals from this condition and cryoprotect 
them, to reduce radiation damage, in 20% glycerol and 20% ethylene glycol, before 
cryo-cooling in liquid nitrogen. I tested the concentration of the cryoprotectants prior to 
crystal picking and used 2 different cyroprotectants as they can affect the crystal 
diffraction quality (McFerrin and Snell, 2002). The crystals were then taken to Diamond 
light source microfocus beamline I24 to test their diffraction. An initial exposure of a 
crystal to a 10µM x 10µM x-ray beam at a wavelength of 0.9686Å, revealed a beautiful 
protein diffraction pattern, diffracting to a resolution of 2.0Å (Fig.57).  
 





Figure 57 Diffraction Image from a RING_Ube2T crystal 
Diffraction image obtained at Diamond Light Source, I24, from a RING_Ube2T crystal from a 
condition containing 1.6M ammonium sulphate, 0.1M NaCl, and 0.1M HEPES pH 7. The 
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 Data collection and Structure solution of the human RING-
Ube2T complex 
This section will describe the data collection of the RING_Ube2T crystals and the 
subsequent data processing required for the successful structure solution of the RING-
Ube2T complex. 
 
5.1.1 Data collection and data processing of the RING-Ube2T complex 
Obtaining a structure of the RING-Ube2T complex was dependent, like all other x-ray 
crystal structures, on the ability to collect a full dataset that could be processed. Once 
the data are processed, one can proceed to structure solution. 
 
5.1.1.1 Data Collection 
All 16 RING_Ube2T crystals were tested for diffraction and datasets were collected for 
the best diffracting crystals at Diamond Light source I24 beamline with a wavelength of 
0.9686Å. For data collection, 3 initial diffraction images at rotation angles 0o, 45o and 
90o, for each crystal, were used to predict the unit cell and crystal space group using 
EDNA (Incardona et al., 2009). Once the unit cell and spacegroup were assigned a 
strategy for the data collection parameters, the number of degrees of data, oscillation 
and starting angle was determined. It is important to take time to devise a good data 
collection strategy to ensure a full set of unique reflections is collected for structure 
determination (Dauter, 2010). Most programs will predict a data collection strategy, 
including EDNA, however, it is always important to check the strategy. The minimum 
requirement for data collection based on the predicted unit cell dimensions a = 109.3Å, 
b = 109.3Å, c = 117.7Å, α = 90o, β = 90o, and γ = 90o and spacegroup P4 for the 
RING_Ube2T crystals was 90o. I therefore collected 180o of data, with an oscillation of 
0.2o and 0.05sec exposure to the beam. This resulted in 900 images being collected at 
2.0Å resolution. The reason for collecting the additional 90o of data is because 
observing the reflections more then once increases the signal-to-noise ratio, improving 
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the measurement of the data. In total I collected 6 full datasets of the RING_Ube2T 
crystals. 
 
5.1.1.2 Data Processing 
A raw x-ray diffraction dataset contains two pieces of information, which are the 
intensities of the measured reflections (I) and how these recorded reflections 
geometrically relate to one another. As hundreds of 2D images are collected for a single 
dataset, data processing is required to obtain a single file containing all the measured 
intensities (I/σ) from all possible reflections, assigned to their 3D geometric place i.e. 
reflection indices (h, k, l). 
 
To ensure the best dataset was used for structure solution I processed all 6 
RING_Ube2T datasets using D*Trek (Pflugrath, 1999). The best dataset was assessed 
for the completeness of the measured data at the highest observed resolution (Dauter, 
2010). I will describe the data processing for the actual dataset taken on for structure 
solution of the RING_Ube2T complex.  
 
Initially, D*Trek carried out spot finding from a raw diffraction image of RING_Ube2T 
with a sigma level set to 3, locating 73 spots (Fig.58). Confident that the software could 
find diffraction spots the next step was to index the image. Indexing assigns the 
reflections with their reflection indices in reciprocal space and determines the crystal 
geometry – the bravis lattice, unit cell dimensions and spacegroup. For the 
RING_Ube2T crystal, D*Trek determined the unit cell dimensions as a = 109.3Å, b = 
109.3Å, c = 117.7Å, α = 90o, β = 90o, and γ = 90o. The program prompts the user for 
selection of the spacegroup. I chose the spacegroup P4, as it had the highest symmetry 
with a low penalty score (least-squares residual) of 1.021% (Table 17).  
 





Figure 58 Spot finding on a diffraction image from RING_Ube2T crystal 




Table 17 Possible space groups for RING_Ube2T data 
The output table of the possible spacegroups for the RING_Ube2T data from D*Trek. 
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The mosaic spread for the data was 0.3. D*Trek then carries out a refinement process 
where it refines the hardware parameters (the beam centre, detector distance and 
orientation) and then refines the crystal geometry.  
 
To ensure that the reflection spots on the diffraction images were being located 
correctly with the assigned crystal geometry I ran predict in D*Trek. Inspection of 
several images confirmed the software was able to correctly predict partial and full 
reflections. The data are then integrated to obtain the final intensity value for all 
reflection spots, also correcting for background noise. For the RING_Ube2T data all 
900 images were integrated. Once integration of all the data was carried out I was able 
to assign the spacegroup using dtcell. dtcell confirmed the bravis lattice P4 predicted 
from indexing and suggested the spacegroups P41212 or P43212 (Table 18). I selected 
P41212 as the final spacegroup because more protein crystals are observed with this 
spacegroup and hence a higher probability score than for P43212. However, at this stage 
in structure determination there is no way of knowing what the exact spacegroup is until 
structure solution (see section 5.1.2). 
 
 
Table 18 Spacegroup Analysis from dtcell 
 
The final stage of data processing is scaling and merging the data. The measured 
intensities contain important information for structure solution and preserving the 
difference in intensities is vital. However, the measured intensities for reflections will 
vary throughout a dataset due to the variability in the crystal diffracting power, radiation 
damage and the length the x-rays travelling through a crystal at different orientations. 
Therefore to collate the final data into a single file format but preserve the intensity 
information, reflections with the same index (h, k, l) and symmetry related index, are 
scaled to give the same intensities. In D*Trek this process is called scaling and 
averaging. Initially, I included all the data, 900 images to 2.0Å resolution but the 
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statistics indicated some radiation damage to the data. I therefore cutback the resolution 
to a final 2.25Å and removed the last 350 images. The final overall measured intensity 
(I/σ) was 5.2, indicating a good signal detected for the data with an overall Rmerge of 
0.154, for assessment of the data quality (Table 19A). The overall completeness and 
multiplicity of the data was 100% and 8.8 respectively (Table 19B). The I/σ was 
relatively weak (1.0) and the Rmerge relatively high (0.861) for the highest resolution 
shell (Table 19A and B). However, due to the high multiplicity of the data there would 
be some useful high-resolution data measured for structure solution and refinement 




Table 19 Analysis from Scaling and Merging data in D*Trek 
The output tables from scaling and averaging the data from D*Trek. A) A table showing the 
Rmerge values and I/σ values for the resolution shells of the RING_Ube2T data. B) A table 
showing the multiplicity and completeness for the resolution shells of the RING_Ube2T data. 
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5.1.2 Structure solution of the RING-Ube2T complex 
After data processing, the final file contains the miller indices (h, k, l) with the 
measured intensities and sigma values for all the reflections. However, to solve a 
structure there is one fundamental piece of information missing from the processed data 
and that is the relative phase of the reflections, known as the ‘phase problem’. There are 
several methods to solve the ‘phase problem’. As structures of Ube2T (PDB code 
1YH2) and of the homologous Drosophila FANCL (PDB code 3K1L) already exist, I 
could utilise the phases from these models for structure solution. This method is termed 
molecular replacement (MR).  
 
I employed the program Phaser (McCoy et al., 2007) in the Phenix GUI (Echols et al., 
2012), which utilises maximum likelihood theory, to find a structure solution. Phaser 
requires an input file of the processed data in a .mtz format and ensembles of the 
structure models that it will calculate structure factors from. As D*Trek produces a .ref 
file of the final processed reflections, I used CCP4 to convert the file format to .mtz, for 
compatibility with Phaser.  
Importantly, the quality of the structure search models chosen for use in Phaser, can 
determine the success of structure solution. Typically, when there is more than one 
protein molecule in the crystal, it is useful to search for the largest and most 
homologous molecule first. I therefore used the Ube2T structure, residues 1-154, as the 
first search model, because it is 100% homologous and the larger of the two protein 
molecules present in my crystal (Fig.59). The second search model, the Drosophila 
FANCL RING domain, was harder to define, as the sequence homology is only 29%. I 
therefore removed flexible regions from the N and C-terminus and used the remaining 
Drosophila FANCL RING domain residues 312-371 as the second search model 
(Fig.59). 
 




Figure 59 Search models used for Molecular Replacement 
The structures of Ube2T, residues 1-154, PDB code 1YH2 and Drosophila FANCL RING 




Additionally, Phaser requires the copy number for each of the protein molecules it is 
searching for in the asymmetric unit (ASU), which can be estimated by the Matthews 
coefficient. The Matthews coefficient predicts the copy number of protein molecules in 
the ASU from the estimation of the crystal solvent content, based on the molecular 
weight of the protein molecules and the unit cell dimensions of the crystal (Kantardjieff 
and Rupp, 2003, Matthews, 1968). 2 copies of the RING domain and 2 copies of Ube2T 
were predicted in the ASU with a crystal solvent content of 52% (Table 20). I therefore 




Table 20 Matthews coefficient predictions for RING_Ube2T crystal 
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Lastly, the spacegroup P41212 has the enantiomorph spacegroup P43212. Again I 
instructed Phaser to search for solutions in both spacegroups. 
 
Phaser uses the maximum likelihood theory for rotation and translation searches and a 
packing function to find a structure solution. Possible solutions for identifying 
components of the ASU are given rotation function z-scores (RFZ), translation function 
z-score (TFZ) and a packing function score. Increments in the log-likelihood gain 
(LLG) between solutions of the individual ASU are observed. Once Phaser has located 
solutions for all components of the ASU, Phaser will then output a structure solution for 
the x-ray diffraction data. Phaser was successful in finding a molecular replacement 
solution for the RING_Ube2T complex in spacegroup P43212, with 2 copies each of 
Ube2T and the RING domain (Table 21).  
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5.1.3 Refinement and Model Validation 
The initial output model and electron density maps from Phaser were inspected in Coot 
(Emsley and Cowtan, 2004) to ensure they were correlated (Fig.60).  
 
 
Figure 60 Electron density maps and initial model output from Phaser of the RING-
Ube2T Structure 
Image taken from Coot of the initial output model of the RING-Ube2T complex represented by 
a yellow line model. The initial electron density map is represented by blue chicken wire. 
 
 
The iterative process of manual model rebuilding in Coot to interpret the electron 
density maps derived from the data, and computationally improving the calculated 
phases was undertaken. This process is known as refinement and I used the program, 
Phenix.refine (Afonine et al., 2005) which utilises the maximum likelihood theory to 
refine and improve the phases. An example of the iterative model rebuilding that I 
undertook for the RING_Ube2T structure can be seen in Figure 61, where the initial 
model clearly does not fit the electron density (Fig.61A). I therefore removed the model 
in this region, re-refined the data and rebuilt the model into the electron density 
(Fig.61B). TLS and torsion angle NCS restraints were used during refinement to further 
enhance the model and improve the maps to interpret the model from. 





Figure 61 Images of electron density maps for the RING_Ube2T Structure 
A) Initial electron density map and model of the RING-Ube2T complex, clearly showing the 
initial model (yellow), not fitting into the initial electron density maps (blue chicken wire) 
derived from the x-ray diffraction data. B) Shows the rebuild of the model (green) into the 
electron density map (blue chicken wire) and difference density map (purple chicken wire for 
positive electron density). Both images were taken from Coot. 
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To monitor the refinement process, R-factors are used to measure the fit of the model to 
the actual data. Two numbers are used Rwork, which corresponds to the working set of 
data and Rfree, which are a set of reflections (6%, for the RING_Ube2T data) that are 
set aside after data processing and not used in refinement. Rfree is important as it helps 
prevent model overfitting associated with this data and subsequently should always be 
higher then Rwork. However, the user should be aware that the randomly selected set of 
R-free reflections can be related to the Rwork set of reflections by NCS. This relation 
increases with the more NCS molecules present in the ASU. 
The data were also cutback to 2.35Å resolution and the last 150 images removed as the 
R-factors were getting stuck in the highest resolution shell. The final RING_Ube2T 
model best interpreting the data had a final Rwork and Rfree of 21.2% and 24.8%, 
respectively. 
 
Phenix.refine continually validates the model for geometry, stereochemistry and 
rotamer outliers for each round of refinement, by utilising MolProbity (Chen et al., 
2010). The final RING_Ube2T model overall has a good geometry with root-mean-
squared deviation (rmsd) of 0.004 and 0.67 for bond length and bond angles, 
respectively. The model was also assessed for rotamer outliers using the Ramachandran 
plot with 97.5% in the favoured regions (Fig.62A). There were two rotamer outliers 
from Chain A of Ube2T, His15 and Met34 (Fig.62B and C). His15 has been modelled 
with the unfavoured rotamer form, as the nitrogen-epsilon 2 forms a hydrogen bond of 
length 2.9Å with the main chain oxygen from Pro320 of Chain X. If His15 were 
modelled with the nitrogen-delta 1 forming a hydrogen bond with the hydroxyl group of 
Try313 of Chain X the bond length would be 3.2Å and still be in an unfavourable 
rotamer position.  
 
 





Figure 62 Ramachandran plot and rotamer analysis for the RING_Ube2T model 
A) Ramachandran plot indicating 97.5% of the rotamer for the RING-Ube2T structure are in the 
favoured region. For B and C the model of RING-Ube2T complex is in shown in yellow with 
the symmetry molecule in brown. The electron density maps are represented by blue chicken 
wire. Both images were taken from Coot. B) Chain A of Ube2t showing the His15 in an 
unflavoured rotamer position. C) Chain A of Ube2t showing the Met34 in an unfavoured 
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 Structural Analysis of the human RING-Ube2T complex 
This section will describe the structure of the RING_Ube2T complex derived from the 
x-ray diffraction data described in the last section.  
 
The model of the RING_Ube2T structure contains 2 copies of the Ube2T molecule, 
Chain A and Chain B interacting with 2 copies of the human FANCL RING domain, 
Chain C and Chain D, respectively in the ASU. The 2 Ube2T molecules superpose with 
an rmsd of 0.5Å and the 2 RING molecules superpose with an rmsd of 0.43Å. There 
was no observable electron density for the 14-residue linker in the polypeptide chain 
linking the C-terminus of the RING domain to the N-terminus of Ube2T. Additionally 
there are missing regions of the model, as there was no observed or interpretable 
electron density in these regions. These regions are; the C-terminal extension residues 
155-197 for both molecules of Ube2T, the loop region from residue 27-32 in Chain B of 
Ube2T (Fig.63A), the N-terminus of the RING domain residues 289-298 for Chain C 
and 289-302 for Chain D and finally residues 352 and 353 in Chain D of the RING 
domain, due to a symmetry contact (Fig.63B). Analysis of the structure was carried out 
on the two interacting pairs, Ube2T Chain A with RING domain Chain C and Ube2T 
Chain B with RING domain Chain D. 
 





Figure 63 Electron density maps with missing density for RING_Ube2T model 
A) The loop region from residue 27-32 in Chain B of Ube2T (yellow line model) is missing due 
to the lack of interpretable electron density (represented by blue and purple chicken wire) in the 
region. B) Residues 352 and 353 were not modelled in Chain D of the RING domain (yellow 
line model), because of the lacking electron density (blue and purple chicken wire) due to a 
symmetry contact (brown line model) on a 2-fold symmetry axis (white dot). Both images were 
taken from Coot. 
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5.1.4 Overall Structure of the human RING-Ube2T complex 
Overall the structure of the RING-Ube2T complex assumes the same topology as the 
monomeric RING-E2 complex structure, c-Cbl-UbcH7 (Zheng et al., 2000) (Fig.64A 




Figure 64 Overall Structure of the FANCL RING domain-Ube2T complex 
A) Overall structure of the FANCL RING domain-Ube2T complex. The RING domain is 
coloured purple with its two structural zinc atoms represented by grey spheres. Ube2T is 
coloured green with the catalytic cysteine marked by a pink star. B) Structure of the RING-E2 
structure, c-Cbl-UbcH7 adapted from PDB code (1FBV). C-Cbl RING domain is coloured 
green with its two structural zinc atoms represented by grey spheres. UbcH7 is coloured blue 
with the catalytic cysteine represented by a pink star. 
 
Ube2T adopts the typical UBC –fold, comprising a 4-stranded beta meander, flanked by 
an N-terminal helix and two C-terminal helices (Fig.64A). To test whether Ube2T 
binding the RING domain results in any structural conformational change to Ube2T, I 
carried out a superposition with the unbound structure of Ube2T (PDB code 1YH2) 
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(Fig.64A). Superposition revealed an rmsd of 0.67Å, indicating that no structural 
rearrangements occur when Ube2T is bound to the FANCL RING domain. 
The human FANCL RING domain like other RING domains, contains two structural 
zinc atoms (Fig.65). These atoms are co-ordinated by cysteines (Cys 307, 310, 324, 329, 
337, 359 and 361) and a histidine (His334) in a (Cys)4, His, (Cys)3 arrangement forming 
a cross brace structure (Fig.65B). The arrangement of cysteine and histidines differs 
slightly to the arrangement observed in other RING domains, (Cys)3, His, (Cys)4 
(Brzovic et al., 2001, Zheng et al., 2000, Huang et al., 2011). This unusual arrangement 
is also noted in the Drosophila FANCL structure and is therefore a conserved structural 
feature of FANCL (Cole et al., 2010). The FANCL RING domain also contains the 
helix observed in other RING domains (Fig.65C). 
 
 
Figure 65 Analysis of the domains of the RING-Ube2T complex 
A) Ube2T coloured green overlaid with UbcH7 coloured pink (from PDB code 1FBV) showing 
the structural conservation of the UBC fold. A pink star represents the position of the catalytic 
cysteine and the grey oval represents the RING binding interface of E2s. B) A schematic 
representing the cross brace structure of the human FANCL RING domain. Grey circles 
represent the zinc atoms. X can be any residue. C) Overlay of the human FANCL RING domain 
of FANCL coloured purple with the c-Cbl RING domain coloured green (from PDB code 
1FBV). 
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5.1.5 Comparison of the human FANCL RING domain to the Drosophila 
FANCL RING domain 
The Drosophila FANCL and Human FANCL proteins are poorly conserved in sequence 
~20%. Although the sequence conservation is poor, my analysis of the human URD 
domain of FANCL (discussed in chapter 3) revealed that the overall domain 
architecture of FANCL is conserved. However, my structure also highlighted a 
secondary structure difference. Therefore I undertook structure comparison analyses of 
the human RING domain against the Drosophila RING domain.  
 
A superposition of the Human and Drosophila RING domains revealed an rmsd of 1.7Å. 
Again, like the structural comparison between the Drosophila DRWD and human URD 
domain, the superposition shows good global structural conservation of the FANCL 
RING domains. Furthermore, inspection of the actual overlaid structures revealed a 
distinct secondary structure difference, where the last α-helix of the Drosophila RING 
domain is actually a β-strand in the human RING domain (Fig.66A). A structure based 
sequence alignment of FANCL homologues suggests the β-strand is conserved in all 
other species (Fig.66B).  
 




Figure 66 Secondary Structure Comparison of the human and Drosophila FANCL RING 
domains. 
A) The FANCL human and Drosophila RING domains overlaid coloured blue and green 
respectively. Grey spheres represent the structural zinc atoms. B) Structure based sequence 
alignments of the FANCL RING domains. Red bars represent conserved residues with orange 
and yellow bars representing less conserved residues. Zinc co-ordinating residues are marked 
with a grey circle. Drosophila RING domain residues involved in packing against the 
Drosophila DRWD domain in the full-length Drosophila FANCL structure are represented by 
cyan squares. 
 
Interestingly, the α-helix of the RING domain in the full-length structure of Drosophila 
FANCL hydrophobically packs against the DRWD domain. I therefore wanted to 
analyse the hydrophobic surface of the human RING domain and compare it to the 
Drosophila RING domain. The surface analysis reveals that overall the surface exposed 
hydrophobic regions are greater for the Drosophila RING domain (Fig.67). There is a 
well-conserved hydrophobic patch in both the Drosophila and human RING domains, 
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which is the region required for E2 binding (Fig.67 top panel). The other large 
hydrophobic patch on the Drosophila RING domain is less conserved in comparison to 
the human RING domain (Fig.67 bottom panel). Interestingly, this hydrophobic patch is 
responsible for the association with the DRWD domain in Drosophila FANCL. 
Additionally, the Drosophila FANCL RING domain residues, Leu326, Phe375, Leu378, 




Figure 67 Surface Analysis of the human and Drosophila RING domains 
Surface representations of the human and Drosophila RING domains. Hydrophobic surfaces are 
represented in green. The top images show the E2 binding surface, which is well conserved. The 
bottom images show the Drosophila RING domain surface that packs against the Drosophila 
DRWD domain. 
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My structural analysis of the RING domains suggested that the association between the 
RING domain and the URD domain might differ in the human FANCL structure to that 
of the Drosophila. I therefore assessed the human URD and RING domains for complex 
formation. ASEC revealed no observable complex being formed between the 2 human 
FANCL domains (Fig.68A). To resolve a complex by ASEC requires the components 
of the complex to have high affinity for one another, typically in the nano-molar range. 
I therefore have conducted preliminary ITC experiments of the possible human URD-
RING domain interactions, as ITC is able to measure much weaker affinities. The 
preliminary ITC experiments reveal that there is no interaction between the 2 human 
domains (Fig.68B). However, as the ITC experiments are preliminary they require 
repeating before fully concluding this result.  
 
 
Figure 68 Interaction Analysis of the human RING and URD domain 
A) Analysis of the potential complex formation between the RING and URD domains of human 
FANCL, by ASEC. No complex formation is observed between the human RING and URD 
domains (blue line). The ASEC profile of the URD domain is overlaid in red. B) Preliminary 
ITC experiment between the human URD and RING domains. 
 
These structural analyses of the human and Drosophila RING domains, along with the 
initial biochemistry experiments, highlight possible differences between Drosophila 
FANCL and other species, in terms of the domain associations within FANCL. Further 
structural and biochemical work are needed to conclude these differences. 
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Structural Analysis of the RING-Ube2T interface 
I carried out structural analysis of the RING-Ube2T interface to gain an understanding 
of how FANCL interacts with Ube2T and how RING E3 ligases select for particular 
E2s.  
 
Overall the interface between the FANCL RING domain and Ube2T buries at total 
surface area of ~700Å, as calculated by PISA (Krissinel and Henrick, 2007). A central 
hydrophobic interaction between Pro62, Phe63 and Pro100 of Ube2T and Ile309, 
Trp341 and Pro360 of the RING domain forms the core of the interface (Fig.69A). This 
central hydrophobic interface is conserved, as documented by other RING-E2 structures 
(Pruneda et al., 2012, Plechanovova et al., 2012, Dou et al., 2012b, Zheng et al., 2000). 
Interestingly, the hydrophobic surface of the FANCL RING domain is extended by 
Tyr311, which is involved in pi stacking with Arg6 and Arg9 of Ube2T (Fig.69B). Of 
note, Arg9 in Ube2T Chain A is not seen in the interaction interface due to its 
displacement by a symmetry molecule.  
 
Further analysis of the interface reveals a unique and extensive electrostatic and 
hydrogen bonding network between FANCL and Ube2T. The residues contributing to 
these interactions are Arg6, Arg9, Ser5, Arg60, Arg99, Ser101, Asn103 of Ube2T and 
RING domain residues Asp306, Tyr311, Glu340, Ser363 with main chain interactions 
with RING domain residues Ile309, Cys310, Tyr361 (Fig.69C). 





Figure 69 Interface of the FANCL RING domain-Ube2T complex 
The FANCL RING domain is coloured purple and Ube2T is coloured green. Grey spheres 
represent zinc atoms. A) The hydrophobic interface between the FANCL RING domain and 
Ube2T. B) The additional hydrophobic RING domain residue, Tyr311, involved in pi stacking 
with Arg6 and Arg9 from Ube2T. C) The extensive electrostatic and hydrogen bonding network 
between FANCL RING domain and Ube2T. Dashed lines represent interactions. 
 
Determinants of the exclusive E3-E2 pair, FANCL-Ube2T 
FANCL has the choice of ~40 E2s in the human genome (Sheng et al., 2012). However, 
FANCL exclusively pairs with the E2, Ube2T for the monoubiquitination of FANCD2 
(Machida et al., 2006, Alpi et al., 2008).  Therefore understanding the determinants of 
the FANCL-Ube2T pairing is important for understanding both the FA pathway and the 
pairings of RING E3 ligases with their E2s.  
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The biochemical work of the FANCL RING domain-Ube2T interaction (discussed in 
chapter 4) suggested a canonical RING-E2 binding mode. Indeed, my structure of the 
RING-Ube2T complex certainly shows typical RING domain-E2 association, as 
observed in other RING-E2 structures. However, my detailed structural analysis of the 
RING-Ube2T interface exposed an extensive hydrogen bonding and electrostatic 
interaction network. To understand whether this additional interaction network is 
unique and significantly contributing to the FANCL-Ube2T pairing, I undertook the 
laborious task of producing structure-based sequence alignments with other E2 and 
RING structures (Fig.70). In total I structurally aligned 12 E2s with Ube2T and 11 
RING and 2 U-box domains (structurally related to relate to RING domains) with the 
FANCL RING domain. PDB codes for structures used are listed in appendix A. 
 




Figure 70 Structure-Based Sequence Alignments of E2s and RING domains 
Residues that are completely conserved are represented by red bars, with decreasing 
conservation represented by orange and yellow bars. Green circles represent residues involved 
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in the conserved RING-E2 hydrophobic interface. Purple circles represent residues involved in 
the extensive electrostatic and hydrogen bonding network between FANCL RING domain and 
Ube2T. A) A structure based sequence alignment of E2s compared to Ube2T. B) A structure 
based sequence alignment of RING and U-box domains compared to the human FANCL RING 
domain. Grey boxes represent zinc co-ordinating residues. 
 
As expected, the alignments reveal that the hydrophobic core residues seen in other 
RING-E2 interfaces, Ile309 and Trp341 of FANCL and Pro62, Phe63 and Pro100 of 
Ube2T are well conserved (Fig.70). Interestingly, Tyr311, which extends the 
hydrophobic interaction of FANCL with Ube2T, is poorly conserved (Fig.70B). To 
assess these FANCL RING domain residues for Ube2T binding I generated and purified 
to homogeneity single point mutants, Ile309Ala, Tyr311Ala, and Trp341Ala. 
Subsequently, I assessed each RING domain point mutant for their ability to complex 
with Ube2T, by ASEC (Fig.71). As predicted, the conserved canonical RING-E2 
binding residues, Ile309 and Trp341, when mutated to alanine, result in a loss of Ube2T 
interaction (Fig.71). Loss of Ube2T interaction was also observed when the RING 
domain residue Tyr311 that extends the hydrophobic interaction with Ube2T, was 
mutated (Fig.71).  
 





Figure 71 FANCL RING domain residues required for Ube2T binding 
ASEC experiments analysing the RING domain single point mutants for complex formation 
with Ube2T (pink line). The RING domain profiles are overlaid in green and Ube2T profiles are 
overlaid in blue. Comparison to the WT RING domain show none of the RING domain mutants 
are able to form a complex and interact with Ube2T. 
 
Importantly, the structure-based sequence alignments reveal the additional interacting 
residues Ser5, Arg6, Arg9, Arg60, Arg99, Ser101, Asn103 of Ube2T and RING domain 
residues Asp306, Tyr311, Glu340, Ser363 are less well conserved (Fig.70). This 
suggests that these interactions are unique to the RING-E2 pair, FANCL-Ube2T. The 
nature of the additional bonding network suggests these weak interactions are 
collectively contributing to the RING-Ube2T interface. Therefore mutating a single 
residue involved in the additional bonding network would probably not have an affect 
on the RING-Ube2T interaction. In order to assess the importance of this additional 
bonding network I tested the FANCL RING domain for interactions with other E2s, 
Chapter 5. Results 
 
 159 
Ube2D3 and Ube2L3. Both posses the conserved central hydrophobic interface residues 
but are poorly conserved in the additional residues (Fig.70). ASEC demonstrated that 
neither Ube2D3 nor Ube2L3 were competent for binding the FANCL RING domain 
(Fig.72). I also carried out the converse experiment, testing the ability of Ube2T for 
binding another RING domain, Rbx1, by ASEC (Fig.72). Again, Rbx1 possesses the 
conserved hydrophobic core residues but not the additional interacting residues (Fig.70). 
ASEC revealed that Ube2T was unable to complex with Rbx1 (Fig.72).  
 
 
Figure 72 FANCL-Ube2T complex is exclusive 
ASEC experiments analysing the RING for complex formation with other E2s and Ube2T for 
complex formation with another RING domain, Rbx1 (all pink line). The E2 profiles are 
overlaid in blue and the RING domain profiles are overlaid in green.  
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These biochemistry studies reveal that collectively the residues contributing to the 
additional interacting network are important for determining the E3’s selectivity for its 
specific E2, in this case, FANCL for Ube2T. 
 
Although FANCL does not complex with other E2s, the conserved nature of both the 
E2 UBC-fold and the central hydrophobic interface suggests the possibility that in the 
absence of Ube2T FANCL could function with another E2. To assess the function of 
FANCL with other E2s I undertook an in vitro FANCD2 monoubiquitination assay.  
Both Ambrose Cole (previous member of the Walden Lab) and I spent many months 
trying to generate stable, soluble, purified human FANCL. Unfortunately, although 
protein can be made, quality control analyses reveal that once the N-terminal tag is 
removed the full-length FANCL aggregates and becomes insoluble. Therefore, I turned 
to the Xenopus tropicalis FANCL protein for use in the assay developed by Jennifer 
Miles in the Walden Lab. To ensure the Xenopus tropicalis FANCL RING domain 
bound human Ube2T, as observed with the human RING domain, I assessed the 
interaction by ASEC (Fig.73A). Indeed, Xenopus tropicalis FANCL interacts with 
human Ube2T. I therefore went ahead with the assay. I incubated Xenopus laevis 
FLAG-FANCD2, E1, ATP, HA-Ub, and FANCL in assay buffer with different E2s. I 
assessed FANCL function with the following E2s, Ube2L3, Ube2D3, Ube2L6, and the 
Ub polymerising E2 pairing Ube2N/Ube2V1. Firstly, my assay reveals that when 
FANCL and Ube2T are added together the monoubiquitination of FANCD2 occurs 
(Fig.73B lane 1 and 2), confirming the observations of others (Alpi et al., 2008, Sato et 
al., 2012). Importantly, my assay demonstrates that only when FANCL is paired with 
Ube2T, FANCD2 becomes monoubiquitinated (Fig.73B). I also observe that Ube2D3 
alone is capable of polyubiquitinating FANCD2 in my assay (Fig.73B lane 5). The 
Ube2D family of E2s have been shown to be very promiscuous in their ability to 
ubiquitinate free lysines (Brzovic and Klevit, 2006, Wenzel et al., 2011). Importantly, 
the addition of FANCL (Fig.73B lane 6) does not change the modification to a 
monoubiquitination event, nor does it enhance the amount of polyubiquitinated 
FANCD2.  
 





Figure 73 FANCL-Ube2T complex strictly monoubiquitinates FANCD2 
A) ASEC of the Xenopus tropicalis RING domain forms a complex with Ube2T (purple line). 
The Xenopus tropicalis RING domain is overlaid in blue and Ube2T is overlaid in green. B) 
Anti-HA Ub western blot of the in vitro FANCD2 monoubiquitination assay. 
 
 
The affinity between the FANCL RING domain and Ube2T is unusually high in terms 
of Ub biology (previously discussed in chapter 4). Mutating the canonical RING-E2 
binding residue Phe63 of Ube2T does not totally abolish the binding, as assessed by 
ITC (chapter 4). I therefore wanted to test whether the function of FANCL for 
monoubiquitinating FANCD2 would be affected by a reduction in the affinity between 
FANCL and Ube2T. In order to test this hypothesis I used the purified Ube2TF63A 
mutant in the in vitro assay. The assay clearly shows that loss of the high affinity 
interaction between FANCL and Ube2T results in the loss of FANCD2 
monoubiquitination (Fig.73B lane 11 and 12). One possible explanation for the 
requirement of the high affinity between FANCL and Ube2T is to favour the 
equilibrium for the complex, allowing for FANCD2 to be recruited to FANCL and 
subsequently become monoubiquitinated. Testing this hypothesis would require further 
biochemistry analysis, such as understanding the dynamic relationship, the association 
and dissociation rates, between FANCL and Ube2T.  
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My structure and biochemical analyses of the FANCL RING domain-Ube2T complex 
all suggest that in the cellular environment where FANCL has the choice of ~40 E2s, 
FANCL will select Ube2T for the monoubiquitination of FANCD2. In order to 
recapitulate the cellular environment I incubated the FANCL RING domain with a mix 
of E2s. The mix contained purified Ube2T as well as Ube2L3 and Ube2D3 and I 
assessed for RING-Ube2T complex formation by ASEC and mass spectrometry. The 
ASEC reveals that indeed the FANCL RING domain selects an E2 and forms a complex 
(Fig.74). Analysis of the collected fractions from ASEC, by SDS-PAGE gel, reveals 2 
proteins in the complex peak (Fig.74). One is clearly the RING domain as it resolved 
with an MW of ~9kDa, consistent with the RING purification SDS-PAGE gels. The 
other appears to be separated at the correct height for Ube2T ~22.5kDa, with the other 
E2s Ube2D3 observed in the rest of the fractions at their mw of ~16.7kDa for Ube2D3 




























However, to ensure the RING domain had selected Ube2T I sent the resolved E2 band 
from the SDS-PAGE gel for protein identification by mass spectrometry. The mass 
spectrometry experiment was undertaken by the protein analysis and proteomics facility 
at the LRI. Indeed, mass spectrometry of the E2 sample in the complex confirmed it as 
Ube2T with no trace of other E2 peptides (Fig.75). 
Figure 74 FANCL selects 
for Ube2T from a mix of 
E2s 
Chromatogram profile of 
human RING domain mixed 
with Ube2T, Ube2D3 and 
Ube2L3 (pink line). 
Chromatogram profiles of 
the RING domain (green 
line) and Ube2T (blue line) 
are overlaid. SDS-PAGE 
analysis of the collected 
fractions from the ASEC 
experiment. 




Figure 75 Mass Spectrometry Analysis of the E2 in complex with the Human RING 
domain 
A) Proteins identified in the sample from SDS-PAGE analysis by trypsin digest and 
mass spectrometry. B) Amino acid sequence of Ube2T and the peptide coverage 
identified by mass spectrometry highlighted in yellow. 
 
 
In conclusion, my structure and biochemical analysis of the RING-Ube2T complex 
reveals an additional electrostatic and hydrogen bonding network that is unique to the 
FANCL-Ube2T pair. Importantly, this additional network is required for FANCL to 
select Ube2T from all the other E2s in the cellular environment and for FANCL 
function in monoubiquitinating FANCD2. 
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Chapter 6. Discussion 
 
Synopsis 
This PhD project set out to determine the molecular details and interactions of the E3 
ligase, Human FANCL that is essential to the Fanconi Anemia DNA repair pathway. 
Central to this project was the structure determination of Human FANCL. Structural 
analyses were then used as the basis for biochemistry studies to understand FANCL’s 
interactions. Detailed below are the main findings from this PhD project: 
 
• 75% of Human FANCL, the URD and RING domains, were structurally 
determined. 
• Comparisons of the Human and Drosophila FANCL structures reveal global 
structural similarity, revealing conservation of FANCL’s E3 ligase function. 
• The URD domain of Human FANCL is responsible for binding substrates 
FANCD2 and FANCI. 
• The RING domain of Human FANCL is responsible for binding the E2, Ube2T. 
• Residues involved in both substrate and E2 binding on FANCL have been 
assigned. 
• The Human FANCL RING domain-Ube2T complex was also structurally 
determined revealing the molecular details of FANCL’s selectivity for this 
particular E2. 
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Our understanding of the FA pathway has rapidly progressed in the last 2 decades 
thanks to the clinicians, FA researchers and not least the patients. During this period 
genetic and cell-based studies have so far attributed 16 genes to FA. These genes all 
contribute to a cellular pathway essential to repairing DNA ICL damage, required for 
both cancer prevention and ultimately our genome stability. Researchers have also 
discovered the key event of the pathway, the monoubiquitination of substrates, which 
signals for the repair of DNA ICL damage. However, the molecular details that underlie 
the mechanisms of the FA pathway, regulating the ubiquitination and ICL repair are still 
not understood. Therefore further biochemistry and structural studies are essential for 
the understanding of the FA pathway and its molecular targeting for future treatments of 
FA and cancer. 
 
The structure determination for Human FANCL provides the first atomic details of the 
Human FA pathway. It also provides a framework to map current and future FANCL 
patient mutations and understand the molecular implications of these mutations for 
patients. Importantly, the structure of Human FANCL is conserved with the furthest 
known structural homologue, which is Drosophila FANCL. This finding validates the 
use of all the different model systems used to study and understand FA. Furthermore, 
the N-terminal portion of Human FANCL, which corresponds to the ELF domain in the 
Drosophila FANCL structure, has not yet been structurally determined. This is due to 
the inability to produce any highly purified soluble material of or including the N-
terminal portion of Human FANCL. As there is no apparent FA CC in the Drosophila 
system but it is an absolute requirement for patients, it is possible that the N-terminal 
region of Human FANCL interacts and is structurally stabilized by the FA CC. 
 
Interestingly, the FA pathways role in DNA damage ICL repair makes it a potential 
druggable target for cancer patients, as the majority of traditional chemotherapeutic 
agents induce DNA ICL damage (Deans and West, 2011, Lord and Ashworth, 2012). 
Inhibiting the FA pathway in conjunction with chemotherapy could enhance the 
efficacy of chemotherapeutics. A potential way of inhibiting the FA pathway would be 
blocking the interactions of FANCL to disrupt the monoubiquitination of substrates and 
thereby preventing the repair of the DNA ICL damage. Design of such potential 
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therapeutics requires the molecular and atomic details of these interactions. The 
structure of the FANCL-Ube2T interface provides the first molecular and atomic details 
of a Human FANCL interaction. Importantly, the FANCL-Ube2T structure reveals a 
network of additional interactions surrounding the generic E3-E2 interface that is 
essential for FANCLs selectivity for this particular E2. Furthermore, our studies 
indicate that only the FANCL-Ube2T pairing is sufficient for the monoubiquitination of 
FANCD2. These findings mean a potential therapeutic could be designed for this 
specific E3-E2 pair by disrupting the network of additional interactions outside the 
generic E3-E2 interface without disrupting interactions of other E3-E2 pairs.   
Other FANCL interactions that could be inhibited are with the substrates or the FA CC.  
However, the molecular details surrounding interactions with the FA CC are lacking 
and there are still many questions that surround the substrate interactions (discussed 
below). Importantly, for any therapeutic that inhibits the FA pathway for a short term, 
the effects must be carefully assessed. 
 
Together the structural and biochemistry work presented in this thesis have established 
the beginnings for understanding the molecular details surrounding FANCL responsible 
for the key event of the Human FA pathway, the monoubiquitination of substrates, 
FANCD2 and FANCI. However, there are still many unanswered questions: 
 
What is the role of the FA CC in the Human FA pathway? 
It is clear from patients that the FA CC is an absolute requirement for the E3 ligase 
function of FANCL in vivo. However, how the other FA CC members support 
FANCL’s E3 ligase activity is a major unanswered question. It may be that the FA CC 
provides structural stability, especially as we are unable to express soluble material of 
the N-terminal region of Human FANCL. Additionally, the FA CC may play a role in 
FANCL’s cellular localisation, as FANCL is found in both the cytosol and the nucleus 
(Meetei et al., 2003). Also, there is evidence for FA CC members existing as 
subcomplexes (Medhurst et al., 2006, Thomashevski et al., 2004, Taniguchi and 
D'Andrea, 2002), with one group suggesting FANCL exists as a subcomplex with 
FANCB and FAAP100 (Ling et al., 2007). If such subcomplexes exist, what are their 
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functions? And importantly, what FA CC members constitute a subcomplex with 
FANCL and how do they support FANCL’s E3 ligase activity?  
 
Many studies have attempted to address such questions using co-immunoprecipitation, 
yeast and mammalian 2 and 3-hybrid studies (reviewed in (Hodson and Walden, 2012)). 
However, structure based biochemistry work is lacking. Therefore structural studies of 
the FA CC and particularly those that incorporate FANCL are required to understand 
the role of the FA CC and how it supports FANCL’s E3 ligase activity. 
 
How does FANCL activate ubiquitin conjugated Ube2T for the monoubiquitination 
event? 
The recent structures of RING domains bound to ubiquitin conjugated E2s reveal 
additional interactions to the RING –E2 binding interface are required to lock the 
thioester bound C-terminal tail into a position favourable for nucleophilic attack from 
the incoming substrate lysine (Dou et al., 2012b, Dou et al., 2013, Plechanovova et al., 
2012, Pruneda et al., 2012). Three of these structures are of dimeric RING E3 ligases 
and establish the function of the second RING domain, which rather then binding the 
E2, provides the additional interactions with the conjugated ubiquitin (Dou et al., 2012b, 
Plechanovova et al., 2012, Pruneda et al., 2012). The most recent structure is of a 
monomeric RING E3 ligase, which reveals an additional phosphorylated region to the 
RING domain is required for the interaction with ubiquitin (Dou et al., 2013). As the 
monomeric E3 ligases vary in size, with some requiring different post translational 
modifications for function and can exist as single polypeptides or as multi-subunit 
complexes it is harder to predict such additional domains. Therefore to understand how 
FANCL aids the release of ubiquitin from Ube2T requires further structural studies of 
Human FANCL bound to a ubiquitin conjugated Ube2T. 
 
How are the substrates monoubiquitinated on a specifically selected lysine? 
How a specific substrate lysine is selected for ubiquitin modification still remains 
unclear in the ubiquitin field. The work in this thesis has shown FANCL’s direct 
interactions with substrates in vitro and assigned the residues on FANCL involved in 
the interactions. However, the molecular details for lysine selection on the substrates by 
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FANCL are still not understood. This is partly because there are still questions 
surrounding the substrates themselves. Does the FANCD2-FANCI complex interact 
with FANCL? Or must the substrate complex dissociate first? What causes the complex 
to associate and dissociate – the monoubiquitination, the phosphorylation?  
 
Structures of FANCL with the substrates or with the substrate complex will aid the 
understanding of how a specific lysine is selected for modification. Additionally, 
biophysical experiments to determine the kinetics for the assembly and disassembly of 
the substrate complex and also for substrate binding, using both PTM modified and 
unmodified substrates, will also help answer these proposed questions. 
 
How is substrate modification restricted to a monoubiquitination event? 
Understanding the control of specific ubiquitin modifications on substrates is a major 
question in the ubiquitin field. The unusually high affinity between FANCL and Ube2T 
compared to other RING E2 interactions, proposes the idea that perhaps FANCL and 
Ube2T exist as a complex within the cell. However, the E2-E1 binding site overlaps 
with the E2-E3 binding site (Huang et al., 2005b, Huang et al., 1999, Zheng et al., 2000), 
which raises the question of how would Ube2T, accept an activated ubiquitin molecule 
from the E1? Interestingly, FANCL contains a UBC-fold indicative to E2s and the 
structurally homologous RWD fold and an E2-like fold, suggesting FANCL could 
potentially bind the E1, whilst in complex with Ube2T. Initial biochemistry experiments 
would need to be undertaken to ascertain an in interaction between FANCL and E1 to 
test this hypothesis. 
 
Alternatively, the high affinity between FANCL and Ube2T could be to allow the 
monoubiquitinated substrate to dissociate first from FANCL before Ube2T. Thus 
preventing another ubiquitin conjugated Ube2T to bind FANCL, whilst the 
monoubiquitinated substrate is still bound. This model would therefore allow only a 
single ubiquitin to be added to the substrate. In order to test this model, further 
information regarding the dissociation and association rates and constants are required 
for both Ube2T and substrates. 
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My thesis project has established the beginnings of understanding Human FANCL’s 
molecular details, which are key to understanding the mechanisms of the FA pathway. 
However, as proposed in this discussion, there are still many more exciting avenues to 
explore regarding FANCL, it’s E3 ligase activity and the FA pathway. 
 
This research was originally published in: 
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(Kamadurai et al., 2009) 
First structure: (Vijay-Kumar et al., 1987) 
2JF5 K63 linked ubiquitin chains (Komander et al., 2009) 
2XEW K11 linked ubiquitin chains (Bremm et al., 2010) 




(Freudenthal et al., 2011) 




(Shen et al., 2005) 
First Structure: (Whitby et al., 1998) 
1Z2M ISG15 (Narasimhan et al., 2005) 
3CMM Ubiquitin E1 enzyme (Lee and Schindelin, 2008) 
1FBV c-Cbl UbcH7 complex (Zheng et al., 2000) 
4AUQ 
Dimeric RING BIRC7, 
UbcH5B-Ubiqutin complex 
(Dou et al., 2012b) 
3ZNI 
Monomeric RING b-Cbl, 
UbcH5B-Ubiquitin complex 
(Dou et al., 2013) 
1ERJ WD40 domain of TUP1 (Sprague et al., 2000) 
3ZVZ PHD domain of UHRF1 (Lallous et al., 2011) 
3K1L Drosophila FANCL (Cole et al., 2010) 
3S4W FANCD2/FANCI complex (Joo et al., 2011) 
1YH2 Ube2T (Sheng et al., 2012) 
1UKX RWD domain of GCN2 (Nameki et al., 2004) 
3RZ3 Ube2R1 (Ceccarelli et al., 2011) 
2YB6 Ube2B (Hibbert et al., 2011) 
3K9O Ube2K (Ko et al., 2010) 





(Sheng et al., 2012) 2Z5D Ube2H 
2F4W Ube2J2 
4F52 Rbx1 (Duda et al., 2012) 
4KBL HHARI (Duda et al., 2013) 
4K7D Parkin (Trempe et al., 2013) 
3HCT Traf6 (Yin et al., 2009) 
3RPG RING1b (Bentley et al., 2011) 
3L1Z E4b (Benirschke et al., 2010) 
2YHO IDOL (Zhang et al., 2011) 
4AP4 RNF4 (Plechanovova et al., 2012) 
2Y43 Rad18 (Huang et al., 2011) 
4EPO RNF8 (Campbell et al., 2012) 
 
Table 22 PDB codes used in this thesis 
A table containing all PDB codes used throughout this thesis and their corresponding reference. 






Appendix B: Additional Methods and Buffer Recipes 
 
Below is a list of additional protocols and buffer recipes. They are listed in alphabetical 
order. 
 
2x non-reducing SDS gel loading buffer 
4M Urea, 0.15mM Tris pH 6.8, 5mM EDTA, 2% SDS, 10% glycerol, 0.2% (w/v) 
Bromophenol Blue. 
 
2x SDS gel loading buffer 




All antibiotics were prepared in sterile water followed by sterile filtering using a 








Sulphate Gibco 0.05g/ml 10in01,000
Ampicilin0
Sodium0Salt Sigma 0.1g/ml 10in01,000
Gentamycin0
Sulphate Sigma 0.05g/ml 10in05,000  
Table 23 Antibiotics 
This table shows the antibiotics used in this study and where they were purchased. This table 





Coomassie Brilliant Blue Stain 
2.5g Coomassie Brilliant Blue, 0.5L 100% Methanol, 0.1L Glacial Acetic Acid, 0.4L 
water. 
 
DNA gel  
1% (w/v) DNA agarose gels were made by dissolving 1g of agarose powder into 100ml 
of TAE buffer and microwaved until agarose had melted. The agarose was left to cool 
for approximately 5 minutes and then 10µl of ethidium bromide was added. The liquid 




Proteins requiring protein identification by mass spectrometry analysis were ran on 4-
12% SDS PAGE gel (Invitrogen) in NuPAGE® MOPS buffer (Invitrogen). The 
proteins were visualized using SimplyBlue™ SafeStain (Invitrogen) as per the 
manufacturers guidelines. The protein bands were cut out in a biological hood to 
prevent contamination from keratin and placed in 0.3ml eppendorf tubes with 100µl of 
water added to prevent the gel sample form drying out. The samples were then sent to 
the LIF Protein Analysis and Proteomics facility for mass spectrometry analysis. 
Results were viewed using the scaffold 4 software. 
 
SDS PAGE 
SDS PAGE were generated by first making the separating gel and leaving to set, 
followed by adding the stacking gel on top and leaving to set. To generate a 12% 
separating gel 17mls of 1.5M Tris pH 8.8, 21mls of 40% acrylamide, 30mls of water, 
700µl of 10% SDS, and lastly 700µl 10% of APS and 28µl of TEMED were added 
together and mixed in a glass beaker. The mixture was then pipetted into gel moulds 
leaving enough room to add the stacking gel later.100% propanol was pipetted onto top 
and the gels were left to set. Once set the 100% propanol was poured away and the tope 
of the gels washed with water. The stacking gel was made in a glass beaker by adding 
3.8ml of 1.5M Tris pH6.8, 3.8mls of 40% acrylamide, 21.8mls of water, 300µl of 10% 




blue powder. The mixture was mixed and pipetted onto the set separating gel and left to 
set. Gels were stored at 4oC in wrapped in damp tissue and saran wrap. 
 
TAE Buffer 





Appendix C: Protease Expression and Purification 
As this study required milligrams of purified protein the demand for purified protease 
was also high. Therefore in order to meet the amounts of protease required Ulp1, His-




To generate the E.coli cultures, 50µl of BL21 cells (made in the Walden lab, originally 
from Invitrogen) were transformed with 150ng-200ng of the plasmids containing either 
His-Ulp1 or His-TEV protease (see transformation protocol page 55). Transformed cells 
were then placed into a 250ml conical flask containing 100ml of LB media 
supplemented with 50µg/ml of kanamycin antibiotics for His-Ulp1 and 100µg/ml of 
ampicillin for His-TEV protease (for antibiotic preparation see Appendix A) and 
incubated overnight at 37oC at 180rpm. 4L of LB were also warmed to 37oC overnight. 
The large-scale E.coli protease expression was carried out in 2L baffled canonical flasks 
containing 1L of the warmed LB media supplemented with either 50µg/ml of 
kanamycin or 100µg/ml of ampicillin antibiotics. Each 2L flask was inoculated with 
8mls of overnight culture and incubated at 37oC at 185rpm. Once the OD600nM had 
reached 1.7 (approximately 3.5-4 hours) the incubator was turned down to 30oC and the 
cells induced with 750µM IPTG added directly to the LB media to express the protease.  
The cells were harvested after 5 hours of protein expression by centrifugation at 4000rcf 
for 20 minutes at 4oC, (J6MC centrifuge, Beckman Coulter). 
 
All the remaining stages for protein extraction and purification were carried out on ice 






In order to extract the protease from the E.coli cells were lysed by re-suspending them 
in 5mls/L of lysis buffer containing 75mM Tris pH 7.5, 500mM NaCl, 1mM BME, 
30mM imidazole. 20mls of cells were then sonicated in 50ml flacons for 15 seconds 5x 
with 30-second breaks in between on ice. After sonication cell debris was removed by 
centrifugation at 32,000rcf at 4oC for 45 minutes (Allegra™64R, Beckman Coulter). 
The lysis supernatant was then added to equilibrated Ni-NTA agarose to bind the His 
tagged proteases (1ml/L of E.coli cells) and left overnight on a roller at 4oC.  
The following day the lysis supernatant was removed form the agarose by 
centrifugation at 1000rcf at 4oC (Allegra™ X-22R, Beckman Coulter) and the lysis 
supernatant retained. The agarose was then washed by adding 10cvs of lysis buffer and 
leaving on a roller for 15 minutes at 4oC. After washing the lysis buffer was removed 
from the agarose by centrifugation as just described. The lysis supernatant kept from 
before the wash was again added to the agarose to bind any remaining His tagged 
proteases, and left for 1 hour on the roller at 4oC.  The removal of the lysis supernatant 
and the lysis buffer wash step were repeated. Further washing of the agarose was 
carried out in a gravity flow column by adding 10cvs of wash buffer containing 50mM 
Tris pH 7.5, 200mM NaCl, 1mM BME. The His tagged proteases were then eluted from 
the agarose using 4cvs of elution buffer containing 50mM Tris pH 7.5, 200mM NaCl, 
1mM BME, 500mM imidazole. The pH of the elution buffer must be checked to 
prevent the protein from precipitating out. This elution step was repeated once more and 
the elutions were pooled and concentrated to 10mls.  
 
To achieve a high purity of His-Ulp1 and His-TEV protease the next stage of 
purification was by size exclusion chromatography. S200 and S100 16 60 columns (GE 
Healthcare) equilibrated in wash buffer containing 50mM Tris pH 7.5, 200mM NaCl, 
1mM BME were used to further purify the His-Ulp1 and His-TEV proteases 
respectively (Fig.76 and 77). 
 
To generate untagged Ulp1 1mg of His-TEV protease per litre of E.coli expressing Ulp1 
was added in an overnight dialysis step at 4oC. 2L of dialysis buffer was used 




following day the Ulp1 protease was concentrated to 10mls and ran on an S200 16 60 
column equilibrated in wash buffer containing 50mM Tris pH 7.5, 200mM NaCl, 1mM 
BME (Fig.78). 
 
After size exclusion chromatography all proteases were concentrated to 1-2mg/ml and 







Figure 76 Purification of His-Ulp1 
Chromatogram from size exclusion chromatography and the corresponding peak fractions 







Figure 77 Purification of His-TEV protease 
Chromatogram from size exclusion chromatography and the corresponding peak fractions on 





Figure 78 Purification of Ulp1 
Chromatogram from size exclusion chromatography and the corresponding peak fractions 
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